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ASPIDOFRACTININE: THE CURIOUS CHEMISTRY OF THE INDOLINYL 
RADICAL 
by Kerri Joanne Stenning 
 
This  thesis  is  concerned  with  the  total  syntheses  of  the  natural  products 
aspidospermidine and aspidofractinine. These targets are noteworthy not only for 
the  biological  activity  displayed  within  the  class  but  also  for  their  interesting 
molecular  architecture.  Herein,  two  routes  towards  the  natural  products  are 
presented. Key features of the first route, a unified approach to both targets via the 
indolinyl radical, include the elegant construction of the core ABDE ring system, a 
mild  lactam  reduction  and  synthesis of  the  key  cyclic  imine.  The  second  route 
features a highly efficient Stille coupling and a Wittig olefination. Attempts to effect 
a critical radical cyclisation reaction are also discussed. 
  The chemistry of the C2 indolinyl radical is investigated, in particular the influence 
of the C3 indolinyl substitution upon the radical pathway followed. A discussion of 
the study and its findings is presented in Chapter 4. 
  A  review  of  synthetic  approaches  to  these  natural  products  since  2007  is 
presented in Chapter 1, in addition to details on their isolation, characterisation 
and  biosynthesis,  and  an  overview  of  their  biological  activity.  Experimental 
procedures and characterisation data are provided in Chapter 6.     ﾠ
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Chapter 1: Introduction 
 
1.1 Background 
Alkaloids are organic bases containing one or more nitrogen atoms and are found 
primarily in plants and to a lesser degree in microorganisms and animals. They are 
classified according to the nitrogen-containing source: piperidine, indole, quinoline, 
for example. The nitrogen atoms in alkaloids arise from amino acids and often the 
amino acid constitutes a large portion of the alkaloid skeleton. 
 
One of the major groups of alkaloids in plants is the terpenoid indole family which 
contains  more  than  3000  recognised  alkaloids.  These  alkaloids  are  found 
predominantly  in  eight  plant  families,  of  which  Apocynaceae,  Loganiaceae  and 
Rubiaceae  represent  the  most  abundant  sources.  Almost  all  structures  in  this 
group contain a tryptamine portion, and the remaining nine / ten carbon fragment 
can be divided into three main structural types; Corynanthe (e.g. akuammicine 2), 
Aspidosperma (e.g. tabersonine 4) and Iboga (e.g. catharanthine 5, Figure 1).
1 
 ﾠ
Figure 1: The terpenoid indole alkaloids. 
It is the nine / ten carbon fragment that is of terpenoid origin, being derived from 
the terpene secologanin 1. When combined with the tryptamine portion all three 
groups can be accessed through rearrangement of the terpenoid residue, with the 
Aspidosperma and Iboga groups arising from removal of a three-carbon unit from 
the  Corynanthe  framework  and  reattachment  at  one  of  two  points  (Figure  1). Chapter 1: Introduction 
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Where a nine carbon unit is in place, as in akuammicine 2, it is usually the carbon 
highlighted with a circle that is lost, which corresponds to the carboxylate group of 
secologanin 1 with loss through hydrolysis / decarboxylation. 
 
The  Aspidosperma  alkaloids  are  the  largest  group  of  indole  alkaloids  and  are 
categorised into seven subclasses based on common structural attributes. In each 
case the subclass is exemplified by the parent member, namely aspidospermidine 
6,  aspidofractinine  7,  quebrachamine  8,  vincadifformine  9,  vindolinine  10, 
meloscine 11 and kopsine 12 (Figure 2).
2 
 ﾠ
Figure 2: The Aspidosperma alkaloid subclasses. 
The subjects of this thesis, aspidospermidine 6 and aspidofractinine 7, are both 
the  parents  of  their  individual  subclasses.  Whilst  both  alkaloids  bear  little 
substitution  on  the  Aspidosperma  framework  they  remain  structurally  complex 
targets.  Each  target  contains  a  pentacyclic  fused  [6.5.6.5.6]  skeleton  and 
aspidospermidine  6  has  four  contiguous  stereocentres.  Aspidofractinine  7  has 
additional complexity, boasting an extra six-membered ring (Figure 3).  
 ﾠ
Figure 3: Labelling and numbering of the natural product systems.
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1.2 Isolation and Structural Elucidation 
The  Aspidosperma  alkaloids  are  found  predominantly  in  South  America  and 
Mexico  and  are  isolated  primarily  from  plants  belonging  to  Plumerioideae,  a 
subfamily  of  the  Apocynaceae.
2,4  Aspidospermidine  6  was  isolated  in  1961  by 
Biemann et al. from the bark of Aspidosperma quebracho blanco, a tree native to 
northern  Argentina.
5  Using  a  combination  of  alumina  and  gas-phase 
chromatography  for  separation  and  mass  spectrometry  for  identification, 
approximately twenty alkaloids of reasonable purity were isolated from the crude 
extract.  Of  these,  fifteen  were  analysed  in  detail,  three  of  which  were  already 
known  species,  namely  yohimbine  13  (Figure  4),  aspidospermine  14  and 
quebrachamine 8.
3 
 
Figure 4 
Examining the mass spectra of the twelve remaining alkaloids it was found that 
they  could  be  divided  into  two  structurally  distinct  groups.  The  first  group,  A, 
showed  characteristic  fragmentation  patterns,  in  particular  a  significant  peak  of 
mass 124 that indicated a relationship to aspidospermine 14, whose spectrum had 
been  previously  obtained.  The  second  group,  B,  showed  characteristic 
fragmentation patterns which all contained a significant peak of mass 136. One 
alkaloid, with an abundance of 1%, was determined to have a molecular weight of 
282 and had a fragmentation pattern which suggested it fell into the first group, 
and  was  therefore  termed  alkaloid  282A.  By  examining  the  characteristic 
fragmentations  of  alkaloids  in  group  A,  Biemann  et  al.  were  able  to  deduce  a 
common fragmentation pathway for all six of these alkaloids (Scheme 1). Chapter 1: Introduction 
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Scheme 1: Generalised fragmentation pattern. 
Fragmentation  is  initiated  by  cleavage  of  the  C12íC19  bond,  which  leads  to 
cleavage of the C ring through expulsion of C3íC4 as ethylene.  This relieves 
strain  within  the  fused  ring  system  and,  although  three  bonds  are  broken,  an 
aromatic ring system is gained in the formation of an indole. The resultant charged 
fragment  15  then  breaks  down  further,  this  time  across  the  two-carbon  unit 
tethering the heterocyclic rings. Cleavage of the C10íC11 bond is favoured as the 
resultant  positive  charge  at  C10  can  be  stabilised  by  the  nitrogen  lone  pair, 
affording the characteristic ion 16 of mass 124. The resultant radical intermediate 
17 is also stabilised by conjugation to the aromatic ring system. In general terms, 
this correlates to a characteristic fragmentation pattern of [M]
+>0í@
+ and [124]
+. 
The constant presence of the peak of mass 124 allowed the authors to conclude 
that  the  piperidine  moiety  was  unsubstituted  in  all  cases.  Furthermore,  the 
fragmentation to ion 15 proved the unsubstituted nature of the C3íC4 two-carbon 
unit in all alkaloids of this group. It therefore followed that all differing substitution 
must be confined to the indolyl moiety, on either the nitrogen or aryl component 
(indicated as R
1, R
2 and R
3 in Scheme 1). 
 
Alkaloid 282A exhibited a mass spectrum that followed this general fragmentation 
pattern, showing characteristic peaks at 282, 254 and 124. The molecular weight 
of  282  indicated  that  the  core  aspidospermine  skeleton  featured  no  additional 
substitution, leading them to conclude that the structure was that of 6, which they 
named aspidospermidine.
3 In 1963 Smith and Wahid reported the specific rotation Chapter 1: Introduction 
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of  aspidospermidine  6  (>Į]   +17°,  in  ethanol)  and  proposed  the  absolute 
stereochemistry illustrated in Figure 3.
6 
 
Aspidofractinine 7 was also isolated as a minor alkaloid a few years later in 1963 
from the leaves of Aspidosperma refractum by Schmid and co-workers.
7 As with 
aspidospermidine  6,  the  structural  elucidation  was  based  predominantly  on  the 
mass  spectral  data  and  the  characteristic  fragmentation  patterns.  The  initial 
fragmentation  of  aspidofractinine  7  is fission  of  the  C12íC19  bond,  again  with 
aromatisation  providing  the  driving  force.  This  affords  fragment  ion  18,  which 
undergoes further bond fission at the two benzylic positions to give fragment ions 
19í22  (pathway  a,  Scheme  2). When  the  fission  of  the  C  and  D  rings  occurs 
without loss of ethylene, in a homolytic fashion (pathway b, Scheme 2), ion 23 is 
formed,  which  then  fragments  to  give  firstly  ion  24  and  subsequently  25.  This 
characteristic  peak  is  also  seen  in  the  mass  spectrum  of  aspidospermidine  6. 
When this mass spectral data (with key ions at 280, 252, 158, 144, 124 and 109) 
was combined with the NMR data, which showed an absence of both the methyl 
VLJQDODQGWKHVLJQDOFRUUHVSRQGLQJWR&LQWKHµDVSLGRVSHUPLQHILQJHUSULQW¶, the 
structure of aspidofractinine 7 was successfully assigned.
2 
 
Scheme 2: Fragmentation pattern for aspidofractinine 7. 
The  specific  rotation  was  not  reported  until  a  year  later  >Į@D  í c=0.581  in 
chloroform) when the same group isolated aspidofractinine 7 from the leaves of  Chapter 1: Introduction 
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Pleiocarpa tubicina.
8 The assignment of the absolute stereochemistry by Schmid 
et  al.  in  1964  of  the  natural  material,  (±)-aspidofractinine  7,  was  based  on 
comparison  of  the  OCD  (optical  circular  dichroism)  spectra  of  the  acetylated 
natural  material,  (±)-N-acetylaspidofractinine  28  and  that  of 
(+)-N-acetyl-aspidofractinine  27,  obtained  through  degradation  of  natural              
(±)-minovincine  26  (Scheme  3).  However,  the  absolute  stereochemistry  of                 
(±)-minovincine 26 was only assigned based on the similarity of structure between 
itself and that of (±)-vincadifformine 9. Whilst (±)-vincadifformine 9 had its absolute 
stereochemistry  confirmed  by  total  synthesis  at  that  time,  that  of  natural               
(±)-minovincine  26  had  not.  In  fact,  both  (+)-  and  (±)-minovincine  26  exist  in 
Nature,  thus  leading  to  the  absolute  stereochemistry  of 
(+)-N-acetylaspidofractinine 26 initially being inferred for (±)-aspidofractinine 7. It 
was not until 2009 that the correct absolute stereochemistry was confirmed by the 
total synthesis of (+)-aspidofractinine 7 by Spino and Gagnon (vide infra Chapter 
1.6).
9 Synthesis of the unnatural enantiomer of aspidofractinine 7 and subsequent 
single  crystal  X-ray  analysis,  as  well  as  taking  into  account  the  expected 
stereochemistry from the reaction sequence, allowed the authors to assign with 
certainty the correct absolute stereochemistry. 
 
Scheme 3: Schmid and co-workers¶ determination of absolute stereochemistry. 
It  is  interesting  to  note  that  stereochemical  consistency  amongst  the 
Aspidosperma  alkaloids  at  any  one  stereocentre  is  not  observed.  This  is  in 
contrast to the Corynanthe alkaloids, for whom consistency is observed almost 
completely throughout the group for at least one stereocentre.
2 However, when 
considering  the  biosynthetic  pathways  this  is  perhaps  not  unexpected  ±  the 
biosynthetic pathway of the Corynanthe alkaloids contains no rearrangement of 
the  terpenoid  fragment,  secologanin  1  (Figure  1).
1  The  biosynthesis  of  the 
Aspidosperma alkaloids, however, proceeds with a skeletal rearrangement of the Chapter 1: Introduction 
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terpene residue. This is highlighted by the achiral intermediates akin to 36 which 
are implicated in the biosynthetic pathways of the Aspidosperma alkaloids. 
 
1.3 Biosynthesis  
Studies carrLHGRXWLQWKHODWH¶VDQGHDUO\¶VE\DQXPEHURIJURXSVKDYH
resulted in proposed biosynthetic pathways for the terpenoid indole alkaloids. The 
biosynthesis  for  all  three  major  terpenoid  indole  alkaloid  groups  (Corynanthe, 
Aspidosperma and Iboga) begins with the enzymatic conversion of tryptophan 29 
to tryptamine 3 with tryptophan decarboxylase (Scheme 4).
10 
 ﾠ
Scheme 4: Biosynthetic pathway for the Aspidosperma alkaloids. 
Tryptamine  3  then  reacts  with  the  aforementioned  secologanin  1  in  a 
stereoselective  Pictet-Spengler  condensation  catalysed  by  the  enzyme 
strictosidine  synthase.  Strictosidine  30  is  then  deglycosylated  by  strictosidine 
deglucosidase  to  form  a  reactive  hemiacetal  that  opens  to  form  a  dialdehyde Chapter 1: Introduction 
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intermediate. This dialdehyde reacts with the secondary amine of the strictosidine 
skeleton  to  afford  4,21-dehydrogeissoschizine  31  after  allylic  isomerisation. 
4,21-Dehydrogeissoschizine 31 is the common intermediate for all three alkaloid 
groups and it is at this point that the pathways diverge. From here onwards no 
further  enzymes  for  the  construction  of  the  Aspidosperma  skeleton  have  been 
successfully  identified.  For  the  Aspidosperma  alkaloids  the  next  stage  is  the 
formation of  preakuammicine  33,  though  the  mechanism  still  remains unknown 
despite  several  proposed  pathways.  Reduction  of  preakuammicine  33  gives 
stemmadenine 34 which rearranges to afford the acrylic ester dehydrosecodine 
36.  Cycloaddition  of  dehydrosecodine  36  is  then  presumed  to  install  the 
Asidosperma alkaloid framework; however, as yet there is no evidence for this 
reaction in the plant.  
 
Aspidofractinine-type  alkaloids  are  thought  to  originate  in  Nature  from 
intermediates  similar  to  minovincine  26  via  hydrolysis  of  the  ester  followed  by 
decarboxylation  to  give  intermediates  akin  to  38.
11  Cyclisation  via  an 
intramolecular Mannich reaction to the Į-position of the indole then forms the F 
ring of the aspidofractinine-type alkaloids, with a final reduction of the ketone then 
affording aspidofractinine 7 (Scheme 5). Again, details as to the enzymes involved 
in these processes are yet to be established. 
 
Scheme 5: Biosynthesis of aspidofractinine 7. 
 
 Chapter 1: Introduction 
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1.4 Biological Importance and Activity 
In  2002  a  study  into  the  antimalarial  activity  of  a  range  of  Aspidosperma-type 
alkaloids  was  published.
12  Twelve  alkaloids  with  the  aspidospermine  skeleton 
were tested in vitro for their activity against Plasmodium falciparum, the parasite 
responsible  for  the  most  severe  forms  of  malaria.  The  alkaloids  were  tested 
against two strains of P. falciparum, a chloroquine-resistant strain with an IC50 of 
445  nM  and  a  chloroquine-sensitive  strain  with  an  IC50  of  79  nM.  The 
antiplasmodial activity of the alkaloids against both strains was evaluated after two 
time  periods  of  incubation  of  the  parasite  culture,  namely  24  and  72  hours 
(Table 1).  
 
Alkaloid  R  R
1  R
2 
Chloroquine-resistant 
(445 nM) IC50 ȝ0VG 
Chloroquine-sensitive 
(79 nM) IC50 ȝ0VG 
24 h  72 h  24 h  72 h 
i*  H  H  H  16.3 ± 2.9  3.8 ± 0.7  11.0 ± 1.7  4.6 ± 0.5 
ii  H  H  OMe  19.5 ± 7.2  3.2 ± 0.9  13.1  5.1 
iii  CHO  H  H  16.1 ± 3.0  5.6 ± 0.7  22.0 ± 7.1  5.9 ± 1.5 
iv  CHO  OMe  H  11.8 ± 0.9  4.1 ± 0.6  9.3 ±  2.4  6.6 ± 1.4 
v  C(O)CH3  OMe  H  22.3 ± 11.6  5.6 ± 1.3  nd
a  nd
a 
vi
b  C(O)CH3  OH  H  15.1 ± 1.9  12.2 ± 5.2  21.5 ±  6.5  20.3 ± 6.2 
vii  C(O)CH3  H  H  7.4  6.2  34.0  15.4 
viii  C2H5CO  OMe  H  15.4 ± 4.2  12.7 ± 4.2  27.2  8.7 
ix  C2H5CO  H  H  17.7 ± 4.9  28.5 ± 13.0  40.8 ±  3.8  22.6 ± 2.5 
x  C2H5CO  OMe  H  52.8 ± 7.1  25.6 ± 2.7  113.1  55.3 
xi  C2H5CO  OMe  OMe  90.4 ± 43.7  59.2 ± 5.4  44.4  28.0 
xii  C(O)CH3  OMe  H  149.7 ± 27.6  49.5 ± 3.7  169.3  57.3 
aNot determined; 
bHemisynthetic alkaloid. 
Table 1: Antimalarial activity of some Aspidosperma alkaloids. 
 ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ
* ﾠThe authors name both alkaloids i and v as aspidospermine, however the structural substitutions 
actually denote i as aspidospermidine and v as aspidospermine. We have taken the nomenclature 
to be at error and herein refer to alkaloid i as aspidospermidine. ﾠChapter 1: Introduction 
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The IC50 data shows two distinct groups, a more active group (alkaloids i±v, vii 
and viii) with IC50 values LQWKHUDQJHRIí0IRUERWKVWUDLQVDIWHU
hours, and a less active group (alkaloids ix±xii) with IC50 values in the range of 
í0 after 72 hours. Aspidospermidine 6 is within the more active group 
(alkaloid i), with an IC50 of 3.8±0.7 µM after 72 hours with the chloroquine-resistant 
strain and an IC50 of 4.6±0.5 µM with the chloroquine-sensitive strain. 
 
There are definite structural similarities within each of the two groups, the more 
active group all possessing a free ethyl side chain, compared with the less active 
group all possessing a tetrahydrofuran ring in the same position. The members of 
the less active group also contain a phenolic moiety. In order to assess whether 
the tetrahydrofuran ring or the phenol is responsible for the detrimental effect on 
antimalarial activity the authors synthesised demethylaspidospermine (alkaloid vi). 
This alkaloid features a free ethyl side chain and a phenol and as such exhibited 
an  increased  activity,  an  IC50  of  12.2±5.2  µM.  Thus,  it  was  concluded  by  the 
authors that the presence of a tetrahydrofuran ring was the likely cause of the 
decrease in antiplasmodial activity of the alkaloids. 
 
As part of the same study the combinatory antimalarial activities of two alkaloids 
(alkaloids  iii  and  v)  were  determined  by  the  addition  of  growing  sub-inhibitory 
dilutions of chloroquine to sub-inhibitory dilutions of the alkaloid. After 24 and 72 
hours the growth inhibition was then analysed. It was established that the alkaloids 
had  a  chloroquine-potentiating  effect.  Therefore,  the  authors  concluded  that 
Aspidosperma DONDORLGVPD\UHSUHVHQWµSRWHQWLDODJHQWVIRUUHYHUVDORIUHVLVWDQFH
WRFKORURTXLQH¶
12 
 
Whilst  aspidofractinine  7  is  as  yet  devoid  of  any  reported  bioactivity,  other 
Aspidosperma alkaloids have found success as therapeutic agents, most notably 
the  dimeric  alkaloids  vinblastine  39  and  vincristine  40  (Figure  5).
13  They  were 
isolated  from  a  Madagascan  periwinkle,  Catharanthus  Roseus,  of  the 
Apocynaceae family, a small shrub now common to the tropics.
1 Vinblastine 39 
and  vincristine  40  are  both  bisindole  alkaloids  made  up  of  two  monoterpenoid 
indole alkaloids of the Aspidosperma genera and both have been utilised in cancer 
chemotherapy.
 Chapter 1: Introduction 
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Figure 5 
Whilst these two dimeric alkaloids exhibit little structural difference, the types of 
cancer that respond to each of them vary significantly. Vinblastine 39 ﾠis used to 
WUHDW +RGJNLQ¶V GLVHDVH ZKLFK DIIHFWV WKH O\PSK JODQGV OLYHU DQG VSOHHQ By 
contrast,  vincristine  40  can  be  used  against  a  much  wider  range  of  cancers, 
including  breast  and  cervical  cancer,  small  cell  lung  cancer  and  lymphomas. 
However, it is particularly used against childhood leukaemia, resulting in high rates 
of remission. It is evident from the differences in these target areas that vincristine 
40 boasts enhanced antitumour activity over vinblastine 39; however, this comes 
at a price as it is also more neurotoxic. It is interesting to note that the increased 
importance  of  vincristine  over  vinblastine  is  not  reflected  in  the  plant,  as 
Catharanthus Roseus actually produces a larger quantity of vinblastine 39. Both 
alkaloids are injected into the patient and are usually used in combination with 
other  anticancer  drugs.  They  work  by  inhibiting  cell  mitosis  by  binding  to  the 
protein tubulin in the mitotic spindle; this prevents polymerisation into microtubules 
and stops cell mitosis.
1 
 
However, only very small amounts of vincristine 40 and vinblastine 39 are present 
in plants, with more than 500 Kg of Catharanthus Roseus needed to acquire just 
1 g  of  vincristine  40,  a  meagre  0.0002%  yield!  This  is  the  lowest  yield  of  any 
medicinally  important  alkaloid  isolated  for  commercial  use.  Not  only  this,  but 
extraction  is  difficult,  expensive  and  extremely  wasteful  of  the  raw  material. 
Synthetic routes to vincristine 40 and vinblastine 39 and their monomer alkaloid 
units are therefore of great significance. 
 
It is clear that not only does aspidospermidine 6 represent a biologically important 
compound  with  respect  to  its  antimalarial  activity  but  that,  in  general,  the Chapter 1: Introduction 
12 ﾠ
 ﾠ
development  of  synthetic  routes  towards  the  Aspidosperma  alkaloids  is  a 
challenging and important goal for organic synthesis. Aspidospermidine 6, being 
the least functionalised Aspidosperma alkaloid, has received the greatest attention 
from the synthetic community. 
 
1.5 Previous Syntheses of Aspidospermidine 
The  first  synthetic  forays  within  this  family  were  the  pioneering  syntheses  of 
aspidospermine  14 and  quebrachamine  8 by  Stork and  Dolfini  in  1963,  whose 
Fischer  indole  approach  to  the  pentacyclic  core  of  these  alkaloids  influenced 
syntheses of members of the family for many years.
14 
 
The  synthesis  of  key  intermediate  48  began  with  a  sequence  of  pyrrolidine 
enamine alkylations of butyraldehyde 41, firstly with methyl acrylate and then with 
methyl vinyl ketone. The resultant cyclohexenone 43 was then protected as the 
acetal  and  treated  with  aqueous  ammonia  to  afford  amide  44.  Reduction  with 
LiAlH4 and successive acid and base treatment then installed the C and E rings to 
give  45.  Acetylation  with  chloroacetyl  chloride  and  subsequent  cyclisation  then 
installed  the  D  ring,  with  a  final  ketone  protection,  reduction  and  deprotection 
sequence giving the desired tricyclic ketone 48 (Scheme 6). 
 
a) Pyrrolidine, methyl acrylate; b) aq. AcOH, RT, 67% over two steps; c) pyrrolidine, methyl vinyl ketone; d) aq. AcOH,  , 
48% over two steps; e) H
+, (CH2OH)2; f) aq. NH3, RT; g) LiAlH4; h) H3O
+; i) HO
í; j) chloroacetyl chloride; k) KOtBu, benzene; 
l) H
+, (CH2OH)2; m) LiAlH4; n) H3O
+. 
Scheme 6: 6WRUNDQG'ROILQL¶Vkey intermediate. Chapter 1: Introduction 
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Fischer  indole  cyclisation  of  tricyclic  ketone  48  with  o-methoxyphenylhydrazine 
and phenylhydrazine installed the ABCDE ring systems of aspidospermine 14 and 
quebrachamine 8 respectively. Reduction of indolenines 49 and 50 then afforded 
the natural products aspidospermine 14 and quebrachamine 8 (Scheme 7). 
 ﾠ
a) Phenylhydrazine, AcOH,  ; b) KBH4; c) o-methoxyphenylhydrazine, AcOH,  ; d) LiAlH4; e) acetic anhydride. 
Scheme 7: 6WRUNDQG'ROILQL¶Vendgame for aspidospermine 14 and quebrachamine 8. 
Over the following four decades aspidospermidine 6 has been the focus of over 
twenty total syntheses which can be classified according to their disconnection 
approaches.  The  majority  of  these  syntheses  follow  one  of  three  synthetic 
strategies (Scheme 8). 
 
Scheme 8: Approaches to the synthesis of aspidospermidine XX. 
The strategy based on the Fischer indole cyclisation approach is referred to herein 
as strategy I (Scheme 8). By contrast, strategy II uses a cyclisation-rearrangement 
sequence  to  install  the  CDE  rings.  This  approach  was  first  demonstrated  by Chapter 1: Introduction 
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Harley-Mason et al. in 1967, whereby dimethyl acetal  55 underwent cyclisation 
with  tryptamine  to  form  tetracycle  51.
15  Treatment  with  acid  then  induced  a 
rearrangement, presumed to proceed via the carbocation resulting from loss of the 
hydroxyl  moiety.  Reduction  with  LiAlH4  then  completed  the  synthesis  of 
aspidospermidine  6  in  an  overall  yield  of  20±25%  based  on  tryptamine 
(Scheme 9). This approach has subsequently been used by a number of groups to 
complete asymmetric total syntheses of the natural and unnatural enantiomers of 
aspidospermidine  6,  setting  the  stereochemistry  at  the  quaternary  centre  using 
cyclic analogues akin to 55. 
 ﾠ
a) Pyrrolidine, allyl bromide; b) trimethyl orthoformate; c) O3 then NaBH4; d) tryptamine, boiling AcOH; e) 40% H2SO4 or 
BF3Et2O, 100 °C; f) LiAlH4. 
Scheme 9: Harley-0DVRQ¶VDSSURDFK ﾠ
The final strategy, strategy III, is based upon the late installation of the D ring. 
Magnus and co-workers were the first to exemplify this approach in 1982, using a 
Pummerer reaction of sulfoxide 60 followed by heating in chlorobenzene to give 
the desired pentacycle 62 in 81% over the two steps (Scheme 10).
16 Treatment 
with  Raney
®  nickel  and  reduction  with  LiAlH4  afforded  aspidospermidine  6  in 
11.7% overall yield from aldehyde 58. Chapter 1: Introduction 
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a) NaH, glyme, imidazole, 4-methoxybenzenesulfonyl chloride,  , 2 h, 70%; b) tBuNH2, DCM,  , 1 h; c) nBuLi, THF, MeI, ±
78 °C±RT, 16 h, 43% over two steps; d) 2-(thiophenyl)ethylamine, 100%; e) 63, chlorobenzene, 140 °C, 2.75 h, 33%; 
f) mCPBA, DCM, NaHCO3, 0 °C, 97%; g) trifluoroacetic anhydride, DCM, 0 °C, 10 min; h) chlorobenzene, 130 °C, 2.5 h, 
81% over two steps; i) Raney
® nickel, EtOH, RT, 1 h, 81%; j) LiAlH4, THF, RT, 48 h, 54%. 
Scheme 10: 0DJQXV¶DSSURDFKWRDVSLGRVSHUPLGLQH6. 
0DJQXV¶DSSURDFKSDYHGWKHZD\IRUDQXPEHURIV\QWKHVHVXVLQJWKHVDPHD 
ring installation strategy, using alternative methods to construct the prerequisite 
ABCE ring system. A number of alternative methods to install the  D ring have 
VLQFH EHHQ SXEOLVKHG KRZHYHU FRPPRQ WR DOO LV 0DJQXV¶ RULJLQDO WDFWLF RI
installing the ABCE ring system first, with construction of the D ring in the final 
stages of the syntheses. 
 
A small number of syntheses do not fall into these three strategic groups. For a full 
review  of  all  syntheses  of  aspidospermidine  6  from  isolation  to  2007  see 
S. Whiting  PhD  thesis.
17  The  following  literature  review  focuses  on  the  total 
syntheses published post 2007. 
 
There have been 7 total syntheses since 2007, with all save one conforming to 
one of the disconnection strategies outlined previously. The majority build on Stork 
DQG'ROILQL¶VDSSURDFKIRFXVVLQJRQWKHV\QWKHVLVRINHWRQH48. In 2007, Coldham 
et al. utilised a cyclisation / cycloaddition cascade to synthesis ketone 48 in just Chapter 1: Introduction 
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nine steps from commercially available ethyl 3-bromopropionate 64, a significant 
LPSURYHPHQWRQ6WRUN¶VRriginal 14 step route (Scheme 11).
18  
 
Ethyl 3-bromopropionate 64 was transformed in two steps to dibromoketone 65 via 
a known procedure, with protection followed by elimination then affording alkene 
66.
19  Two  alkylations,  firstly  with  butyronitrile  and  then  with 
1-bromo-3-chloropropane  proceeded  in  excellent  yields  in  afford  nitrile  67. 
Reduction of the nitrile to the aldehyde then gave the precursor to the key step, 
68.  The  cyclisation  /  cycloaddition  cascade  was  promoted  with  CSA  in  the 
presence of glycine. Formation of the imine and cyclisation to the tethered alkyl 
halide  gave  the  required  azomethine  ylide  after decarboxylation.  Intramolecular 
dipolar cycloaddition then completed the sequence to afford the desired tricycle 69 
as a single diastereoisomer in excellent yield (79%) when considering that in a 
single  step  four  bonds,  three  rings  and  three  new  stereocentres  have  been 
installed.  The  synthesis  of  ketone  48  was  then  completed  by  the  concomitant 
acetal  deprotection  and  epimerisation  Į to  the  ketone  to  afford  the  cis  /  cis 
configuration. The synthesis was conclXGHGIROORZLQJ6WRUNDQG'ROILQL¶VSURWRFRO
in 42% yield over three steps (viz. 48ĺ6). 
 
a) EtMgBr, Ti(O
iPr)4, Et2O; b) NBS, CCl4, 82% over two steps; c) (CH2OH)2, pTSA, PhH,  , 6 h, 86%; d) KOtBu, THF / PhMe 
  &í57  K %;  e)  butyronitrile,  LDA,  THF,  then  66,  í &  K  I /'$ 7+) WKHQ -bromo-3-
FKORURSURSDQHí&KJ',%$/+'&0í&R[DOLFDFLGKJO\FLQH&6$3K0H , 18 h, 79%; i) HCl, 
THF,  , 1 h, 88%; j) PhNHNH2, PhH,  , 2.5 h; k) AcOH, 95 °C, 2.5 h; l) LiAlH4, THF,  , 13 h, 42% over three steps. 
Scheme 11: ColdhaP¶V total synthesis of aspidospermidine 6. Chapter 1: Introduction 
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In  another  example  of  utilising  a  cascade  process  to  synthesise  ketone  48, 
Ishikawa  and  co-workers  used  a  double  Michael-Claisen  reaction  sequence  to 
install ring C and complete the enantioselective synthesis of (+)-aspidospermidine 
6.
20 Thus, 2-pentanone 70 was treated with excess tbutyl acrylate and base to 
form thermodynamic enolates 71 and 73 which underwent double Michael addition 
and subsequent Claisen cyclisation to form 74 (Scheme 12). 
 
a) tButyl acrylate (4 equiv.), KOtBu (2 equiv.), tBuOH / THF (1:1), 0 °C, 3 h. 
Scheme 12: ,VKLNDZD¶V double Michael-Claisen reaction sequence. 
A single step transformed 2-pentanone 70 into dione 74, forming three new bonds 
and one new stereocentre. The authors designed an optical resolution of dione 74 
via  Lewis  acid-catalysed  enamine  formation  with  (S)-1-phenylethylamine.  Thus, 
the desired diastereoisomer was separated and transformed into enol ether  76, 
with  DIBALH  reduction,  mesylation  and  subsequent  SN2  reaction  with 
ethanolamine followed by an intramolecular Michael addition affording the CE ring 
system 78. Chlorination of 78 then set up an intramolecular alkylation to achieve 
the  enantioselective  synthesis  of  ketone  48.  The  transformation  to 
(+)-aspidospermidine 6 was then completed in the usual manner (viz. 48ĺ6) in an 
overall yield of 5.2 % from dione 74 (Scheme 13). 
 
a) Zn(OTf)2, (S)-1-phenylethylamine, MeCN, 50 °C, 99%; b) NaH, ClCO2Me, THF, then HCl, MeOH, 75%; c) DIBALH, 
3K0Hí&KG) MsCl, Et3N, THF, RT, 10 h, 59% over two steps; e) ethanolamine, MeOH, RT, 2 h; f) MsCl, Et3N, 
THF, RT, 20 h; g) NaH, THF, RT, 3 h, 46% over three steps; h) PhNHNH2, AcOH; i) NaBH4, EtOH, 51% over two steps. 
Scheme 13: ,VKLNDZD¶V enantioselective synthesis of (+)-aspidospermidine 6. Chapter 1: Introduction 
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In 2009 Canesi et al. reported a total synthesis of aspidospermidine 6 via ketone 
48  using  an  oxidative  Hosomi-Sakurai  reaction.
21  Phenol  79  was  appropriately 
substituted  to  direct  the  allyl  addition  in  the  subsequent  key  step.  Thus, 
4-ethylphenol  79  was  brominated  to  afford  the  ortho-dibrominated  species  80 
which when silylated afforded phenol 81 (Scheme 14). This was then subjected to 
the  oxidative  Hosomi-Sakurai  conditions  to  give  4-disubstituted  dienone  82 
exclusively.  Hydroboration  followed  by  mesylation  gave  dienone  83  which  was 
WUHDWHGZLWK)XNX\DPD¶s sulfonamide 87 in an SN2 fashion. Deprotection of the 
nitrogen moiety also led to concomitant addition of thiophenol to afford 85. Further 
deprotection  of  the TBDMS  group  with  TBAF  gave  the free  alcohol as  well  as 
cyclisation of the free amine to form the C and E rings via a Michael addition in a 
PDQQHU DNLQ WR ,VKLNDZD¶V V\QWKHVLV 7KH VLPLODULW\ RI WKHVH DSSURDFKHV WKHQ
extended  to  the  D  ring  closure,  which  was  achieved  by  chlorination  and 
base-induced alkylation to afford the desired tricycle, in this case in 84% yield. 
Desulfurisation  with  Raney
®  nickel  then  completed  the  synthesis  of  ketone  48, 
which was transformed into aspidospermidine 6 in 43% over three steps.  
 ﾠ
a) Br2'&0&í57K; b) HMDS, THF,  , 45 min, then n%X/L7+)í&í57 12 h, 87%; c) PhI(OAc)2, 
allyltrimethylsilane, (CF3)2CHOH, 0 °C, 15 min, 56%; d) 9-BBN, THF, RT, 2 h, then H2O2, K2CO3, 0 °C, 5 min, 72%; e) MsCl, 
lutidine, DCM, RT, 2 h, 97%; f) NaH, 87'0)57í&K; g) K2CO3, PhSH, MeCN, RT, 12 h, 85%; h) TBAF, 
THF, RT, 5 h, 87%; i) MsCl, Et3N, DCM, RT, 2 h, 79%; j) KOtBu, PhMe, RT, 12 h, 84%; k) Raney
® nickel, EtOH, RT, 1 h, 
85%; l) PhNHNH2, PhH, 80 °C, 2 h; m) AcOH, 118 °C, 4 h; n) LiAlH4, THF, RT, 30 min, 43% over three steps. ﾠ
Scheme 14: Canesi and co-worker¶s synthesis of (±)-aspidospermidine 6. Chapter 1: Introduction 
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The  most  recent  example  of  the  synthesis  of  aspidospermidine  6  via  6WRUN¶V
ketone 48 is that of Cho et al., reported in 2010, in which a tandem conjugate 
addition-alkylation of cyclohexenone 96 was used to install the D and E rings in a 
single  step  (Scheme  15).
22  The  pendant  ethyl  group  was  first  installed  on 
3,5-dibromo-2-pyrone  88  in  a  palladium-catalysed  coupling  to  afford  diene  89 
(Scheme 15). Diels-Alder reaction with phenyl vinyl sulfide afforded bicyclolactone 
90  in  good  yield  and as  a mixture  of  exo  /  endo  isomers, both of  which  were 
progressed  as  the  thiophenyl group  is removed  later in  the  synthesis.  Lactone 
opening then gave the appropriately functionalised C ring, 91, in an excellent yield. 
A  series  of  functional  group  manipulations  afforded  aldehyde  92,  which  was 
subjected to Horner-Wadsworth-Emmons olefination with stabilised phosponate 98 
to give (E)-93.   
 ﾠ
a) PdCl2(PPh3)2, Et3Al-Me2N(CH2)2OH, PhMe, 100 °C, 1 h, 55%; b) phenyl vinyl sulfide, PhMe, 100 °C, 68%; c) NaOMe, 
MeOH, 96%; d) TBSCl, 96%; e) DIBALH, PhMe, í78 °C, 1 h, 88%; f) Raney
® nickel, EtOH, 30 min, 80%; g) DMP, DCM, 
87%; h) NaH, 98, DME, 85%; i) NiCl2, NaBH4; j) TBAF, Et3N, 65% over two steps; k) DMP, DCM, 87%; l) LiOH, THF / H2O, 
98%; m) (COCl)2, then Cl(CH2)2NH2, Et3N, DCM, 63%; n) NaH, DMF, 0 °C, 60%; o) (CH2OH)2; p) BH3THF, THF; q) aq. HCl, 
THF, 62% over three steps; r) PhNBocNH2, pTSA, EtOH; s) LiAlH4, THF,  , 45% over two steps. ﾠ
Scheme 15: &KR¶V synthesis of (±)-aspidospermidine 6. Chapter 1: Introduction 
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Selective reduction of the eneoate alkene, TBS deprotection, oxidation and ester 
saponification  then  gave  the  required  cyclohexenone  moiety  95  for  the  key 
conjugate  addition-alkylation.  The  amine  tether  was  introduced  via  the  acid 
chloride  (viz.  95ĺ96).  The  conjugate  addition-alkylation  was  then  promoted  by 
treatment with NaH in DMF to install the D and E rings in a yield of 60%. The 
synthesis of ketone 48 was then completed by selective reduction of the amide 
carbonyl in an acetal protection-amide reduction-deprotection sequence. Fischer 
indole cyclisation using the Boc-protected hydrazine in the presence of pTSA, a 
deviation from Stork and DolfLQL¶VRULJLQDOSURWRFRODIIRUGHGDVSLGRVSHUPLGLQH6 in 
45% yield from ketone 48. 
 
Another  common  approach  towards  aspidospermidine  6  is  the 
cyclisation-rearrangement sequence of Harley-Mason et al. Two recent syntheses 
have used this approach as their basis, those of Iwabuchi et al. and Tomioka et 
al.,  both  reported  in  2009.
23,24  Iwabuchi  and  co-workers  utilised  an  acetonide 
moiety  as  a  directing  group  to  induce  the  enantioselective  synthesis  of 
(+)-aspidospermidine 6 from enone 99, for which they had previously reported a 
synthesis  via  a  chemoenzymatic  process.
23  Thus,  the  necessary  pendant  ethyl 
group was installed via conjugate addition and in situ trapping as silyl enol ether 
100. Oxidation followed by selective 1,2-reduction afforded allylic alcohol 101 as 
the only product (Scheme 16).  
 
a) (W0J%U&X,+03$7(6&O7+)í&íí& b) Pd(OAc)2, O2, DMSO, 50 °C, 9 h, 89% over two steps; c) NaBH4, 
CeCl3+220H2+í&; d) Me2NC(OMe)2Me, Ph2O,  , 2 h, 86%; e) LiEt3BH, THF, 0 °C, 100%; f) H2, 10% Pd / C, 
EtOAc, 100%; g) HIO4+2O, dioxane / H2O (1:1), RT; h) TPAP, NMO, DCM, RT, 94% over two steps; i) tryptamine, PhMe, 
, 2 h; j) cat. H2SO4, PhOH, 50 °C, 1 h, 70% over two steps; k) 40% aq. H2SO4, 110 °C, 1.5 h; l) LiAlH4, THF,  , 2 h, 51% 
over two steps.  
Scheme 16: Iwabuchi¶V synthesis of (+)-aspidospermidine 6. Chapter 1: Introduction 
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Acetamide  102  was  then formed  using  an Eschenmoser rearrangement. When 
treated  with  LiEt3BH  this  material  gave  the  hydroxyethyl  103  required  for  a 
Harley-Mason rearrangement. The directing / protecting acetonide group was then 
removed via hydrolysis, giving a 1,2-diol which, when oxidatively cleaved, formed 
the resultant dialdehyde which in turn cyclised directly to the lactol. Oxidation then 
yielded  lactone  104 DQ LQWHUPHGLDWH FRPPRQ WR ERWK ,ZDEXFKL DQG 7RPLRND¶V
syntheses.  Amide  formation  with  tryptamine  followed  by  Pictet-Spengler 
cyclisation afforded tetracycle 51 in good yield over two steps. The synthesis was 
completed using Harley-0DVRQ¶VSURWRFROQDPHO\WKHDFLG-induced rearrangement 
of 51 to form the pentacyclic core followed by reduction of the resultant indolenine 
to give (+)-aspidospermidine 6 in 51% yield. 
 
Tomioka  et  al.  published  their  own  enantioselective  synthesis  of 
í-aspidospermidine  6  within  months  of  Iwabuchi.  They  also  targeted  bicyclic 
lactone intermediate 104 and used the same modified Harley-Mason end game.
24 
A  tandem  asymmetric  conjugate  addition-alkylation  strategy  was  the  key 
transformation  of  their  enantioselective  synthesis  (Scheme  17).  Thus,  the 
conjugate  addition  of  lithium  amide  106  to  cyclopentene  107  and  subsequent 
in situ alkylation with ethyl iodide produced two contiguous stereocentres and new 
&í1DQG&í&ERQGVLQRQHSRWLQDQLPSUHVVLYH\LHOGDQGe.e. (94%, 95% e.e.; 
85%, >99% e.e. after recrystallisation of its hydrochloride salt). 
 
a) 1093K0Hí&KWKHQí&KWKHQ(W,+03$ 7+)í&K 
Scheme 17: 7RPLRND¶VWDQGHPDV\PPHWULFFRQMXJDWHDGGLWLRQ-alkylation protocol. 
The hydrochloride salt of cyclopentane 108 was transformed into alkene 111 via a 
sequence of methylation, N-oxidation and Cope elimination (Scheme 18). Ester 
reduction  followed  by  oxidation  to  the  corresponding  aldehyde  set  up  a  Wittig 
reaction to lengthen the carbon chain. Hydrolysis of the resultant enol ether to the 
aldehyde and subsequent reduction with NaBH4 afforded alcohol 112. Oxidative 
cleavage of the cyclopentene initially gave a lactol which was oxidised to lactone 
104 in 85% yield over two steps. Lactone opening with tryptamine then formed Chapter 1: Introduction 
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amide  113,  with  a  modified  version  of  Harley-0DVRQ¶V VWUDWHJ\ FRPSOHWLQJ WKH
enantioselective  synthesis  RI í-aspidospermidine  6  in  37%  yield  for  the 
cyclisation-rearrangement and reduction steps. 
 
a) NaBH3CN, HCHO, aq. MeCN, then mCPBA, tBuOH, then Al2O3, 65%; b) LiAlH4, Et2O, 97%; c) TPAP, NMO, 4Å MS, 
DCM; d) Ph3P=CH(OMe), THF; e) HCl (5 M), Et2O; f) NaBH4, MeOH, 79% over five steps; g) OsO4, NMO, aq. acetone, then 
NaIO4; h) TPAP, NMO, 4Å MS, DCM, 85% over two steps; i) tryptamine, nBuOH,  , 2 h, 75%; j) 40% H2SO4,  , 2.5 h; 
k) LiAlH4, THF,  , 1.5 h, 37% over two steps.  
Scheme 18: Tomioka¶V V\QWKHVLVRIí-aspidospermidine 6. 
The most  recent  synthesis to  be  reported  is  that  of Waser  et al.
25  This formal 
synthesis of (±)-aspidospermidine 6 is unique amongst those discussed herein, 
not  falling  into  any  of  the  classic  strategies  previously  outlined  (vide supra 
Scheme 8).  The  synthesis  features  a  catalytic  homo-Nazarov  cyclisation  of 
aminocyclopropane  119  as  the  key  step.  This  gave  access  to  120,  a  late 
LQWHUPHGLDWH LQ :HQNHUW DQG +XGOLFNê¶V   synthesis  of  aspidospermidine  6 
(Scheme 19).
26 
 
a)  n%X/L &E]&O (W, 7+) í & ;  b)  NaBH4,  MeOH;  c)  H2SO4,  THF,  93%  over  two  steps;  d)  &X27I3K0H, 
N2CHCO2Et, DCM, 76% d.r. 1:1; e) BF3(W2O, DCM; f) NaOH, H2O / THF / EtOH (1:1:3), 91% over two steps; g) DMTMM, 
1007+)0H1+20H+&O; h) indole-1-carboxylic acid, tBuLi, LiCl, THF, 67%; i) Pd(MeCN)4(BF4)2, MeCN; j) H2, 
Pd / C, 100%; k) (CH2Br)2, K2CO3,  .  
Scheme 19: Waser¶V synthesis of (±)-aspidospermidine 6. Chapter 1: Introduction 
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The approach began with į-valerolactam 114, which underwent protection as the 
N-Cbz  product  and  the  ethyl  group  installation  in  a  single  step  (Scheme  19). 
Reduction  with  NaBH4  followed  by  elimination  then  afforded  dehydropiperidine 
115. Cyclopropanation with ethyl diazoacetate and catalytic copper triflate afforded 
aminocyclopropane  116  as  a  1:1  mixture  of  diastereoisomers,  which  were 
equilibrated  to  the  exo  isomer when  treated  with  boron  trifluoride  etherate  and 
saponified to give 117. Transformation into the Weinreb amide 118 and coupling to 
indole-1-carboxylic acid in quantitative yield afforded the homo-Nazarov precursor 
119,  with  deprotection  of  the  N-carboxy  indole  upon  work  up  (no  yield  was 
reported).  Treatment  with  catalytic  Pd(MeCN)4(BF4)2  induced  the  key 
transformation  with  removal  of  the  Cbz  group  then  completing  the  formal  total 
synthesis. 
 
1.6 Previous Syntheses of Aspidofractinine 
In  stark  contrast  to  the  interest  in  aspidospermidine  6  as  a  synthetic  target, 
aspidofractinine  7  has  been  the  subject  of  only  six  reported  total syntheses  to 
date, two of which originated from the same group.
9,27,28,30,32,33 The syntheses can 
be  broadly  categorised  into  two  approaches  based  on  the  mode  of  F  ring 
formation, namely a Diels-Alder reaction or acetyl cyclisation (Figure 6). 
 ﾠ
Figure 6: F ring installation strategies. 
Ban and co-workers were the first to achieve a successful total synthesis in 1976, 
following this in 1986 with a second route featuring a common intermediate and 
different end game.
27,28 Their earlier synthesis utilised a Diels-Alder reaction with 
nitroethylene  to  install  the  F  ring,  whilst  the  second  synthesis,  published  one 
decade later, used the acid-promoted cyclisation of an acetyl to an indolenine. 
Both  routes  proceed  via  intermediate  129  (Scheme  20).
29  Condensation  of 
2-hydroxytryptamine 123 with acetal 124 afforded oxindole 125, which was then 
acylated with ȕ-chloropropionyl chloride to give 126 after acetal hydrolysis. Chapter 1: Introduction 
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a)  Basic  aq. EtOH,  63% E ȕ-chloropropionyl  chloride; c)  H3O
+; d)  NaOH,  EtOH /  DCM,  RT,  89%;  e) BF4
íEt3O
+,  1,2-
dichloroethane, 65 °C, 20 h, 51%; f) NaH, DMSO,  , 60 h, 31±50%; g) TsCl, DCM. 
Scheme 20: 6\QWKHVLVRI%DQ¶VLQWHUPHGLDWH
29 
Base-induced  elimination  afforded  Michael-acceptor  127,  which  underwent 
addition  when  exposed  to  Lewis  acid  to  afford  tetracycle  128  in  modest  yield. 
Finally, deprotonation with NaH and vigorous heating facilitated C ring closure. 
 
In their first approach Ban and co-workers set the scene for their key Diels-Alder 
reaction  through  reduction  and  dehydration  of  129  to  form  diene  130.
27  This 
smoothly  underwent  a  Diels-Alder  reaction  with  nitroethylene  in  DCM  at  room 
temperature  in  80%  yield  (Scheme  21).  A  sequence  of  functional  group 
manipulations then completed the first total synthesis of aspidofractinine 7 in 14 
steps. 
 
a) NaBH4, EtOH / THF (1:1), RT, 87%; b) anhydrous pyr., PBr3, PhH, RT, 74%; c) nitroethylene, DCM, RT, 12 h, 80%; d) H2 
(5.3 atm), PtO2, 90%; e) NaNO2, aq. AcOH, 55 °C, 5 h, 43%; f) LiAlH4, 1,2-dimethoxyethane,  , 3 h; g) H2, Pt, EtOAc, 100% 
over two steps. 
Scheme 21: %DQ¶VILUVWWRWDOsynthesis of aspidofractinine 7. Chapter 1: Introduction 
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7KH JURXS¶V VHFRQG JHQHUDWLRQ DSSURDFK ZDV  based  on  an  acylation  and 
acid-promoted cyclisation strategy to install the F ring starting with pentacycle 129 
(Scheme  22).
28  Acylation  was  effected  via  Michael  condensation  with  vinyl 
sulfoxide,  which  was  followed  by  concomitant  reduction  to  the  sulfide  and 
formation of the thiolactam using P4S10. Desulfurisation with Raney
® nickel then 
produced enol ether 134, reduction of which followed by hydrolysis afforded 135. 
Attempted chlorination of alcohol 135 failed, instead giving isomeric alcohol 136. 
However,  hydrogenation  followed  by  tosyl  deprotection  and  concomitant 
indolenine  formation  gave  the  desired  precursor  for  the  F  ring  formation,  121. 
Treatment  with  dilute  HCl  afforded  the  hexacycle  smoothly  in  90%  yield,  with 
reduction of the remaining ketone completing the synthesis of (±)-aspidofractinine 
7  in  17  steps,  a  longer  sequence  than  the  original  Diels-Alder  approach 
(Scheme 22). 
 ﾠ
a) LiN(TMS)2, PhSOCH=C(Cl)OCH3, THF, ±50 °C, 60%; b) P4S10, THF,  , 78%; c) Raney
® nickel, THF,  , 67%; d) LiAlH4, 
THF, ±50 °C; e) aq. H2SO4, THF, 86% over two steps; f) SOCl2, DCM, pyr., ±50 °C, 30 min, then aq. NaHCO3, 53%; g) H2, 
Pt, EtOAc, 100%; h) Na-naphthalene, THF, ±78 °C, 50%; i) dilute HCl, 110 °C, 1.5 h, 90%; j) Huang-Minlon reduction (KOH, 
N2H4H2O, (CH2OH)2,  ) 74%. 
Scheme 22: %DQ¶VVHFRQGWRWDOV\QWKHVLVRIDVSLGRIUDFWLQLQH7. 
In  1989  Gramain  et  al.  UHSRUWHG D URXWH WR %DQ¶V NH\ LQWHUPHGLDWH 137,  thus 
constituting  a  formal  total  synthesis  of  (±)-aspidofractinine  7.
30  The  synthesis 
began with N-benzyl aniline 138 which was condensed with 1,3-cyclohexanedione 
139 to afford enaminone 140 (Scheme 23). On irradiation in benzene, this gave 
tricycle  141  in  an  impressive  quantitative  yield  with  excellent  stereocontrol. 
Alkylation of the thermodynamic enolate with iodoacetamide then installed the D Chapter 1: Introduction 
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ring  with  contemporaneous  aminol  formation.
31  Dehydration,  N-alkylation  and 
reduction  of  the  amide  moiety  followed  by  acylation  then  gave  143.  LiAlH4 
reduction of 143 gave the 1,4-addition product, the alcohol moiety of which was 
deprotected with rhodium(III) chloride followed by acidic hydrolysis. Tosylation of 
the free alcohol then gave 144. Intramolecular cyclisation was next effected using 
NaH  to  afford  the  core  pentacycle  145.  Hydrogenolysis,  oxidation  and  acetyl 
cyclisation completed the formal total synthesis. 
 ﾠ
a) pTSA, PhH, Dean and Stark,  , 20 h, 98%; b) hȣ, PhH, 100%; c) KH, ICH2CONH2, THF, 93%; d) DCM,  , 4Å MS, 100%;  
e) KH, I(CH2)3Oallyl, THF; f) LiAlH4, THF,  ; g) CH3COCl, Et3N, DCM, 72% over two steps;  h) LiAlH4, THF, 20 °C, 5 min, 
60%; i) DABCO, RhCl3, EtOH / H2O; j) H3O
+, EtOH / H2O; k) TsCl, py., 0 °C, 48 h; l) NaH, PhH,  , 20% over four steps; m) 
H2, Pd / C, EtOH / CHCl3; n) (COCl)2, DMSO, Et3N; o) HCl, MeOH,  , 85% over three steps. 
Scheme 23: *UDPDLQ¶VIRUPDOV\QWKHVLVRIDVSLGRIUDFWLQLQH7. 
In the same year, Lévy et al. reported a double cyclisation strategy to install both 
the C and F rings.
32 This approach focussed on an oxindolic acetyl cyclisation in a 
PDQQHU DNLQ WR %DQ¶V VHFRQG DSSURDFK IROORZHG E\  an  acid-promoted 
cyclisation / decarboxylation sequence. The prerequisite  ABDE ring system was 
constructed using 2-hydroxytryptamine 149 and aldehyde 148, in turn accessed 
from ketone 146 in two steps (Scheme 24). Tetracycle 150 was then subjected to 
the  double  cyclisation  sequence  to  afford  ketolactam  152  either  directly  using 
pTsOH in boiling toluene, or in a more stepwise fashion via pentacycle 151. The 
stepwise  sequence  was  realised  so  that  the  authors  could  determine  in  which 
order  the  two  rings  closed.  Ketolactam  152  was  sequentially  reduced  by 
conversion to thioketal 153 and its removal with Raney
® nickel. Reductive removal Chapter 1: Introduction 
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of  the  remaining  carbonyl  with  LiAlH4  completed  the  total  synthesis  of 
aspidofractinine 7 in just seven steps and 1.4% overall yield. 
 
a) Methyl acrylate, cat. Triton-B (PhCH2NMe3OH), K2CO3, PhH,  , 20 h, 26%; b) O3, Sudan III, 65%; c) PhMe, Dean and 
Stark,  , 2 h then AcOH,  , 5 h, 40%; d) pTSA, PhMe,  , 15 h, 50%; e) Me3OBF4; f) NaH, DMF, 48 h, 20 °C, 52%; g) pTSA, 
PhMe, 20%; h) (CH2SH)2, AcOH, BF3, RT, 12 h, 70%; i) Raney
® nickel, EtOH, 87%; j) LiAlH4, 70%. 
Scheme 24: Lévy¶Vtotal synthesis of aspidofractinine 7. 
%XLOGLQJRQ%DQ¶VILUVWDSSURDFKWenkert and Liu used a Diels-Alder reaction in 
their  1994  synthesis,  in  this  case  using  phenyl  vinyl  sulfone  as  the  dienophile 
(Scheme 25).
33 ,QFRQWUDVWWR%DQ¶VV\QWKHVLVWKHLUDSSURDFKIHDWXUHGDQHDUO\
incorporation of the E ring, utilising 154 as a key intermediate. Exposure of this to 
boron trifluoride etherate with heating  induced a cascade cyclisation sequence, 
neatly forming the C and D rings, albeit in low yield (39%). Subsequent oxidation 
and  N-protection  afforded  Į,ȕ-unsaturated  ketone  156,  which  was  selectively 
UHGXFHG DQG GHK\GUDWHG LQ D PDQQHU DNLQ WR %DQ¶V ZRUN WR DIIRUG GLHQH 157. 
Diels-Alder  cycloaddition  with  phenyl  vinyl  sulfone  proceeded  slowly,  requiring 
high  temperatures  and  long  reaction  times,  namely  120  °C  and  four  days, 
compared to the analogous Diels-$OGHUUHDFWLRQLQ%DQ¶VDSSURDFK+RZHYHUWKH
product  was  obtained  in  a  pleasing  75%  yield.  N-Deprotection  with  lithium 
ethanethiolate,  desulfurisation  with  Raney
®  nickel  and  a  final  reduction  of  the 
amide moiety completed the synthesis. Chapter 1: Introduction 
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a) BF3(W2O, 85 °C, 10 min, 39%; b) Pb(OAc)4, CHCl3,  , 15 min, 85%; c) nBuLi, ClCO2Me, THF, 96%; d) NaBH4, CeCl3, 
MeOH, 75%; e) BF3(W2O, 88%; f) phenyl vinyl sulfone, PhH, 120 °C, 4 d, 75%; g) EtSLi, HMPA, THF, 93%; h) Raney
® 
nickel, 
iPrOH, 88%; i) LiAlH4, THF,  , 1 h, 76%. 
Scheme 25: Wenkert¶Vtotal synthesis of aspidofractinine 7. 
The first asymmetric synthesis of aspidofractinine 7 was reported in 2009 by Spino 
and Gagnon in a unique approach leading to the unnatural enantiomer (+)-7.
9 The 
key  features  included  a  stereoselective  cyclopropanation  to  introduce  the 
quaternary centre at the BCD ring juncture with complete stereocontrol, combined 
ZLWK:HQNHUW¶V'LHOV-Alder reaction with phenyl vinyl sulfone to install the F ring. 
The  stereoseletivity  is  imparted  by  the  addition  of  chiral  auxiliary  166  to  the 
alkynyllithium  resulting  from  vinyl  bromide  160  (Scheme 26). The  two  resulting 
diastereoisomers  were  separated  after  Red-Al
®  reduction  to  give  allylic  alcohol 
162  in  good  yield  and  d.e.  (>99%).  The  chiral  integrity  was  then  transferred 
through formation of the carbamate 163, followed by dehydration to the isocyanate 
164 with in situ protection as the Troc protected amine 165 with Cl3CCH2OH (viz. 
162ĺ165). Chapter 1: Introduction 
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a) MeOCHCl2, TiCl4'&0í&E&%U4, Et3N, PPh3'&0í&F1D+0'67+)í&WKHQnBuLi, 
THF, 166; d) Red-Al
®, THF, 25 °C, 71% over two steps; e) Cl3CC(O)NCO, THF, 0 °C, 1 h then aq. K2CO3, MeOH, 0 °C, 1 h, 
96%; f) TFAA, Et3N, DCM, 0 °C; g) Cl3CCH2OH, 87% over two steps, d.r. 11:1. 
Scheme 26 
Deprotection  was  then  followed  by  alkylation,  acylation  and  ring-closing 
metathesis  (RCM)  to  afford  the  ABC  ring  system  168,  the  latter proceeding  at 
URRP WHPSHUDWXUH XVLQJ *UXEEV¶ VHFRQG JHQHUDWLRQ FDWDO\VW ZLWK FRQFRPLWDQW
removal  of  the  chiral  auxiliary  (Scheme  27).  The  key  stereoselective 
cyclopropanation was then accomplished, firstly by formation of the Į-diazoketone 
from Į-bromoketone 168 followed by Cu(I)-catalysed cyclopropanation to form the 
ABCD ring system 169 with complete stereoselectivity and in good yield. The E 
ring was then installed through a 6-exo-trig radical cyclisation in excellent yield, 
with subsequent reductive deprotection and ring-opening of the cyclopropane to 
afford indolenine 171. Oxidation with phenylseleninic acid gave enimine 172 which 
under  the  Diels-Alder  conditions  tautomerised  to  the  required  diene.  The 
Diels-Alder product 158 LVDQLQWHUPHGLDWHLQ:HQNHUW¶VUDFHPLFV\QWKHVLV
and the synthesis was completed in two steps using their reduction protocol. Chapter 1: Introduction 
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a) Zn, AcOH, THF, RT; b) I(CH2)3Cl, MeCN, K2CO3, 77% over two steps; c) BrCH2COCl, Et3N, DCM, 84%; d*UXEEV¶,,
DCM, RT, 86%; e) (TsNH)2, DBU, THF, 92%; f) CuOTf, DCM, 76%; g) NaI, acetone; h) Bu3SnH, AIBN, PhH,  , 92% over 
two steps; i) Na, anthraceQH'0(í&j) PhSeO2H, THF / pyr. 6:1,  , 61%; k) phenyl vinyl sulfone, PhH, 90 °C, 
5 h, 55%; l) Raney
® nickel, iPrOH,  , 67%; m) LiAlH4, THF,  , 70%.
 
Scheme 27: Spino¶Vtotal synthesis of (+)-aspidofractinine 7. 
It was the completion of this stereoseletive synthesis that confirmed the absolute 
VWHUHRFKHPLVWU\RIQDWXUDODVSLGRIUDFWLQLQHí-7. This was the same as that which 
had been assumed by Schmid et al. for natural aspidofractinine 7 in WKH¶V.
8 
The stereochemistry of the synthesised unnatural enantiomer (+)-7 was confirmed 
by single crystal X-ray analysis, OCD spectra and through logical extrapolation of 
the synthetic sequence. In addition, all spectral data proved to be identical to that 
reported in the literature for the natural enantiomer  except the >Į@D (vide supra 
Chapter 1.2).
9 
 
1.7 Conclusions 
The  Aspidosperma  alkaloids  represent  the  largest  family  of  terpenoid  indole 
alkaloids with more than 250 members. The family is known to originate in Nature 
from the terpene secologanin 1 and tryptamine 3. Whilst a biosynthetic pathway Chapter 1: Introduction 
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has  been  elucidated,  many  of  the  enzymatic  details  remain  unresolved.  The 
subjects of this thesis, aspidospermidine 6 and aspidofractinine 7, are the parents 
of their individual subclasses and were isolated in 1961 and 1963 respectively. 
 
Significant synthetic interest has surrounded the area since their isolation due to 
their interesting molecular architecture and the biological activity shown within the 
family. Related natural products have found clinical applications, namely dimeric 
indole  alkaloids  vinblastine  39  and  vincristine  40,  whose  monomeric  units  are 
members of the  Aspidosperma family. Aspidospermidine 6 itself has also been 
shown to display activity against the parasite Plasmodium falciparum. However, 
aspidofractinine 7 has no reported biological activity to date. 
 
It is evident that the synthetic interest in the Aspidosperma alkaloids has led to the 
discovery  and  implementation  of  a  diverse  range  of  methodologies  and  that 
aspidospermidine  6,  as  the  least  funtionalised  member,  provides  a  convenient 
scaffold on which to exemplify these strategies. 
   Chapter 1: Introduction 
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Chapter 2: Our Strategies 
 
Our two strategies towards the targets aspidospermidine 6 and aspidofractinine 7 
share a common disconnection: radical closure of the C ring and, in the case of 
route I, the F ring of aspidofractinine 7 (Scheme 28). This represents a unique 
approach  to  the  total  syntheses  of  these  natural  products  as  the  majority  of 
previous syntheses involve the installation of the C ring prior to the assembly of 
the ABDE core system. Those that install it at a later stage have used indole and 
oxindole
 centres to achieve C / F ring closure rather than radical pathways.
27,32,33 
 
Scheme 28: Our retrosynthetic analysis. 
 
2.1 Radical Translocation 
µ7KHLQWUDPROHFXODUDEVWUDFWLRQRIDQDWRPXVXDOO\K\GURJHQRUJURXSE\DUDGLFDO
FHQWUHWKLVUHVXOWVLQDUHSRVLWLRQLQJRIWKHVLWHRIWKHXQSDLUHGHOHFWURQ¶
34 
 
Direct  activation  of  CH  bonds  is  an  attractive  goal  in  synthetic  chemistry  as  it 
allows targets to be synthesised with little prefunctionalisation and excellent atom 
economy. Thus, radical translocation is a particularly useful process as it allows 
the functionalisation of sites that may otherwise be unreactive. Abstraction usually 
occurs in a 1,5-fashion as this allows reactive conformers to accommodate the 
stereoelectronic preference for an X--H--C bond angle close to 180° (Figure 7). 
The  translocation  step  is  driven  by  the  formation  of  a  more  stable  radical 
intermediate  DQG WKH IRUPDWLRQ RI D UHODWLYHO\ VWURQJ ERQG LH $Uí+ ZKHQ
FRPSDUHGZLWKWKHERQGWKDWLVEURNHQLHDON\Oí+ Chapter 2: Our Strategies 
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Figure 7: 1,5-H atom abstraction. 
Our  initial  approach  was  inspired  by  reports  in  the  literature  of  indolines 
undergoing  radical  translocation.  Whilst  investigating  the  synthesis  of 
phenanthridines using radical cyclisation strategies, Lobo et al. reported that the 
treatment of indoline 180 under radical forming conditions afforded the expected 
debrominated  product  181  and  a  small  amount  of  indole  182  (Scheme  29).
35 
7KHUHIRUHWKHDU\OUDGLFDOSURGXFHGE\KRPRO\VLVRIWKH&í%UERQGPXVWKDYH
undergone  radical  translocation  via  1,5-H  atom  abstraction  to  create  a  radical 
intermediate at C2 of the indoline before aromatisation to afford indole product 
182. 
 
a) Bu3SnH, AIBN, PhH,  . 
Scheme 29 
In  1995  Undheim  and  co-workers  employed  radical  translocation  en  route  to 
Į-substituted amines (Scheme 30).
36 Samarium(II) iodide was used to initiate the 
homolysis of o-benzylhalides, subsequent radical translocation, cross-over to the 
corresponding  organosamarium(II)  intermediate  185  and  finally  addition  to 
pentan-3-one, giving 186. To the best of our knowledge this represents the only 
example  in  the  literature  of  a  C2  indolinyl  radical  resulting  from  radical 
translocation being used for the elaboration of an indoline motif.  
 
a) SmI2, HMPA, THP, Et2CO, 68%. 
Scheme 30: 8QGKHLP¶VUDGLFDOWUDQVORFDWLRQ. Chapter 2: Our Strategies 
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We believed that intramolecular additions of the C2 indolinyl radical could offer 
great  scope for the  synthesis of  new  polycyclic  heterocyclic  ring  systems,  with 
good  regio-  and  diastereocontrol.  In  the  context  of  our  synthetic  ambitions  we 
envisaged  that  functionalisation  at  the  C2  position  via  radical  translocation 
followed by radical addition to a proximal alkene would offer a powerful method for 
the construction of these complex natural ring systems under mild and selective 
conditions.  
 
Applying  this  radical  translocation  /  cyclisation  approach  to  a  retrosynthetic 
analysis of our targets gave indolines 187 and 188 as our key intermediates. We 
believed  that  the  aryl  radical  formed  by  homolysis  of  the  aryl-halide  bond  of 
indoline 187 would undergo translocation via 1,5-H atom abstraction to C2 of the 
indoline. The indolinyl radical would then undergo a 6-endo-trig cyclisation to the 
terminal  alkene  to  establish  the  C  ring  of  aspidospermidine  6  (Scheme  31). 
Moreover, we believed that by subjecting diiodide 188 to the same sequence we 
could  similarly  install  the  F  ring  of  aspidofractinine  7  using  a  double 
activation / tandem cyclisation approach. ﾠ 
 
Scheme 31: Our proposed disconnection for aspidospermidine 6 and aspidofractinine 7. 
Taking into account the rigid molecular framework of the tetracyclic intermediates 
187 and 188, we believed that 6-endo-trig cyclisation rather than the ubiquitous 
5-exo-trig  pathway  was  more  likely.  The  terminal  carbon  of  the  alkene  can 
approach close to the C2 radical centre whereas addition to the internal carbon of 
the  alkene  would  need  to  proceed  via  a  more  strained  reactive  conformer 
(Figure 8).   Chapter 2: Our Strategies 
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Figure 8 
 
2.2 Radical Cyclisation to Pyridine 
Our second strategy was inspired by previous work of the group on the addition of 
carbon-centred radicals to heteroaromatics and, more specifically for this case, the 
addition to pyridyl moieties. The first radical addition to a pyridine was reported by 
Mohlau  and  Berger  in  1893.
37  They  discovered  that  thermal  decomposition  of 
benzene diazonium chloride in pyridine afforded 2-phenylpyridine (18%) as well as 
a trace amount of 4-phenylpyridine. Radical additions to pyridines then received 
little  attention  for  many  years,  presumably  due  to  their  poor  yielding  and 
XQVHOHFWLYHQDWXUH,QWKH¶VLQWHUHVWZDVUHLJQLWHGLQWKHDUHDIROORZLQJZRUN
by Dou and Minisci, who both showed that under acidic conditions such radical 
additions gave dramatically improved yields and regioselectivities.
38,39 
 
It was not until 1989 that the first example of an intramolecular radical addition to a 
pyridyl moiety was reported. Nanni and co-workers reported radical addition to an 
azo group, followed by 6-exo/endo-trig cyclisation to the adjacent pyridine in an 
intramolecular fashion (viz. 190ĺ194, Scheme 32).
40 
 ﾠ
a) di-isopropyl peroxydicarbonate, PhH, 60 °C; b) diethyl azodicarboxylate. 
Scheme 32: Nanni¶VSLRQHHULQJZRUNRQLQWUDPROHFXODUUDGLFDODGGLWLRQs to pyridine. Chapter 2: Our Strategies 
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One year later Murphy et al. reported further intramolecular radical additions to 
S\ULGLQH ULQJ V\VWHPV 7KH\ H[WHQGHG 0LQLVFL¶V SUHYLRXV ZRUN E\ VKRZLQJ WKH
potential for cyclisation to pyridinium salts such as 195 (Scheme 33).
41 
 ﾠ
a) Bu3SnH, AIBN, MeCN/THF, 60%. 
Scheme 33: Murphy¶VLQWUDPROHFXODUF\FOLVDWLRQ 
The Harrowven group were the first to apply intramolecular radical additions to 
pyridine  to  natural  product  synthesis  when  in  1998  they  reported  the first  total 
synthesis of toddaquinoline 200.
42 In their key step arylbromide 197 was subjected 
to  standard  radical  forming  conditions  and  gave  a  separable  1:1  mixture  of 
benzoquinolines  198  (toddaquinoline  methyl  ether)  and  199.  These  products 
resulted from cyclisation of the intermediate aryl radical to C6 and C4 of the pyridyl 
moiety respectively (Scheme 34). 
 
a) Bu3SnH, AIBN, PhMe, 80 °C, 4 h, 198:199 1:1, 58%. 
Scheme 34: Harrowven et al.¶V key radical cyclisation en route to toddaquinoline 200. 
In  2001  Harrowven  et  al.  reported  further  studies  on  radical  cyclisations  to 
pyridines,  noting  that  the  intramolecular  radical  addition  to  the  ȕ-carbon  of  a 
pyridine is a µIDFLOHSURFHVV¶when the aryl radical intermediate and the pyridine are 
linked  by  a  cis-alkene.
43  Treatment  of  azastilbene  201  under  radical  forming 
conditions afforded solely the 6-exo/endo-trig cyclisation product 202 in 47% yield 
(Scheme 35).  Chapter 2: Our Strategies 
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a) Bu3SnH, AIBN, PhMe, 80 °C, 47%. 
Scheme 35 
The authors reported no discernible 5-exo-trig addition in this system. Indeed, a 
5-exo-trig cyclisation product was only isolated when conformational rigidity was 
lost  through  the  reduction  of  the  azastilbene  alkene  to  203.  This  slowed  the 
6-exo/endo-trig cyclisation pathway significantly, with the increased flexibility in the 
tethering chain allowing ipso-substitution to compete (Scheme 36). 
 ﾠ
a) Bu3SnH, AIBN, PhMe, 80 °C, 47%. 
Scheme 36 
The advantages offered by intramolecular radical addition to pyridines over the 
intermolecular  variant  appear  numerous,  with  improvements  in  both  yield  and 
selectivity  being  noted.  Tethering  of  the  radical  precursor  to  the  pyridine  can 
ensure that a radical intermediate is held in close proximity to the pyridine ring. 
This  reduces  the  likelihood  of  potential  intermolecular  side  reactions  and  limits 
regiochemical  outcomes  as  the  radical  is  constrained.  Consequently,  only 
additions  to  adjacent  carbon  centres  are  available.  With  this  in  mind,  the  key 
disconnection for our target, aspidospermidine 6, is detailed in Scheme 37. Chapter 2: Our Strategies 
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Scheme 37: Our proposed disconnection for aspidospermidine 6. 
It is worth noting that vinyl bromide 177 may be cis or trans in configuration as the 
&í%U ERQG LV KRPRO\VHG UHVXOWLQJ LQ D YLQ\O UDGLFDO LQWHUPHGLDWH WKDW LV
configurationally  labile.  Cyclisation  to  the  proximal  pyridine  in  a  6-exo/endo-trig 
fashion  would  construct  the  ABCE  tetracycle,  a  common  intermediate  in  many 
previous syntheses.
25,26,44 The installation of the D ring could then be achieved in a 
number of different ways. For example, a Pummerer reaction as used by Magnus 
and  co-workers (vide  supra  Scheme  10),  the  addition  of 1,2-dibromoethane  as 
used  by  Wenkert  et  al.  (vide  supra  Scheme  19),  or  via  radical  ring  closure 
techniques  as  exemplified  by  Nicolaou  et  al.  in  the  total  synthesis  of 
haplophytine.
16,26,45 
   Chapter 2: Our Strategies 
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Chapter 3: Results and Discussion 
Unified Approach Towards the Total Syntheses of 
Aspidospermidine and Aspidofractinine 
 
With our key disconnection proceeding via indolines 187 and 188, an investigation 
began  on  efficient  means  of  constructing  the  core  ABDE  ring  system.  In  1999 
Carreira  et  al.  reported  the  Lewis  acid-mediated  ring-expansion  of 
cyclopropyloxindoles with imines to form spiro[6.5.5] ring systems (Scheme 38).
46 
 ﾠ
a) MgI2, THF, 125 °C, sealed tube, 19 h. 
Scheme 38: &DUUHLUD¶V0J,2 mediated union. 
The mechanism is thought to proceed via cyclopropyl ring cleavage followed by 
ring-closure,  using  MgI2  both  for the  Lewis  acidity  of  the metal centre  and  the 
nucleophilicity  of  the  iodide  counterion  (Figure  9).  Three  pathways  have  been 
postulated, although pathway I has largely been discounted due to the need for a 
nucleophilic  counterion  (no  reaction  was  observed  with  Mg(OTf)2)  indicating  a 
ring-opening step involving the halide counterion as featured in step A, pathway II 
(viz. 212ĺ217ĺ216) and III (viz. 217ĺ218ĺ214). 
 
Figure 9: Possible mechanistic pathways.
46 Chapter 3: Results and Discussion 
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When  applied  to  our key  intermediate  this  elegant  chemistry  gives  us  our  key 
synthons, namely cyclopropanes 219 and 220 and imine 221 (Scheme 39).  
 
Scheme 39 
 
3.1 Forming the ABDE Core Structure 
Cyclopropane  219  was  synthesised  smoothly  in  three  steps  from  commercially 
available  oxindole  222  in  an overall  yield  of  61%.  N-Benzylation followed  by  a 
modified  Wolff-Kishner  reduction  then  gave  oxindole  224.  Cyclopropanation  by 
means of a double SN2 alkylation with dibromoethane completed the sequence 
(Scheme 40).  
 ﾠ
a) 2-Bromobenzyl bromide, K2CO3, KI, MeCN, RT, 17 h, 98%; b) N2H4+2O,  , 2 h, 90%; c) NaH, 1,2-dibromoethane, 
0 &í57K. 
Scheme 40:  Cyclopropyl oxindole 219 formation.
17 
Due to the complexity involved in preparing divinyl imine 221 a model system was 
sought while an efficient route for its synthesis was developed. The obvious choice 
was cyclic imine 226, which exists as the trimer, 227, and can be prepared in a 
one  pot,  two-step  process  by  oxidation  of  piperidine  225.  In  our  hands  the 
published procedure gave imine 226 in a disappointing 11% yield.
47 Nonetheless, 
the  concise  nature  of  the  synthesis  allowed  large  quantities  to  be  prepared 
(Scheme 41). Chapter 3: Results and Discussion 
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a) AcOH, Ca(OCl)2, H2O07%(í&í57K 
Scheme 41:  Model imine formation. 
 With  the  two  fragments  now  in  hand,  attention  turned  to  the  application  of 
&DUUHLUD¶V/HZLVDFLG-mediated union to our system. Cyclopropane 219 and imine 
226 were heated to 125 °C in THF in a microwave reactor (a slight modification of 
&DUUHLUD¶V FRQGLWLRns  where  heating  was  effected  in  a  sealed  tube)  in  order  to 
reduce the reaction time from nineteen hours to just five (Scheme 42). ﾠ 
 
a) MgI2, THF, ȝW, 125 °C, 5 h, 85% d.r. 88:12*. 
Scheme 42:  Cyclopropyloxindole formation. 
As reported by Carreira, a separable mixture of diastereoisomers was isolated with 
the  minor  isomer,  229,  having  the  correct  configuration  for  the  natural  product 
system.  However,  the  major  isomer  was  taken  on  in  the  synthesis  as  these 
systems  are  known  to  equilibrate  to  the  more  thermodynamically  stable 
arrangement  (that  of  the  natural  product  in  the  Aspidosperma  case)  via  a 
retro-Mannich reaction (Scheme 43).
2,14 This phenomena was noted as early as 
1959 by Wenkert and co-workers. Indeed, many oxindolic alkaloids exist in Nature 
as  pairs  of  interconvertible  isomers  as  a  result  (e.g.  rychnophylline  233  and 
isorychnophylline 235, Figure 10).
í 
 
Scheme 43: Retro-Mannich interconversion of stereochemistry. 
 ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ
* The diastereomeric ratio was determined using isolated masses; NMR analysis could not be used 
to determine a representative ratio. Chapter 3: Results and Discussion 
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Figure 10: Interconversion on heating with acetic anhydride. 
It  is  interesting  to  find  that  this  equilibration  occurs  with  our  model  tetracyclic 
system. On standing for two years at RT as an oil, pure minor diastereoisomer 229 
equilibrated to a diastereomeric mixture of 228 and 229 (d.r. 40:60, determined by 
NMR analysis). The major diastereoisomer 228 remained intact suggesting that it 
is the more stable of the pair (Figure 11). 
 
Figure 11: NMR analysis of equilibrated mixture on standing for 2 years in comparison with pure 
major and minor diastereisomers 228 and 229. 
 
3.2 Lactam Reduction 
With  the  key  ABDE  ring  system  in  place,  our  next  task  was  reduction  of  the 
oxindolic carbonyl to give the indoline. However, this proved more troublesome 
than initially thought. We knew that in the natural product system the intermediate 
oxindole  would  contain  terminal  alkenes,  precluding  reducing  agents  such  as 
borane. Furthermore, it would possess a C±Br bond which could be susceptible to 
reduction using powerful hydride sources such as LiAlH4. Chapter 3: Results and Discussion 
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Initial  investigations  focussed  on  the  reduction  of  a  thiolactam  moiety 
(viz. 238ĺ239),  as  the  reduction  of  the  C=S  bond  can  be  undertaken  using 
conditions conducive to the preservation of alkenes and a &í%UERQG7o model 
the procedure, oxindole 236 was triply methylated to give oxindole 237 in excellent 
yield  (Scheme  44).  Conversion  to  the  thiolactam  was  then  induced  using 
bis(trimethylsilyl)sulfide and phosphorous oxychloride in a modest 43% yield after 
use  of  the  more  staQGDUG /DZHVVRQ¶V UHDJHQW SURYHG  unsuccessful.  Reduction 
ZDV WKHQ FDUULHG RXW XVLQJ 0HHUZHLQ¶V salt  in  conjunction  with  NaBH4  to  give 
indoline 239, albeit in poor yield. 
 
a) NaH, 0H,7+)&íRT, 18 h, 93%; b) POCl3, TMS2S, DCM,  , 18 h, 43%; c) Me3OBF4'&0&í57KWKHQ
NaBH40H2+&í57K. 
Scheme 44: Thiolactam reduction. 
In spite of the poor yields we decided to apply the sequence to the ABDE tetracyle 
228. However, when attempts to transform this into the corresponding thioamide 
failed, our attention returned to methods of effecting the direct reduction of the 
oxindolic carbonyl moiety. Alane (AlH3) as a complex with N,N-dimethylethylamine 
has been reported to be an effective reagent for the reduction of amides to amines 
without loss of halide groups.
51  Pleasingly, when tetracycle 228 was treated with 
alane  the  desired  reduction  was  observed,  giving  indoline  240  in  63%  yield 
(Scheme 45). 
 
b) AlH33K0Hí&í57K 
Scheme 45: Alane reduction. 
Fission  of  the  C12íC19  bond  is  commonplace  in  systems  such  as  these  and 
under  radical  forming  conditions  fragmentation  at  this  bond  can  readily  occur Chapter 3: Results and Discussion 
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(vide infra Chapter 3.1). Thus, our model tetracyclic indoline 240 was subjected to 
standard radical forming conditions to test the robustness of the system under the 
NH\VWHSFRQGLWLRQV3OHDVLQJO\QRIUDJPHQWDWLRQDERXWWKH&í&ERQGZDV
observed,  with  the  reduced  benzylindoline  241  being the  only  isolable  product. 
Thus we were confident that our proposed 6-endo-trig cyclisation to construct the 
ABDE  ring  system  would  not  be  compromised  by  fragmentation  at  C3  of  the 
indoline moiety (Scheme 46). 
 ﾠ
a) Bu3SnH, VAZO, PhMe, 18 h, 89%. 
Scheme 46 
However, the presence of the terminal alkenes in the natural product system must 
also  be  considered.  Therefore,  3,3-diallyloxindole  242  was  synthesised  as  a 
representative system on which to test our reduction conditions. This was easy to 
prepare  as  a  double  alkylation  of  oxindole  224  with  allyl  bromide  first  gave 
3,3-diallyloxindole  242  which,  on  treatment  with  alane  underwent  reduction  in 
excellent yield with complete alkene preservation (Scheme 47). 
 ﾠ
a) NaH, allyl bromide, DMF, RT, 16 h, 73%; b) AlH33K0Hí&í57K 97%. 
Scheme 47 
 
3.3 Synthesis of the Key Cyclic Imine  
Our  work  towards  gem-divinyl  imine  221  began  with  an  already  established 
route,
17 utilising a sulfoxide moiety and subsequent elimination to install the two 
vinyl groups. Double alkylation of dimethyl malonate with phenyl vinyl sulfoxide Chapter 3: Results and Discussion 
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followed  by  decarboxylation  and  Michael  addition  with  acrylonitrile  is  used  to 
introduce the carbon backbone of imine 221. The synthesis is then completed by 
thermal elimination of the sulfoxide moieties followed by cyclisation (Scheme 48). 
 ﾠ
Scheme 48 
Pleasingly,  double  Michael addition of dimethyl malonate  246  with  phenyl vinyl 
sulfoxide 247 proceeded smoothly in good yield and on large scale (Scheme 49). 
 ﾠ
a) 1D+'0)&í57G 
Scheme 49 
Malonate  245  was  then  subjected  to  an  elegant  one  pot  Krapcho 
decarboxylation / Michael addition sequence, installing the required three carbon 
chain.  Treatment  with  NaI  in  DMF  at  120  °C  in  the  presence  of  an  excess  of 
acrylonitrile afforded the desired nitrile 244 along with a number of both useful and 
benign side-products (Scheme 50). 
 ﾠ
a) NaI, acrylonitrile, DMF, 120 °C, 12 h, 21% 244, 7% 248, 5% 249, 22% 250. 
Scheme 50 
The  array  of  different  products  is  a  result  of  the  reaction  temperature.  A  high 
temperature  is  needed  to  affect  the  decarboxylation;  however,  the  following 
thermal elimination step also occurs at high temperatures, leading to the formation 
of  elimination  side-products  at  this  stage.  Attempts  to  optimise  the  reaction  by Chapter 3: Results and Discussion 
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prolonging  reaction  times  (>12  h)  led  to  greater  formation  of  elimination 
side-products 249 and 250.  
 
Thermolysis of the bissulfoxide moieties of 244 proceeded in modest yield to give 
gem-divinyl  248.  Pleasingly,  when  subjected  to  the  thermolysis  conditions, 
side-product 250 also gave gem-divinyl 248 (Scheme 51). 
 ﾠ
a) DMF, 120 °C, 5 h, 40%; b) DMF, 120 °C, 5 h, 76%. 
Scheme 51 
A sequence of functional group manipulations, namely ester reduction, oxidation, 
acetal protection and nitrile reduction then afforded the unmasked amine 254 in 
four  steps  (Scheme  52).  However,  the  yields  for  both  reduction  steps  were 
extremely capricious (viz. 248ĺ251, 253ĺ254), presumably due to the number of 
other functional groups present that may be susceptible to reduction. In addition, 
the  final  one  pot  deprotection  /  cyclisation  sequence  proved  to  be  both  poor 
yielding and unreliable. It is also worth drawing attention at this point to our use in 
the first  step of phenyl  vinyl sulfoxide. When  considering  its  role  is  to  install  a 
two-carbon  vinyl  group,  it  is  not  only  an  expensive  reagent  but  also  an  atom 
inefficient process. 
 ﾠ
a) LiAlH47+)í °C, 6 h, í92%; b) DMP, CHCl3, RT, 4 h, 96%; c) (CH2OH)2, pTSA, PhMe, Dean and Stark, 6 h, 95%; 
d) LiAlH4, THF, 60 °C, 4 h, í96%; e) 10% HCl, Et2O, 2 h, then 10% NaOH, 2.5 h, í34%. 
Scheme 52 
In response to the problems inherent to the sulfoxide route, investigations began 
into  alternative  imine  formation  strategies.  Inspiration  was  taken  from  Hoveyda 
and  co-ZRUNHUV¶ HQDQWLRVHOHFWLYH  synthesis of  (+)-quebrachamine  8,  reported  in Chapter 3: Results and Discussion 
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2009.
52 The key step in their synthesis was a catalytic enantioselective RCM of 
divinyl 255 (Scheme 53). 
 ﾠ
a) 257, PhH, RT, 1 h, 84%, 96% e.e.; b) PtO2, H2, EtOH, RT, 1 h, 97%. 
Scheme 53: Hoveyda and co-workers enantioselective RCM.
52 
It was the divinyl moiety that sparked our interest, the efficient installation of which 
is  nontrivial.  Hoveyda  and  co-workers  effected  catalytic  ring-opening  /  cross 
metathesis (ROCM) of spirocyclic lactone 259 in the presence of ethylene to give 
the required gem-divinyl functionality, a protocol we hoped to exploit in our efforts 
towards imine 221. By accessing divinyl lactone 258 XVLQJ+RYH\GD¶VURXWHZH
hoped to complete the construction of imine 221 via the opening of lactone 258 
followed by the application of our original end game (Scheme 54).  
 
Scheme 54: Our revised retrosynthetic analysis of imine 221. 
Thus,  Į-acetylbutyrolactone  260,  was  treated  with  sodium  azide  and  triflic 
anhydride to form the triflyl azide in situ, which in turn gave diazo lactone 261 in 
37%  yield  (Scheme  55).  Cyclopropenation  to  262  was  then  investigated  using 
trimethylsilylacetylene as described by Hoveyda et al. Alas, this too proved to be 
poor yielding in comparison to that reported by Hoveyda et al. (viz. 260ĺ261 66%, 
261ĺ262  64%)  giving  just  12%  yield.  We  believe  that  the  poor  yield  of  the 
cyclopropenation reaction was due to poor solubility of diazo 261 in the reaction 
medium,  trimethylsilylacetylene,  an  observation  not  noted  by  Hoveyda  and  co-
workers. No success was found optimising the cyclopropenation reaction by the 
addition of co-solvents. Given that it was to be the starting point of our synthetic 
sequence, an alternative tactic was sought. Chapter 3: Results and Discussion 
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a) NaN3, TBAB, NaOH, Tf2O, hexanes:MeCN (~1:1), 0 °C, 30 min, 37%; b) Rh2(OAc)4, trimethylsilyl acetylene,  , 16 h, 
12%. 
Scheme 55 
In  an  approach  more  akin  to  our  original  strategy  we  decided  to  attempt  the 
cyclopropenation with diazo malonate 263 (formed in modest yield from dimethyl 
malonate 246 using an established literature procedure (Scheme 56)). Pleasingly, 
in  this  case  the  cyclopropenation  reaction  proceeded  smoothly  to  give 
cyclopropene 264 in 78% yield, a significant improvement on the previous route. It 
is worth noting that the solubility of diazo 263 in trimethylsilyl acetylene was not an 
issue for this transformation, confirming our belief that the poor solubility of diazo 
lactone 261 was responsible for its poor conversion. Finally, desilylation furnished 
the desired cyclopropene 265 in 58% yield. 
 ﾠ
a) p-toluenesulfonyl azide, Et2NH, Et22&í57KERh2(OAc)4, trimethylsilyl acetylene,  , 1.5 h, 78%; c) KOH, 
EtOH, 0 °C, 5 min, 58%. 
Scheme 56 
Despite  the  successful  installation  of  the  cyclopropene  moiety,  attempts  to 
progress  intermediate  265  towards  imine  221  using  our  original  Krapcho 
decarboxylation / Michael addition sequence failed. Alternative strategies to install 
the three-carbon chain on intermediate 265 were also attempted but all proved to 
be unsuccessful (Scheme 57).  
 ﾠ
a) NaI, acrylonitrile, DMF, 120 °C, 12 h; b) NaOMe, MeCN, ClPh,  KF',%$/+í&í57'&0K 
Scheme 57 Chapter 3: Results and Discussion 
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Reduction  of  the  ester  functionality  to  aldehyde  268  afforded  a  variety  of 
unidentifiable  products,  none  of  which  contained  the  desired  aldehyde  moiety, 
whereas attempts to install the nitrile group to give 266 returned only unreacted 
starting material.  
As an alternative strategy we proposed the application of ROCM chemistry to the 
already  formed  six-membered  ring  of  piperidine-2,4-dione  273.  Thus, 
tbutyl-protected  piperidine-2,4-dione  273  was  synthesised  in  three  steps  from 
methyl  acrylate  269  in  an  overall  yield  of  11%  (Scheme  58).  Diazotisation 
proceeded smoothly to afford 274 in 75% yield, which was then subjected to the 
cyclopropenation  conditions.  However,  we  were  again  thwarted  by  solubility 
issues, obtaining cyclopropene 275 in a disappointing 9% yield. 
 ﾠ ﾠ
a) 
tBuNH2, MeOH, RT, 60 h, 67%; b) pivaloyl chloride, Et2O, 0 °C, 4 h, then Et3N, dimethylaminopyridine&í57K
25%; c) NaH, cyclohexane:PhMe (4:1),  45 min then AcOH,  , 3 h, 64%; d) p-toluenesulfonyl azide, Et2NH, Et2O, 0 
&í57K; e) Rh2(OAc)4, trimethylsilyl acetylene,  , 2 h, 9%. 
Scheme 58 
 
3.4 Conclusions 
A method for construction of the ABDE ring system was identified and validated on 
a model system. An efficient route to the prerequisite AB cyclopropane 219 has 
been  established  as  well  as  for  the  model  imine  226,  albeit  in  poor  yield.  In 
addition, a reducing agent for the transformation of the oxindole into the required 
indoline moiety has been identified, this being tolerant to the presence of both 
alkenes and aryl-halide bonds. Chapter 3: Results and Discussion 
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Attempts at improving an already identified route towards imine 221 met with little 
success,  with  a  more  concise  and  atom  economical  route  proving  elusive.  A 
synthesis of imine 221 was undertaken using our established route, wherein the 
gem-divinyl moiety was installed via sulfoxide elimination. However, time and a 
limited  quantity  of  material  prevented  its  application  in  a  Lewis  acid-mediated 
union with cyclopropane 219, and its further elaboration to the natural product ring 
systems. Chapter 4: Results and Discussion 
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Chapter 4: Results and Discussion 
Probing the Chemistry of the Indolinyl Radical 
 
CH activation leading to VHOHFWLYH&í&ERQGIRUPDWLRn with no prefunctionalisation 
is  an  attractive  goal  for  the  synthetic  chemist.  It  is  particularly  attractive  in 
heterocyclic  chemistry  owing  to  their  ubiquitous  presence  in  natural  and 
pharmaceutical products. To that end the functionalisation of indoles and indolines 
has been a significant focus for organic chemistry, and CH activation is a logical 
extension  of  this.  CH  activation  protocols  as  well  as  transition  metal-catalysed 
coupling  reactions  have  been  reported  to  install  aryl,  alkyl,  alkynyl  and  vinyl 
substituents directly onto indoles.
í Intramolecular radical additions to C2 and 
C3  of  the  indole  moiety  have  also  been  reported.
56-62  By  contrast,  the  direct 
functionalisation of indolines has received less attention, with limited examples of 
transition  metal-catalysed  processes  and  only  one  example  via  radical 
translocation to C2 of an indoline (vide supra Chapter 2.1).
í 
 
4.1 Prior Art 
In order to demonstrate the utility of the indolinyl radical as a means of indoline C2 
funtionalisation, initial studies had been undertaken.
17 Notably, when indoline 276 
was treated under standard radical forming conditions tricycle 280 was formed in 
good yield following the desired translocation / cyclisation sequence. Even more 
interesting was that under the same conditions indoline 277 underwent a double 
activation / tandem cyclisation sequence to afford azapropellane 279 in excellent 
yield (Scheme 59). 
 ﾠ
a) Bu3SnH, VAZO, PhMe,  76% d.r. 6:1; b) Bu3SnH, VAZO, PhMe,  90% d.r.1:1. 
Scheme 59: Prior investigations into funtionalisation via the indolinyl radical.
17 Chapter 4: Results and Discussion 
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Intriguingly, when 3,3-dibenzylindoline 281 was exposed to the same conditions, 
the anticipated cyclisation of the indolinyl radical to the proximal aryl group to give 
283  was  outpaced  by  fragmentation  of a  benzyl substituent  to  give  indole  282 
(Scheme 60). This curious result led us to propose that the fate of the indolinyl 
radical was dependent upon its C3 substitution pattern. As such, a study into the 
influence of substitution on the indoline on the radical pathway was carried out. 
 ﾠ
a) Bu3SnH, VAZO, PhMe, 90 °C 95%. 
Scheme 60: Alternative pathway for the indolinyl radical.
17 
 
4.2 Synthesis of the Indolinyl Precursors 
To initiate that study, an array of methyl, alkyl and benzyl substituted indolines 
were synthesised. Our plan was to access 3,3-disubstituted indolines by means of 
a double alkylation of N-benzylated oxindole 224, previously synthesised in two 
steps from isatin (vide supra Chapter 3.1). Monosubstituted analogues would be 
accessed using Aldol reaction of oxindole 236 followed by alkene and oxindole 
reduction (Scheme 61). 
 ﾠ
Scheme 61: Retrosynthetic analysis for indoline substitution. Chapter 4: Results and Discussion 
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Dimethylated indoline 289 was synthesised in two steps from  oxindole 224 via 
double alkylation with methyl iodide followed by reduction with alane in good yield 
(74%). A small quantity of monomethylated product 288 was also isolated from the 
alkylation  step  (Scheme  62).  As  the  method  gave  sufficient  material  for  our 
purposes, optimisation was not deemed necessary. The C3 unsubstituted variant 
was also synthesised in two steps from benzyl alcohol 290. Thus, iodination to 
diiodide 291 proceeded in near quantitative yield followed by transformation of the 
benzyl alcohol to the benzyl chloride using thionyl chloride (viz. 291ĺ292), again 
in excellent yield. Coupling with indoline then gave the desired radical precursor 
293 in modest yield (Scheme 63). 
 ﾠ
a) NaH, MeI, DMF, RT, 16 h, 40% 287, 11% 288; b) AlH3, PhMe, RT, 3 h, 74%. 
Scheme 62 
 ﾠ
a) I2, CF3CO2Ag, CHCl3&í57KE62&O2'&0&í57KFLQGROLQH.2CO3, KI, acetone,  , 
16 h, 41%. 
Scheme 63 
Synthesis of the monosubstituted  indolines began with oxindole 236. For these 
examples the N-bromobenzyl moiety was installed at a later stage in the synthesis, 
after alkene reduction had taken place, to avoid possible problems associated with 
aryl  bromide  reduction.  Thus,  oxindole  was  subjected  to  Aldol  reaction  with 
acetone  and  benzaldehyde  to  afford  Įȕ-unsaturated  oxindoles  294  and  295 
respectively (Scheme 64). Reduction of alkene 294 by hydrogenation was then 
achieved in excellent yield to give 296. Further reduction of the oxindolic carbonyl Chapter 4: Results and Discussion 
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then afforded the desired indoline 297 (33%) and indole 298 (27%). Indoline 297 
was  N-benzylated  with  2-bromobenzyl  bromide  to  afford  the  desired  precursor 
299. Similarly,  after  N-benzylation  and  reduction  of 296  in  a  one  pot,  two-step 
process,  C3-benzylated  oxindole  300  was  synthesised  in  good  yield.  Alane 
reduction, again in poor yield (30%), gave the desired indolinyl radical precursor 
301.  It  is  interesting  to  note  that  the  reduction  of  these  oxindoles  to  the 
corresponding  indolines  proved  low  yielding  when  monosubstituted  at  C3.  This 
being in stark contrast to the good to excellent yields obtained for those substrates 
with  C3  disubstitution.  Presumably  this  is  a  consequence  of  elimination  of  the 
intermediate aluminium alkoxide. 
 ﾠ
a) RR
1CO, piperidine, EtOH,  , 4 h, 67% R=R
1=Me and 86% R=H, R
1=Ph; b) H2, 10% Pd / C, MeOH:DCM (1:1), RT, 4 h, 
100%; c) BH3'067+)&í57 h, 33% 297 and 27% 298; d) 2-bromobenzyl bromide, K2CO3, KI, MeCN, RT, 12 h, 
62%; e) 2-bromobenzyl bromide, K2CO3, KI, MeCN, RT, 12 h, then Zn dust, conc. HCl, RT, 16 h, 64%; f) AlH3, PhMe, 
í78 &í57KJ1D+DOO\OEURPLGH'0)&í57 h, 29% 302 and 21% 303; h) AlH33K0Hí &í57K
71%. 
Scheme 64 
Monobenzylated oxindole 300 was subjected to a second alkylation using NaH 
and allyl bromide to give disubstituted oxindole 302. O-allyl oxindole 303 was also Chapter 4: Results and Discussion 
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isolated in 21% yield as a result of aerial oxidation (Scheme 64). Reduction of 302 
then gave indoline 304, synthesised with the view to carrying out a competition 
experiment under the indolinyl radical forming conditions.  
 
With 3,3-diallylindoline 243 already in hand (vide supra Chapter 3.2) synthesis of 
spiro-analogue  306  was  investigated.  Treating  3,3-diallylindoline  243  with 
Hoveyda-*UXEEV¶,,FDWDO\VW failed to produce any of the desired spirocyclopentene 
306  (Scheme  65).  Therefore  3,3-diallyloxindole  242  was  instead  treated  with 
Hoveyda-*UXEEV¶,,FDWDO\VW at reflux and pleasingly oxindole 305 was isolated in 
88%  yield.  Reduction  of  the  carbonyl  with  alane  completed  the  synthesis  of 
indoline 306 in excellent yield (98%). 
 ﾠ
a) cat. Hoveyda-*UXEEV¶,,3K0H , 22 h, 88%; b) AlH3, PhMe, í78 &í57K 
Scheme 65 
The  final  indolinyl  radical  precursor,  methyl  ester  309,  was  synthesised  to 
investigate the effect of C2 radical stabilisation through conjugation. Commercially 
available  carboxylic acid  307  was  esterified  and  then  N-benzylated  to  give  the 
desired indoline 309 in good yield (Scheme 66). 
 ﾠ
a) SOCl2, MeOH,  , 2 h, 84%; b) 2-bromobenzyl bromide, K2CO3, KI, MeCN, RT, 12 h, 61%. 
Scheme 66 
 
4.3 Indolinyl Radical Reactions 
With all the desired indolinyl radical precursors in hand, each one was subjected to 
the standard radical forming conditions, namely heating a toluene solution of the 
compound at reflux with tributyltin hydride and VAZO as the initiator (Scheme 67). Chapter 4: Results and Discussion 
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The outcome was clear:  fragmentation of C3 benzyl and allyl substituents was 
facile  (see  entries  d  and  e,  Scheme  67),  outpacing  fragmentation  of  alkyl 
substituents  and  hydrogen  atoms.  Allyl  fragmentation  proved  more  facile  than 
benzyl fragmentation in the competition experiment (viz. 314ĺ315+316, Scheme 
68).
66 
 ﾠ
a) Bu3SnH, VAZO, PhMe,  , 18 h. 
Scheme 67: C2 indolinyl radical investigations. 
 ﾠ
a) Bu3SnH, VAZO, PhMe,  , 18 h. 
Scheme 68 
Interestingly,  when  spirocyclopentene  306  was  subjected  to  radical  forming 
conditions no fragmentation was observed (Scheme 69). Reduced product 317 is 
presumed to have formed via radical translocation followed by H-atom abstraction 
from tributyltin hydride.  
 ﾠ
a) Bu3SnH, VAZO, PhMe,  , 18 h, 58%. 
Scheme 69  
We believe that the increased rigidity inherent to the spirocyclic systems restricts 
the orbital overlap, therefore favouring the reductive pathway. It can be seen from Chapter 4: Results and Discussion 
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Figure  12  that  in  the  spirocyclic  system,  whilst  good  nĺı&í& overlap  can  be 
attainedWKHı&í&ĺʌ&í&overlap is poor causing fragmentation to be a disfavoured 
process,  being  more  akin  to  reaction  of  an  alkyl  substituent.  By  way  of  a 
comparison,  the  fragmentation  of  3,3-diallylindoline  243  does  occur  rapidly 
(viz. 243ĺ313e)  due  to  the  good  overlap  that  can  be  attained  throughout  the 
allylic system DVDUHVXOWRIURWDWLRQDOIUHHGRPDERXWWKHı-bonds (Figure 12). 
 
Figure 12: Illustration of orbital overlap in the spirocyclic and allylic systems. 
The same effect was seen previously on the ABDE tetracyclic system (vide supra 
Chapter 3.2). In addition to the orbital overlap effect seen above, we believe that 
the poorer stabilisation that would be given by the adjacent nitrogen to the radical 
product favours the reductive pathway in this case (Scheme 70). 
 ﾠ
a) Bu3SnH, VAZO, PhMe, 18 h, 89%. 
Scheme 70 
Interestingly  when  the  indolinyl radical  was  stabilised  by  conjugation,  loss  of a 
hydrogen  atom  from  C3  did  compete  with  H-atom  abstraction  from  tributyltin 
hydride.  Indeed,  both  the  reduced  and  oxidised  products  320  and  321  were 
formed in a ~3:1 ratio (Scheme 71). This is a significant result when compared 
with the near exclusive formation of the reduced product 312a in the analogous 
reduction of the unstabilised indoline 310a
* (Scheme 67).
 
 ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ ﾠ
*  When  subjected  to  radical  forming  conditions  indoline  310a  gave  reduced  product  312a  in 
excellent yield (95%). In addition, a trace of the tetracyclic product arising from cyclisation of the 
aryl radical to the C2 position was also formed (5%). It can be therefore be inferred that trace 
amounts of the oxidised indole product 313a were formed, despite none being isolated. ﾠChapter 4: Results and Discussion 
60 ﾠ
 ﾠ
 ﾠ
a) Bu3SnH, VAZO, PhMe,  . 
Scheme 71 
4.4 Conclusions 
A  variety  of  indolinyl  radical  precursors  were  successfully  synthesised  using 
alkylation  and  Aldol  reactions.  All  indolines  were  subjected  to  standard  radical 
forming conditions to access the C2 indolinyl radical via aryl radical formation and 
translocation.  We  conclude  that  the  fate  of  the  indolinyl  radical  is  indeed 
determined  by  the  substitution  at  C3  of  the  indoline,  with  hydrogen,  methyl, 
primary and secondary alkyl substituents resisting fragmentation. However, when 
C3 bears a substituent capable of stabilising a radical leaving group we instead 
see cleavage and formation of the indole product (e.g. benzyl, allyl). This is also 
true  of  indolines  unsubstituted  at  C3  but  stabilised  at  the  C2  position  through 
conjugation. In such cases fragmentation at C3 appears more facile, perhaps as a 
result of a slowing of the rate of H-atom abstraction from tributyltin hydride. Chapter 5: Results and Discussion 
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Chapter 5: Results and Discussion 
Radical Cyclisation to Pyridine 
 
Having chosen to install the C ring via radical cyclisation to a pyridyl moiety, work 
began on the development of a synthetic route to the key radical precursor, vinyl 
bromide 177. It was envisaged that a Stille coupling between the indole and pyridyl 
fragments would provide the most efficient access to this system.  
 
5.1 Synthesis of the Stille Coupling Partners 
Initial  investigations  into  the  synthesis  of  suitable  Stille  coupling  partners  were 
carried  out  on  N-methylindole  322  while  an  efficient  route  to  the  1H-indole 
analogue  was  sought.  Thus,  N-methylindolecarbaldehyde  322  was  brominated 
with  NBS  to  afford  323  in  excellent  yield.  Stannylation  with  in  situ  aldehyde 
protection as the Į-amino lithium alkoxide afforded stannane 325, albeit in low 
yield (Scheme 72).
67 It is worth noting that all synthesised stannanes and reactions 
containing  tin  residues  were  purified  using  our  K2CO3  /  silica  chromatographic 
purification technique.
68 
 ﾠ
a) NBS, DMF, RT, 20 h, 94%; b) N,O-dimethylhydroxylamine, nBuLií&íí&KWKHQnBu3SnCl, RT, 16 h, 44%. 
Scheme 72 
With the stannylated indole 325 in hand, attention then turned to the synthesis of 
the  complimentary  coupling  partners,  that  is  the  halide  moiety  on  the  indole 
fragment and the stannane moiety on the pyridyl fragment. Commercially available 
indole-2-carboxylic acid 326 was transformed in a two-step, one pot process to 
aldehyde 327 via the acid chloride. However, as this yielded only 19% over the 
two  steps,  alternative  procedures  were  investigated.  To  that  end,  a  three-step 
procedure  involving  esterification  to  328,  reduction  to  alcohol  329  and  allylic 
oxidation to aldehyde 327 was developed giving a more reasonable 62% overall 
yield (Scheme 73). Chapter 5: Results and Discussion 
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a) SOCl27+)&í&KWKHQPRO3GPPh3)4, Bu3SnH, THF, RT, 1 h, 19% over two steps; b) H2SO4, EtOH,  , 
20 h, 92%; c) LiAlH47+)í&í&KG0Q22, BaMnO4, DCM, RT, 5 d., 68%; e) NBS, DMF, RT, 20 h, 96%; 
f) I2, KOH, DMF, RT, 1.5 h, 99%. 
Scheme 73 
Halogenation of aldehyde 327 then proceeded smoothly and in excellent yield to 
afford  bromoindole  330  and  iodoindole  331  in  96%  yield  and  near  quantitative 
yield  respectively  (Scheme  73).  The  stannyl  coupling  partner  for  the  model 
system, pyridine 333, was synthesised in one step from commercially available 
2-bromopyridine 332 via halogen-lithium exchange and quenching with tributyltin 
chloride (Scheme 74). 
 ﾠ
a) nBuLi, Bu36Q&O7+)í&í57K 
Scheme 74 
 
5.2 Stille Coupling 
The Stille reaction is the palladium-catalysed CíC bond forming reaction between 
an organostannane and an organic electrophile.
69 It is one of the most general 
transformations  in  organic  synthesis,  displaying  high  selectivity  and  broad 
functional group tolerance, making it particularly appealing to the field of natural 
product synthesis.
70 
 
Attempts to effect the coupling of bromopyridine 332 with the stannylated indole 
325  failed  to  afford  any  product.  This  is  perhaps  not  unsurprising  when  the 
electronics of the Stille reaction are considered. The oxidative insertion step is Chapter 5: Results and Discussion 
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most efficient when the halogenated fragment is electron-poor in nature. Similarly, 
in the transmetallation step it is preferable for the stannane to be electron-rich. 
This ideal is more akin to the coupling of haloindoles  330 and 331 with pyridyl 
stannane  333  so  we  hoped  this  would  offer  an  improvement.  Indeed,  upon 
treatment of bromoindole 330 and stannane 333 with 10 mol% Pd(PPh3)4 in the 
presence of stoichiometric copper(II) oxide desired biaryl 334 was isolated, though 
in  a  disappointing  38%  yield.  Fortunately,  iodoindole  331  had  also  been 
synthesised and its coupling with pyridyl stannane 333 was realised in an excellent 
98% yield (Scheme 75).  
 
a) Pd(PPh3)4, CuO, DMF,  , 16 h, 38%; b) Pd(PPh3)4, CuI, DMF, RT, 2 d., 98%. 
Scheme 75 
Copper(I)  additives  have  been  shown  to  dramatically  affect  the  rate  of  Stille 
FRXSOLQJUHDFWLRQV7KHILUVWIRUD\LQWRWKHµFRSSHUHIIHFW¶ZDVE\/LHEHVNLQGDQG
Farina,  who  concluded  that  the  effect  of  copper(I)  salts  was  dependent  upon 
reaction solvent.
71 In ethereal solvents the copper(I) salt acts as a scavenger for 
the neutral ligand (in this case PPh3) released prior to the oxidative insertion step, 
preventing the retardation effect these free ligands would otherwise have on the 
rate-determining transmetallation step. In polar solvents, e.g. DMF, it is thought 
that  a  second  transmetallation  pathway  comes  into  play.  Thus,  the 
organostannane  first  reacts  with,  in  this  case  copper  iodide,  to  afford  an 
iodostannane  by-product  and  a  reactive  organocuprate  that  then  undergoes 
transmetallation in the usual fashion.
72 
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5.3 Ethyl Group Installation 
With  Stille  coupling  partners  331  and  333  now  in  hand  and  conditions  for  the 
coupling  identified,  attention  turned  to  the  incorporation  of  the  ethyl  group 
necessary for the natural product synthesis. It was envisaged that the ethyl group 
could  be  accessed  from  aldehyde  335  using  a  Wittig  olefination  followed  by 
reduction  of  the  resultant  alkene.  Thus,  aldehyde  335  was  prepared  by  direct 
formylation of 2-bromopyridine 332 with DMF (Scheme 76).  
 
a) LDA, DMF, í&íRT, 16 h, 33%. 
Scheme 76 
Despite  the  literature  precedent  for  this  step  and  even  with  extremely  careful 
temperature control this reaction proved to be capricious, with yields ranging from 
í
73 Whilst aldehyde 335 is commercially available, its cost is prohibitive in 
this  case  so  an  alternative  strategy  was  sought.  Radical  bromination  of 
3-methyl-2-bromopyridine  336  with  NBS  in  the  presence  of  substoichiometric 
VAZO and bromine afforded the monobrominated and dibrominated substrates, 
337 and 338 respectively, as a 1:4 mixture. Although the minor product was only 
isolated in 9% yield, on large scales this constitutes an appreciable quantity of 
material. Therefore oxidation and hydrolysis conditions for the conversion of both 
bromination products 337 and 338 to aldehyde 335 were identified (Scheme 77). 
 
a) NBS, VAZO, Br2, PhCF3,  , 3 h; b) NMO, MeCN, RT, 3 h, 61%; c) CaCO3, H2O,  , 15 h, 53%. 
Scheme 77 
A Wittig reaction between aldehyde 335 and methyltriphenylphosphonium bromide 
proceeded smoothly under standard conditions to afford alkene 339 in good yield. Chapter 5: Results and Discussion 
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Treatment  with  p-tosylhydrazide  and  NaOAc  in  refluxing  THF  /  water  formed 
diimide in situ and this smoothly reduced the pendant alkene to afford the desired 
ethyl substituted pyridine 340 in 75% yield after 7 days. 3-Ethyl-2-bromopyridine 
340  was  then  subjected  to  the  stannylation  conditions  identified  for  the  model 
system and, pleasingly, stannane 341 was produced in good yield (Scheme 78). 
 
 
a) nBuLi, MePPh3Br, THF, &íRT, 18 h, 88%; b) ptosyl hydrazine, NaOAc, THF / H2O (1:1),  , 7 d., 75%; c) nBuLi, 
Bu36Q&O7+)í&í573 h, 87%. 
Scheme 78 
Iodoindole  331  and  stannane  341  were  then  subjected  to  the  Stille  conditions 
established  in  the  model  system.  To  our  delight,  the  conditions  proved  to  be 
successful  providing  the  desired  biaryl  342  in  82%  yield  after  18  h  at  RT 
(Scheme 79). 
 
a) Pd(PPh3)4, CuI, DMF, RT, 18 h, 82%. 
Scheme 79: Stille coupling. 
 
5.4 Wittig Olefination 
Owing  to  the  commercial  availability  of  bromomethyltriphenylphosphonium 
bromide,  a Wittig  reaction  was  examined  to  install  the  important  vinyl  bromide 
moiety.
74 Thus, aldehyde 334 was treated with bromomethyltriphenylphosphonium 
bromide in the presence of potassium tbutoxide to afford the desired vinyl bromide 
as a cis / trans inseparable mixture along with side-product dibromoalkene 343 
(Scheme  80).  Despite  the  modest  yield,  no  unreacted  aldehyde  334  was 
recovered. As we had observed significant starting material by TLC analysis we Chapter 5: Results and Discussion 
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postulated that aldehyde 334 was unstable towards silica. Indeed, the purification 
procedure  used  in  the  preparation  of  aldehyde  334  was  our  K2CO3  /  silica 
technique used to remove the organotin residues from the Stille reaction, implying 
an acid-sensitivity. Consequently when subsequent Wittig reactions were purified 
with this basified stationary phase (10% w/w anhydrous K2CO3-silica), aldehyde 
334 was recovered, completing the mass balance. 
 ﾠ
a) BrCH2PPh3
+Br
- (2.2 eq), KO
t%XHT7+)í&í57K3% 343, 24% 343:344:345 (1:1.8:0.2), 6% 344:345 
(1:0.4), or BrCH2PPh3
+Br
- (1.5 eq), NaHMDS (1.3 eq), THF, RT, 16 h, 20% 343, 31% 343:344:345 (1:1.5:1), 22% 334. 
Scheme 80 
Optimisation of reaction conditions met with limited success, with most attempts 
resulting in little or no improvement. Our best conditions utilised a different base, 
namely  NaHMDS,  reaction  stoichiometry  and  addition  sequence,  namely 
preformed ylide was added to aldehyde 334. In addition to an increased yield of 
cis- and trans-alkenes 344 and 345, we also observed an increase in the formation 
of  dibromoalkene  343.  This  is  perhaps  unsurprising  considering  our  proposed 
mechanism, as a slight excess of phosphonium salt is now present. 
 
We  believe  that  dibromoalkene  343  is  formed  from  reaction  of  ylide  347  with 
another molecule of its unreacted self to form dibrominated phosphonium salt 349 
(Scheme 81). In turn, this can undergo the Wittig reaction with aldehyde 334. This 
mechanism is supported by Chapleur et al. who reported the first preparative use 
of this reaction in 2001.
75 Indeed, until their investigations there had only been a 
few  reports  in  the  literature for the formation  of  such a  side-product.
76,77  Using 
phosphorous NMR to follow the course of the reaction, Chapleur et al. were able 
to identify five phosphorylated species after phosponium salt 346 had been treated 
with  KO
tBu  in  THF  for  2  h.  The  identified  species  were  ylide  347  (12.5 ppm), 
phosphonium  salt  346  (14  ppm),  triphenylphosphine  oxide  (21.6  ppm), 
phosphonium  salt  352  (22.5  ppm)  and  dibrominated  phosphonium  salt  349 
(26.7 ppm). The authors noted that no traces of phosphorane 351 were detected Chapter 5: Results and Discussion 
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LQDQ\VWXGLHVFRQFOXGLQJDµUDSLG\OLGHH[FKDQJH¶EHWZHHQ351 and 349, favouring 
the formation of phosphorane 350 and methyltriphenylphosphonium salt 352. This 
provided  strong evidence for the postulated  mechanism  above,  rather than  the 
alternative  method  for  formation  initially  suggested  by  Chapleur,  namely 
electrophilic bromination of the monobromoalkene followed by elimination to give 
the dibromoalkene.  
 ﾠ
Scheme 81: Postulated mechanism for the formation of dibromoalkene 343. 
Using our optimised Wittig conditions a similar study was carried out, analysing the 
reaction of phosphonium salt 346 with NaHMDS at RT by 
31P NMR at various time 
intervals (Figure 13).  
 ﾠ
Figure 13: 
31P NMR spectra of phosphonium salt 346 (1.5 eq.) with NaHMDS (1.3 eq.) in THF. Chapter 5: Results and Discussion 
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Pleasingly,  signals  indicative  of  dibrominated  phosphonium  salt  formation  were 
identified. Although no direct spectral evidence for the presence of dibrominated 
phosphonium  salt  349  could  be  detected  at  the  time  intervals  analysed,  the 
formation  of  phosphonium  salt  352  (22.4  ppm)  was  evident  at  t=15  h.  The 
formation  of  dibrominated  phosphonium  salt  349  can  be  inferred  from  the 
observed presence of methyltriphenylphosphonium salt 352, which ties in with the 
mechanistic postulate. 
 
Phosphonium iodide 356 was also synthesised in 95% yield during the course of 
the Wittig optimisation studies. However, when used in the Wittig reaction no vinyl 
iodide  product  357  was  isolated  (Scheme  82).  The  low  yielding  Wittig 
transformation  could  be  due  to  either  the  steric  bulk  of  the  system  or  pyridyl 
1ĺ
+PR4  coordination.  To  ascertain  whether  either  of  these  explanations  was 
indeed  affecting  the  Wittig  transformation,  phenyl  substituted  indole  359  was 
synthesised  by  the  Stille  coupling  of  iodide  331  and  trimethylphenyltin  358 
(Scheme 83). Indole 359 was formed as an inseparable mixture with unreacted 
iodide  331.  However,  when  subjected  to  the  Wittig  conditions  no  product  was 
observed. As a result we suspect the reason for the poor Wittig yield to be a steric 
issue rather than one resulting from N-coordination. 
 ﾠ
a) PhMe, 100 °C, 20 h, 95%; b) ﾠICH2PPh3
+I
-, NaHMDS7+)í&íRT, 16 h. 
Scheme 82 
 ﾠ
a) Pd(PPh3)4, CuI, DMF,  , 3 h, 41% as a 1.2:1 (359:331) inseparable mixture. 
Scheme 83 Chapter 5: Results and Discussion 
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5.5 Radical Cyclisation 
With  key  precursors  344  and  345  in  hand,  our  investigation  of  the  key  radical 
cyclisation began. As the first action of the radical cyclisation process is homolysis 
of  the  CíBr  bond,  and  it  is  known  that  vinyl  radical  intermediates  are 
configurationally labile, mixtures of cis / trans / dibromoalkene 344, 345 and 343 
were subjected to the radical forming conditions. When vinyl bromide (as a 5:1 
cis /  trans  mixture)  was  treated  with  tributyltin  hydride  and  VAZO  at  reflux  a 
precipitate  was  observed.  Interestingly  pyridinium  salt  361  had  been  formed  in 
60%  yield,  rather  than  the  desired  6-exo/endo-trig  cyclisation  product 
(Scheme 84).  To  the  best  of  our  knowledge  pyridinium  salt  361  represents  a 
unique structural motif. 
 ﾠ
a) Bu3SnH, VAZO, PhMe,  , 16 h, 60%. 
Scheme 84 
Subsequently we discovered that the tributyltin hydride used in the reaction had 
decomposed  prior  to  use.  Consequently,  the  rearrangement  of  vinyl  bromides 
344 / 345 to the condensed heteroaromatic 361 was, in all probability, induced by 
thermolysis.  This  led  us  to  postulate  that  pyridinium  salt  361  arose  from  a 
6ʌ-electrocyclisation reaction followed by rearomatisation with loss of bromide in a 
manner akin to that outlined in Scheme 85. It is worth noting that although this 
OHDGVWRDORVVRIDURPDWLFLW\LQERWKKHWHURF\FOLFULQJVWKHµHQDPLQH¶QDWXUHof the 
indole should accelerate the 6ʌ-electrocyclisation process.  
 ﾠ
Scheme 85: Postulated mechanism. ﾠChapter 5: Results and Discussion 
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In repeating the reaction with fresh reagents, we hoped that the desired radical 
cyclisation reaction might outpace the 6ʌ-electrocyclisation, allowing us access to 
the  desired  ABCE  ring  system  of  aspidospermidine  6.  As  such,  a  mixture  of 
bromoalkenes  343,  344  and  345  (1:1.5:1)  was  heated  at  reflux  with  tributyltin 
hydride  and  radical  initiator  VAZO  (Scheme  86).  Pleasingly,  considerably  less 
pyridinium salt 361 was isolated. However after 16 h at reflux, and despite the 
complete  consumption  of  vinyl  bromide,  none  of  the  desired  6-exo/endo-trig 
product was observed. Furthermore, vinyl stannane 363 was isolated as a minor 
by-product.  The  remainder  of  the  mass  balance  was  attributed  by  crude  NMR 
analysis  to  be  terminal  alkene  364,  resXOWLQJ IURP HLWKHU &í%UERQG KRPRO\VLV
followed by H-atom abstraction from tributyltin hydride or, protodestannylation of 
363, although it was not possible to isolate this product. 
 ﾠ
a) Bu3SnH, VAZO, PhMe,  , 16 h. 
Scheme 86 
 
5.6 Conclusions 
The key intermediates for both the model and natural product systems, aldehydes 
334  and  342,  were  successfully  synthesised  using  high  yielding 
palladium-catalysed coupling reactions. In addition, robust routes to the individual 
Stille  coupling  partners  were  identified.  A  Wittig  reaction  then  provided  small 
quantities of the key intermediate vinyl bromides 343, 344 and 345 in the model 
system, though their synthesis in large quantities was precluded due to a low yield 
even after optimisation. 
The  key  radical  cyclisation  was  investigated  on  the  model  system  with  little 
success.  However,  an  interesting  product  arose  as  a  result  of  competing 
6ʌ-electrocyclisation. This provided tetracyclic pyridinium salt  361 as the major 
product which, to the best of our knowledge, represents a unique structural motif. 
Work is currently ongoing to investigate the scope of the 6ʌ-electrocyclisation with 
a variety of N-containing heterocycles. Chapter 6: Experimental 
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Chapter 6: Experimental 
 
6.1 General Experimental 
Melting Points: Melting points were recorded on Reichert Austria apparatus and 
are uncorrected. 
NMR Spectra:Proton (
1H) and carbon (
13C) spectra were recorded on a Bruker 
AVX300 (300/75 MHz) or Bruker DPX400 (400/100 MHz) spectrometer at 298 K 
unless otherwise stated. Chemical shifts are quoted in parts per million downfield 
of tetramethylsilane with residual solvent as the internal standard. Assignments 
were made on the basis of chemical shifts, coupling constants, DEPT-135, COSY, 
HMQC, HMBC and comparison with spectra of related compounds. Resonances 
are described as s (singlet), d (doublet), t (triplet), q (quartet), app. (apparent) and 
br. (broad). Coupling constants (J) are given in Hz and are rounded to the nearest 
0.1 Hz. 
Infrared  Spectra:  Infrared  spectra  were  recorded  neat  as  an  oil  film  or  solid 
compression using the ATR/golden gate method. Absorption maxima (ȣmax) are 
described  as  s  (strong),  m  (medium)  and  w  (weak)  and  are  quoted  in 
wavenumbers (cm
-1). 
Mass Spectra: ESI mass spectra were recorded using a VG Platform Quadrupole 
Electrospray  Ionisation  mass  spectrometer,  measuring  mono-isotopic  masses 
(mode: ES+ or ES-). EI and CI were measured on a Thermoquest Trace MS. m/z 
values are reported with their percentage abundance relative to the most intense 
signal and, where known, the relevant fragment ion in parentheses. Values for the 
most abundant isotope combination are reported. High resolution mass spectra 
were recorded by Dr. John Langley or Ms. Julie Herniman at the University of 
Southampton  and  are  calculated  to  four  decimal  places  from  the  molecular 
formula. 
Chromatography  Techniques:  Thin  layer  chromatography  was  performed  on 
Merck  DC-Alufolien  60  F254  0.2  mm  precoated  plates.  Product  spots  were 
visualised by UV fluorescence (Ȝmax=254 nm) then stained and heated using, most Chapter 6: Experimental 
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commonly, 5% potassium permanganate in 5% aqueous NaOH solution or  6% 
vanillin in ethanol as appropriate. Flash column chromatography was carried out 
on silica gel (200±400 mesh) with the solvent system used given in parentheses. 
Solvents  and  Reagents:  Commercially  available  reagents  were  purchased  and 
used without further purification. THF and diethyl ether were freshly distilled and 
dried over a purple solution of sodium and benzophenone, toluene and acetonitrile 
were  freshly  distilled  over  sodium  and  dichloromethane  and  chloroform  were 
distilled and dried over CaH2 immediately prior to use. 
   Chapter 6: Experimental 
73 ﾠ
 ﾠ
6.2 Experimental Procedures for Chapter 3 
1-(2-Bromobenzyl)-1H-indole-2,3-dione (223) 
 
To a solution of isatin 222 (2.00 g, 13.6 mmol) in acetonitrile (100 mL) was added 
K2CO3  (3.76 g,  27.2 mmol)  and  KI  (230 mg,  1.36 mmol).  After  45  min, 
2-bromobenzyl  bromide  (3.40 g,  13.6 mmol)  in  acetonitrile  (30 mL)  was  added 
dropwise over 30 min.  After 17 h ethyl acetate (100 mL) and water (100 mL) were 
added and the phases separated.  The aqueous phase was extracted with ethyl 
acetate (3 × 100 mL) then the combined organic phases were washed with brine 
(100 mL),  dried  (MgSO4)  and  the  solvent  removed  in  vacuo  to  afford  the  title 
compound  as  an  orange  solid  (4.19 g,  13.3 mmol,  98%).  These  data  are  in 
accordance with those reported in the literature.
17 
 
MP   177í181°C (EtOH), Lit. 180±182 °C (EtOH).
17 
Xmax  3334 (w), 3097 (w), 2930 (w), 1735 (s), 1643 (m), 1610 
(s), 1530 (m), 1470 (m), 1439 (w), 1373 (m), 1350 (m), 
1279 (w), 1197 (w). 
GH (300 MHz, CDCl3)   7.67±7.50 (2H, m, 2 × ArH), 7.43 (1H, app. td, J=7.8, 1.3 
Hz,  ArH),  7.26±6.95  (4H,  m,  4  ×  ArH),  6.67  (1H,  d, 
J=7.7 Hz, ArH), 4.98 (2H, s, NCH2Ar). 
GC (75 MHz, CDCl3)   182.9 (C=O), 158.4 (C=O) 150.5 (C), 138.5 (CH), 133.2 
(CH), 129.6 (CH), 128.1 (CH), 128.1 (CH), 125.5 (CH), 
124.1  (CH),  122.8  (C),  117.7  (C),  111.1  (CH),  44.0 
(CH2).N.B.  One  quaternary  signal  not  discreetly 
observed. 
LRMS (ES
+)  
79Br: 338 ([M+Na]
+, 100%). 
 
   Chapter 6: Experimental 
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1-(2-Bromobenzyl)-1,3-dihydroindol-2-one (224) 
 
A  suspension  of  N-benzylated  isatin  223  (3.28 g,  10.4 mmol)  in  hydrazine 
monohydrate (20 mL) was heated at reflux for 2 h, then cooled to RT and poured 
into ice water (100 mL).  Following extraction with ethyl acetate (4 × 100 mL), the 
combined organic phases were washed with brine (100 mL), dried (MgSO4) and 
the  solvent  removed  in  vacuo  to  afford  the  title  compound  as  an  orange  solid 
(2.83 g, 9.37 mmol, 90%).  These data are in accordance with those reported in 
the literature.
17 
 
MP   88-97°C (EtOH), Lit. 102±104°C (EtOH).
17 
Xmax   3057 (w), 1710 (s), 1615 (m), 1489 (m), 1466 (m), 1440 
(w), 1376 (w), 1348 (m), 1310 (w), 1268 (w), 1227 (w) 
1196 (w), 1169 (w), 1098 (w). 
GH (300 MHz, CDCl3)   7.52 (1H, dd, J=7.7, 1.1 Hz, ArH), 7.22 (1H, d, J=7.6 Hz, 
ArH),  7.17±7.02  (3H,  m,  3  ×  ArH),  7.01±6.92  (2H,  m, 
2 × ArH), 6.59 (1H, d, J=7.8 Hz, ArH), 4.95 (2H, s, CH2), 
3.61 (2H, s, CH2). 
GC (75 MHz, CDCl3)   175.2  (C=O),  144.0  (C),  134.5  (C),  132.9  (CH), 
129.0 (CH), 128.0 (CH), 127.8 (CH), 127.7 (CH), 124.5 
(CH), 124.3 (C), 122.8 (C), 122.6 (CH), 109.2 (CH), 43.8 
(CH2), 35.8 (CH2). 
LRMS (ES
+)  
79Br: 324 ([M+Na]
+, 100%). 
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¶-(2-Bromobenzyl)-spirocyclopropane-¶-indol-¶-one (219) 
 
To a solution of oxindole 224 (2.77 g, 9.17 mmol) in DMF (50 mL) at 0 °C was 
added  NaH  (60%  in  mineral  oil,  810 mg,  20.2 mmol).    After  1  h  at  0 °C, 
1,2-dibromoethane (3.16 mL, 36.7 mmol) was added dropwise over 5 min.  The 
reaction  mixture  was  warmed  to  RT  and  after  72  h  water  (100 mL)  and  ethyl 
acetate (100 mL) were added and the phases separated.  The aqueous phase 
was extracted with ethyl acetate (100 mL).  The combined organic phases were 
washed  with  water  (4  ×  100 mL)  and  brine  (200 mL),  then  dried  (MgSO4)  and 
concentrated in vacuo.  Purification by column chromatography (10% ethyl acetate 
in  hexanes)  afforded  the  title  compound  as  an  orange  solid 
(2.06 g, 6.28 mmol, 69%).  These data are in accordance with those reported in 
the literature.
17 
 
MP   129-131°C (EtOAc/hexanes), Lit. 115±117 °C (EtOH).
17 
Xmax  3057 (w), 1709 (s), 1615 (m), 1568 (w), 1489 (m), 1466 
(s), 1440 (m), 1420 (w), 1369 (s), 1349 (m), 1309 (w), 
1264 (w), 1230 (w), 1178 (s), 1122 (w). 
GH (300 MHz, CDCl3)   7.51  (1H,  dd,  J=7.9,  1.3  Hz,  ArH),7.15±7.00  (3H,  m, 
3 × ArH),  6.99±6.88  (2H,  m,  2  ×  ArH),6.80  (1H,  d, 
J=7.3 Hz, ArH), 6.65 (1H, d, J=7.7 Hz, ArH), 5.01 (2H, s, 
NCH2Ar), 1.94±1.76 (2H, m, CHHCHH), 1.57±1.43 (2H, 
m, CHHCHH). 
GC (75 MHz, CDCl3)   177.3  (C=O),  142.4  (C),  134.8  (C),  132.9  (CH),  130.7 
(C),  128.9  (CH),  127.8  (CH),  127.7  (CH),  126.8  (CH), 
122.7  (C),  122.3  (CH),  118.4  (CH),  109.0  (CH),  44.1 
(CH2), 27.1 (C), 19.5 (2 × CH2). 
LRMS (ES
+)  
79Br: 350 ([M+Na]
+, 100%). Chapter 6: Experimental 
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2,3,4,5-Tetrahydropyridine (226) 
 
To a solution of piperidine 225 (4.60 mL, 47.0 mmol) in water (4 mL) was added 
glacial acetic acid (3.80 mL, 61.6 mmol). This solution was then added dropwise to 
a slurry of calcium hypochlorite (4.64 g,32.4 mmol) stirred in water (10 mL) and 
MTBE  (10  mL)  at  10  ºC  over  10  min.    After  0.5  h  the  organic  phase  was 
separated and a solution of KOH (3.80 g, 68.8 mmol) in MeOH (10 mL) added 
dropwise at 0 ºC over 15 min.  The reaction mixture was warmed to RT and stirred 
for 16 h. The resultant precipitate was isolated by filtration, washed with methanol 
and the filtrate concentrated in vacuo.  The residue and precipitate were combined 
in water (100 mL) and extracted with diethyl ether (3 × 80 mL). The combined 
organic  phases  were  washed  with  brine  (100  mL),  dried  (MgSO4),  then 
concentrated in vacuo to give a pale yellow oil.  The oil was taken up in acetone 
(10 mL) and cooled to ±20 ºC overnight. The resultant precipitate was isolated by 
filtration and washed with cold acetone to afford the title compound as a white 
solid  (433 mg, 5.21  mmol,  11%).    These  data  are  in  accordance  with  those 
reported in the literature.
47 
 
MP    50±54°C (acetone) 
Xmax  2930 (s), 2856 (m), 2813 (w), 2783 (w), 2725 (w), 1446 
(m), 1378 (w), 1343, (w), 1312 (w), 1286 (w), 1271 (w), 
1257 (w), 1240 (s), 1204 (w), 1188 (m), 1157 (w). 
GH (300 MHz, CDCl3)  3.21±3.00  (3H,  m,  NCH),  2.81  (3H,  m,  3  ×  NCHH),          
2.10±1.97  (3H,  m,  3  ×  NCHH),  1.80±1.47  (15H,  m, 
3 × CH2CH2CHH), 1.40±1.10 (3H, m, 3 × CHH). 
GC (75 MHz, CDCl3)  81.9  (CH),  46.3  (CH2),  29.1  (CH2),  25.7  (CH2),  22.2 
(CH2). 
LRMS (ES
+)  167 ([2M+H]
+, 100%), 250 ([M+H]
+, 6%). 
 Chapter 6: Experimental 
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rel-(1'S,8'aR)-Spiro[3H-indole-3,1'(5'H)-indolizin]-2(1H)-one,2',3',6',7',8',8'a-
hexahydro-1-(2-bromobenzyl)(228)  and  rel-(1'R,8'aR)-spiro[3H-indole-
3,1'(5'H)-indolizin]-2(1H)-one,2',3',6',7',8',8'a-hexahydro-1-(2-
bromobenzyl)(229) 
 
A  solution  of  cyclopropane  219  (100 mg,  0.31 mmol),  imine  226  (67 mg, 
0.27 mmol) and MgI2 (36 mg, 0.13 mmol) in THF (2 mL) was degassed for 30 min.  
The reaction vessel was then heated under microwave irradiation (150 W, 125 °C) 
for 5 h.  After cooling to RT water (10 mL) and ethyl acetate (10 mL) were added.  
The aqueous phase was separated and extracted with ethyl acetate (2 × 10 mL), 
then  the  combined  organic  phases  were  washed  with  brine  (20 mL),  dried 
(MgSO4)  and  concentrated  in  vacuo.    Purification  by  column  chromatography 
(40% ethyl acetate in hexaneVíPHWKDQROLQHWK\ODFHWDWH) afforded firstly 228 
as  a  colourless  oil  (80 mg,  0.20 mmol,  74%)  and  then  229  as  a  colourless  oil 
(11 mg,  0.03 mmol,  11%)  in  a  diastereomeric  ratio  of  88:12  based  on  isolated 
mass. 
 
Data for 228: 
Xmax  2931 (m), 2855 (w), 2793 (w), 1716 (s), 1612 (m), 1486 
(m), 1466 (m), 1440 (m), 1382 (m), 1359 (m), 1318 (w), 
1263 (w), 1200 (w), 1171 (m), 1150 (w), 1113 (w). 
GH (300 MHz, CDCl3)  7.52 (1H, dd, J=7.8, 1.4 Hz, ArH), 7.40 (1H, d, J=7.4 Hz, 
ArH),  7.16±7.01  (3H,  m,  3  ×  ArH),  6.98  (1H,  app.  td, 
J=7.5, 1.1 Hz, ArH), 6.89 (1H, dd, J=7.5, 1.7 Hz, ArH), 
6.56  (1H,  d,  J=7.5  Hz,  ArH),  5.03  (1H,  d,  J=16.7  Hz, 
NCHHAr),  4.85  (1H,  d,  J=16.7  Hz,  NCHHAr),           
3.34±3.20 (1H, m, NCHH), 3.15 (1H, app. d, J=10.6 Hz, Chapter 6: Experimental 
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NCHH),  2.55±2.39  (2H,  m,  NCH2),  2.36  (1H,  ddd, 
J=15.1, 9.2, 2.3 Hz, NCH), 2.11±1.93 (2H, m, 2 × CHH), 
1.68±1.47 (2H, m, 2 × CHH), 1.46±1.26 (1H, m, CHH), 
1.25±1.01 (3H, m, 3 × CHH). 
GC (75 MHz, CDCl3)   179.9  (C=O),  141.9  (C),  134.7  (C),  133.5  (C),  133.0 
(2 × CH),  128.9  (CH),  127.7  (CH),  127.6  (CH),125.0 
(CH), 122.8 (C) 122.6 (CH), 108.7 (CH), 72.1 (CH), 56.6 
(C), 54.2 (CH2), 53.6 (CH2), 43.9 (CH2), 35.1 (CH2), 26.5 
(CH2), 25.1 (CH2), 23.7 (CH2). 
LRMS (ES
+)  
79Br: 411 ([M+H]
+, 99%). 
HRMS  C22H24BrN2O  [M+H]
+  requires  411.1067;  found: 
411.1066. 
 
Data for 229: 
Xmax  3057  (w),  2924  (m),  2853  (w),  2788  (w),  2364  (w), 
1716(s), 1612 (m), 1488 (m), 1467 (m), 1441 (m), 1355 
(m), 1267 (w), 1171 (m), 1113 (w), 1028 (w), 749 (m). 
GH (300 MHz, CDCl3)  7.60  (1H,  dd,  J=7.8,  1.3  Hz,  ArH í + P
6 × ArH),  6.60  (1H,  d,  J=8.0  Hz,  ArH),  5.17  (1H,  d, 
J=16.9 Hz, NCHHAr), 4.86 (1H, d, J=16.9 Hz, NCHHAr), 
í+PNCHHí+PNCHH), 
2.60±2.40 (2H, m, NCH2í+PNCH), 2.14±
1.86  (2H,  m,  2  ×  CHH),  1.84±1.39  (4H,  m,  4 × CHH), 
1.34 (1H, m, CHH), 1.20±1.05 (1H, m, CHH). 
LRMS (ES
+)  
79Br: 411 ([M+H]
+, 99%). 
HRMS  C22H24BrN2O  [M+H]
+  requires  411.1067;  found: 
411.1070. 
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1,3,3-Trimethyloxindole (237) 
 
To a solution of oxindole 236 (1.00 g, 7.51 mmol) in THF (24 mL) was added NaH 
(1.20 g, 30.0 mmol) and MeI (1.64 mL, 26.3 mmol) at 0°C.  The reaction mixture 
was warmed to RT and after 18 h was poured onto saturated NH4Cl (40 mL) and 
the  aqueous  phase  extracted  with  DCM  (3  ×  20  mL).    The  combined  organic 
phases were dried (MgSO4) and concentrated in vacuo.  Purification by column 
chromatography (30%ethyl acetate in petroleum ether) afforded the title compound 
as a pale red oil (1.23 g, 7.02 mmol, 93%).  These data are in accordance with 
those reported in the literature.
79 
 
Xmax  2967 (w), 2927 (w), 1702 (s), 1612 (s), 1492 (m), 1471 
(m), 1459 (m), 1382 (m), 1373 (m), 1347 (m), 1305 (m), 
1247 (m), 1195 (w), 1157 (w). 
GH (300 MHz, CDCl3)  7.27 (1H, app. td, J = 7.5, 1.3 Hz, ArH), 7.21 (1H, dd, 
J=7.3,  0.9  Hz,  ArH),  7.07  (1H,  app.  td,  J=7.5,  0.9  Hz, 
ArH),  6.85  (1H,  d,  J=7.7  Hz,  ArH),  3.22  (3H,  s,  CH3), 
1.38 (6H, s, CH3). 
GC (75 MHz, CDCl3)  181.4  (C=O),  142.6  (C),  135.8  (C),  127.6  (CH),  122.4 
(CH), 122.2 (CH), 108.0 (CH), 44.1 (C), 26.1 (CH3), 24.3 
(2 × CH3). 
LRMS (ES
+)  198([M+Na]
+, 100%). 
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1,3,3-Trimethyl-1,3-dihydroindole-2-thione (238) 
 
To a solution of oxindole 237 (115 mg, 0.66 mmol) in DCM (2 mL) was added 
POCl3 (0.12 mL, 1.32 mmol) dropwise over 5 min.  The reaction mixture was then 
heated at reflux for 2.5 h, then cooled to RT and TMS2S (0.43 mL, 2.05 mmol) 
added.  After a further 18 h at reflux the reaction mixture was cooled to RT and 
concentrated in vacuo.  Purification by column chromatography (2% diethyl ether 
in  petroleum  ether)  afforded  the  title  compound  as  a  pale  yellow  oil  (54  mg, 
0.28 mmol,  43%).    These  data  are  in  accordance  with  those  reported  in  the 
literature.
80 
 
Xmax  2967 (w), 2923 (w), 2860 (w), 1613 (m), 1600 (w), 1458 
(m), 1429 (m), 1364 (s), 1306 (s), 1259 (m), 1154 (m), 
1106 (s), 1071 (w). 
GH (300 MHz, CDCl3)  7.39±7.29  (2H,  m,  ArH),  7.24±7.15  (1H,  m,  ArH),  7.06 
(1H, d, J=7.7 Hz, ArH), 3.67 (3H, s, CH3), 1.45 (6H, s, 
CH3). 
GC (75 MHz, CDCl3)  211.9  (C=S),  143.8  (C),  140.4  (C),  127.8  (CH),  124.2 
(CH), 122.7 (CH), 109.5 (CH), 54.9 (C), 31.4 (CH3), 28.0 
(2 × CH3). 
LRMS (ES
+)  192 ([M+H]
+, 100%). 
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1,3,3-Trimethyl-2,3-dihydro-1H-indole (239): 
 
To a solution of thioamide 238 (134 mg, 0.70 mmol) in DCM (3 mL) at 0°C was 
added Me3O
+BF4
- (108 mg, 0.73 mmol) and then warmed to RT.  After 18 h the 
reaction mixture was concentrated in vacuo to afford an off-white solid which was 
then taken up in methanol (3 mL).  NaBH4 (68 mg, 1.79 mmol) was then added at 
0 °C and after 10 min was warmed to RT.  After 4 h 2 M HCl (4 mL) was added 
and  after  a  further  5  min  the  reaction  mixture  was  basified  with  2  M  NaOH 
(~pH 10).  The reaction mixture was extracted with diethyl ether (3 × 20 mL) and 
the combined organic phases washed with brine (40 mL), then dried (MgSO4) and 
concentrated in vacuo.  Purification by column chromatography (15±25% DCM in 
petroleum  ether)  afforded  the  title  compound  as  a  colourless  oil  (12  mg, 
0.074 mmol,  11  %).   These  data  are  in  accordance  with  those  reported  in  the 
literature.
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Xmax  3024 (w), 2954 (m), 2858 (m), 2801 (m), 2158 (w), 2025 
(w), 1607 (m), 1490 (m), 1461 (m), 1422 (w), 1385 (w), 
1372 (w), 1298 (m), 1279 (m), 1261 (m), 1200 (m). 
GH (300 MHz, CDCl3)  7.13 (1H, app. t, J=7.7 Hz, ArH), 7.05 (1H, d, J=7.0 Hz, 
ArH),  6.74  (1H,  app.  t,  J=7.3  Hz,  ArH),  6.52  (1H,  d, 
J=8.1 Hz,  ArH),  3.10  (2H,  s,  CH2),  2.79  (3H,  s,  CH3), 
1.34 (6H, s, CH3). 
GC (75 MHz, CDCl3)  152.0  (C),  139.2  (C),  127.2  (CH),  121.5  (CH),  117.8 
(CH), 107.3 (CH), 70.3 (CH2), 40.2 (C), 36.0 (CH3), 27.4 
(2 × CH3). 
LRMS (ES
+)  162 ([M+H]
+, 100%). 
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rel-¶SD¶R)-1-(2-Bromobenzyl)-¶¶¶¶¶D¶-hexahydro-¶H-spiro[indo-
line-¶-indolizine] (240) 
 
To a solution of 228 (80 mg, 0.19 mmol) in toluene (2 mL) at ±78 °C was added 
AlH3 (0.5 M in toluene, 0.96 mL, 0.48 mmol) dropwise over 5min.  After a further 
20 min the reaction mixture was warmed to RT for 4 h and then cooled to 0 °C. 
Methanol (1 mL) was added dropwise and then 1 M HCl (1 mL).  The reaction 
mixture was basified with saturated NaHCO3 (~pH 10) and extracted with ethyl 
acetate (3 x 10 mL).  The combined organics were washed with brine (30 mL), 
dried (MgSO4) and concentrated in vacuo.  Purification by column chromatography 
(25±40% ethyl acetate in hexanes) afforded the title compound as a colourless oil 
(49 mg, 0.12 mmol, 63%). 
 
Xmax  3047 (w), 2928 (m), 2852 (w), 2781 (w), 1716 (w), 1604 
(m), 1568 (w), 1486 (m), 1460 (m), 1440 (m), 1380 (w), 
1343 (m), 1152 (m), 1108 (w), 1087 (w), 1024 (m). 
GH (400 MHz, CDCl3)  7.57 (1H, d, J=7.8 Hz, ArH), 7.37 (1H, d, J=7.5 Hz, ArH), 
7.30±7.22(2H, m, 2 × ArH), 7.13 (1H, app. td, J=7.6, 1.1 
Hz, ArH), 7.05 (1H, app. td,  J=7.6, 1.1 Hz, ArH), 6.71 
(1H, app. t,J=7.1 Hz, ArH), 6.41 (1H, d, J=7.7 Hz, ArH), 
4.36 (1H, d, J=16.1 Hz, NCHHAr), 4.20 (1H, d, J=16.1 
Hz,NCHHAr), 3.39 (1H, d, J=9.0 Hz, NCHH), 3.33 (1H, d, 
J=9.0 Hz, NCHH), 3.24±3.05 (2H, m, 2 × NCHH), 2.27±
2.11 (2H, m, 2 × NCHH), 1.99±1.85 (2H, m, CHH and 
NCH),  1.80  (1H,  d,  J=10.6  Hz,  CHH),  1.68  (1H,  d, 
J=12.8Hz, CHH), 1.60±1.37 (3H, m, 3 × CHH), 1.15 (1H, 
qt, J=12.9, 4.0 Hz, CHH), 1.02±0.82 (1H, m, CHH). Chapter 6: Experimental 
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GC (100 MHz, CDCl3)
  150.7 (C), 136.5 (C), 134.8 (C), 131.8 (CH), 128.30 (CH), 
127.50 (CH), 126.44 (2 x CH), 123.97 (CH), 122.46 (C), 
116.85  (CH),  105.65  (CH),  73.38  (CH),  64.96  (CH2), 
53.05 (CH2), 52.95 (CH2), 52.83 (CH2), 51.50 (C), 37.21 
(CH2), 25.39 (CH2), 24.26 (CH2), 23.15 (CH2). 
LRMS (ES
+)  
79Br: 397 ([M+H]
+, 100%). 
 
 
rel-¶SD¶R)-1-Benzyl-¶¶¶¶¶D¶-hexahydro-¶H-spiro[indoline-¶-
indolizine] (241) 
 
A solution of 240 (35 mg, 0.09 mmol), tributyltin hydride (0.05 mL, 0.20 mmol) and 
VAZO (5 mg, 0.02 mmol) in toluene (4 mL) was heated at reflux for 18 h, then 
cooled  and  concentrated  in  vacuo.    Purification  by  column  chromatography 
(10% w/w anhydrous K2CO3-silica; 25% ethyl acetate in hexanes) afforded the title 
compound  as  a  colourless  oil  (25 mg,  0.08 mmol,  89%).  These  data  are  in 
accordance with those reported in the literature.
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Xmax  3029 (w), 2931 (m), 2854 (w), 2360 (w), 1712 (w), 1603 
(m), 1487 (m), 1453 (m), 1359 (w), 1259 (m), 1152 (w), 
1075 (w), 1046 (w), 1026 (w). 
GH (300 MHz, CDCl3)   7.34±7.16  (6H,  m,  6  ×  ArH),  7.01  (1H,  app.  td, 
J=7.6, 1.3 Hz,  ArH),  6.65  (1H,  app.  td,  J=7.4,  0.9  Hz, 
ArH),  6.43  (1H,  d,  J=7.8  Hz,  ArH),  4.26  (1H,  d, 
J=14.9 Hz,  NCHHPh),  4.08  (1H,  d,  J=14.9  Hz, 
NCHHPh), 3.23 (1H, d, J=9.1 Hz, NCHH), 3.15 (1H, d, 
J=9.1 Hz, NCHH),3.13±3.00 (2H, m, 2 × NCHH), 2.19±
2.00 (2H, m, 2 × NCHH), 1.92±1.29 (7H, m, 6 × CHH and Chapter 6: Experimental 
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NCH), 1.09 (1H, app. qt,  J=12.7, 4.0 Hz,  CHH), 0.97±
0.77 (1H, m, CHH). 
GC (75 MHz, CDCl3)
  152.0 (C), 138.6 (C), 136.0 (C), 128.5 (2 × CH), 127.8 
(2 ×  CH),  127.4  (CH),  127.0  (CH),  125.0  (CH),  117.7 
(CH),  106.7  (CH),  74.4  (CH),  65.5  (CH2),  54.1  (CH2), 
53.9 (CH2), 53.5 (CH2), 52.3 (C), 38.1 (CH2), 26.4 (CH2), 
25.3 (CH2), 24.2 (CH2). 
LRMS (ES
+)  319 ([M+H]
+, 100%. 
 
 
3,3-Diallyl-1-(2-bromobenzyl)indolin-2-one (242) 
 
To  a  solution  of  224  (1.00 g,  3.31 mmol)  in  DMF  (50 mL)  was  added  NaH 
(60% in mineral oil, 0.331 g, 8.28 mmol) at RT.  After 2 h allyl bromide (0.72 mL, 
8.28 mmol) in DMF (10 mL) was added dropwise over 15 min.  After 16 h water 
(75 mL) and ethyl acetate (75 mL) were added and the phases separated.  The 
aqueous phase was then extracted with ethyl acetate (2 x 75 mL).  The combined 
organics were washed with water (250 mL), brine (250 mL), then dried (MgSO4) 
and  concentrated  in  vacuo.    Purification  by  column  chromatography  (25±50% 
DCM  in  petroleum  ether)  afforded  the  title  compound  as  a  yellow  solid 
(922 mg, 2.41 mmol, 73%). 
 
MP  118±121 °C. 
Xmax  3057 (w), 2905 (w), 1700 (s), 1641 (w), 1614 (m), 1568 
(w), 1490 (m), 1466 (s), 1440 (m), 1383 m), 1366 (m), 
1349 (m). 
GH (300 MHz, CDCl3)   7.62±7.55  (1H,  m,  ArH),  7.29±7.02  (6H,  m,  ArH),  6.62 
(1H,  app.  dq,  J=7.7,  0.6  Hz,  ArH),  5.57±5.41  (2H,  m, Chapter 6: Experimental 
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2 x CH2CH=CH2),  5.06  (2H,  ddt,  J=17.0,  2.1,  1.2,  Hz, 
2 x CH2CH=CHH),  4.98  (2H,  ddt,  J=10.0,  2.0,  0.8  Hz, 
2 x CH2CH=CHH),  4.99  (2H,  d,  J=0.5  Hz,  NCH2Ar), 
2.75±2.58 (4H, m, 2 x CH2CH=CH2). 
GC (75 MHz, CDCl3)   134.5 (C), 132.8 (CH), 132.4 (2 x CH), 131.1 (C), 128.9 
(CH), 128.0 (CH), 127.9 (CH), 127.5 (CH), 123.4 (CH), 
122.5 (CH), 119.1 (2 x CH2), 109.0 (CH), 53.0 (C), 43.7 
(CH2), 41.5 (2 x CH2), N.B. Three Quaternary signals not 
observed. 
LRMS (ES
+)  
79Br: 785 ([2M+Na]
+, 29%), 404 ([M+Na]
+, 100%). 
HRMS  C21H21BrNO requires 382.0801; Found: 382.0808. 
 
 
3,3-Diallyl-1-(2-bromobenzyl)indoline (243) 
 
To a solution of 242 (113 mg, 0.30 mmol) in toluene (3 mL) at ±78 °C was added 
AlH3 (0.5 M in toluene, 1.2 mL, 0.60 mmol) dropwise.  After 20 min the reaction 
mixture was warmed to RT for 4 h and then cooled to 0 °C.  Methanol (1.5 mL) 
was  added  dropwise  and  then  1  M  HCl  (1.5  mL).    The  reaction  mixture  was 
basified with saturated NaHCO3 (~pH 10) and extracted with ethyl acetate (3 x 10 
mL).  The combined organics were washed with brine (30 mL), dried (MgSO4) and 
concentrated  in  vacuo  to  afford  the  title  compound  as  a  yellow  oil 
(105 mg, 0.29 mmol, 97%). 
 
Xmax  3676 (w), 3647 (w), 3628 (w), 3071 (w), 2976 (w), 2913 
(w), 2838 (w), 2359 (m), 2341 (m), 2194 (w), 2177 (w), 
2158 (m), 2035 (w), 2012 (w), 1969 (w), 1942 (w), 1716 
(w), 1698 (w), 1605 (m), 1489 (s), 1459 (m), 1439 (m). Chapter 6: Experimental 
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GH (300 MHz, CDCl3)  7.48  (1H,  dd,  J=7.9,  1.1  Hz,  ArH),  7.32  (1H,  dd, 
J=7.6, 1.5  Hz,  ArH),  7.18  (1H,  app.  td,  J=7.5,  1.1  Hz, 
ArH), 7.04 (1H, app. td, J=7.6, 1.8 Hz, ArH), 7.01±6.90 
(2H, m, 2 × ArH), 6.61 (1H, app. td, J=7.4, 1.0 Hz, ArH), 
6.31  (1H,  d,  J=7.9  Hz,  ArH),  5.76±5.53  (2H,  m, 
2 × CH2CH=CH2), 5.03±4.92 (4H, m, 2 × CH2CH=CH2), 
4.22 (2H, s, NCH2Ar), 3.17 (2H, s, NCH2C), 2.45±2.28 
(4H, m, 2 × CH2CH=CH2). 
GC (75 MHz, CDCl3)   151.6 (C), 137.4 (C), 134.7 (C), 134.6 (2 x CH), 132.7 
(CH), 129.2 (CH), 128.5 (CH), 127.8 (CH), 127.4 (CH), 
123.3  (C),  123.2  (CH),  117.8  (2  x  CH2),  117.4  (CH), 
106.6  (CH),  63.0  (CH2),  53.41  (CH2),  47.0  (C),  43.0 
(2 x CH2). 
LRMS (ES
+)  
79Br: 368 ([M+H]
+, 100%). 
HRMS  C21H23BrN requires 368.1008; Found: 368.1014. ﾠ
 
 ﾠ
2,2-Bis-(2-phenylsulfinyl-ethyl)malonic acid dimethyl ester (245) 
 
To a solution of dimethyl malonate 246 (8.30 mL, 72.7 mmol) in DMF (160 mL) at 
0 °C was added NaH (60% in mineral oil, 580mg, 14.6 mmol).  After 20 min the 
reaction mixture was warmed to RT and phenyl vinyl sulfoxide (25.0 g, 0.16 mol) in 
DMF (40 mL) added dropwise over 20 min.  After 4 days ethyl acetate (150 mL) 
and water (150 mL) were added and the phases separated.  The aqueous phase 
was washed with ethyl acetate (200 mL).  The organic phases were combined and 
washed with water (3 x 200 mL) and brine (200 mL), then  dried (MgSO4) and 
concentrated in vacuo.  Purification by column chromatography (50% ethyl acetate 
in  hexanes±2%  methanol  in  ethyl  acetate)  afforded  the  title  compound  as  a 
colourless  oil  (23.83 g,  54.6  mmol, 75%).   These  data  are  in accordance  with 
those reported in the literature.
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Xmax  3468  (br.  w),  3050  (w),  2953  (w),  1730  (s),  1477  (w), 
1443 (m), 1308 (w), 1265 (m), 1217 (m), 1170 (m), 1086 
(m), 1041 (m), 998 (w). 
GH (300 MHz, CDCl3)  7.66±7.36 (10H, m, ArH), 3.77±3.48 (6H, m, 2 × OCH3), 
2.75  (2H,  m,  2  ×  CH2CHHSOPh),  2.64±2.42(2H,  m, 
2 × CH2CHHSOPh),  2.32±2.11  (2H,  m,  2  × 
CHHCH2SOPh), 2.05±1.85 (2H, m, 2 × CHHCH2SOPh). 
GC (75 MHz, CDCl3)  170.3 (2 × C=O), 143.0+142.9 (2 × C), 131.2 (2 × CH), 
129.3  (4×  CH),  124.0  (4×  CH),  55.9+55.8  (C),  52.9 
(2 × CH3), 51.1+51.0 (2 × CH2), 25.4+25.3 (2 × CH2). 
LRMS (ES
+)  459 ([M+Na]
+, 100%). 
 
 
4-Cyano-2,2-divinylbutyric  acid  methyl  ester  (248),  (E)-methyl-2-(2-
phenylsulfinyl-ethyl)but-2-enoate  (249),  methyl-2-(2-cyanoethyl)-2-(2-
phenylsulfinyl-ethyl)but-3-enoate  (250), ﾠ 2,2-bis(2-phenylsulfinyl-ethyl)-4-
cyano-butyric acid methyl ester (244) 
 ﾠ
To a solution of malonate 245 (7.28 g, 16.7 mmol) in DMF (150 mL) was added 
sodium iodide (5.0 g, 33.4 mmol) and acrylonitrile (5.5 mL, 90.2 mmol) and then 
heated at 120 °C for 12 h.  The reaction mixture was cooled to RT, ethyl acetate 
(100  mL)  and  water  (100  mL)  were  added  and  the  phases  separated.    The 
aqueous phase was extracted with ethyl acetate (100 mL).  The combined organic 
phases were washed with water (4 x 100 mL), brine (100 mL), then dried (MgSO4) 
and  concentrated  in  vacuo.    Purification  by  column  chromatography  (5%  ethyl Chapter 6: Experimental 
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acetate in hexanes±5% MeOH in ethyl acetate) afforded a mixture of compounds 
(248, 249, 250 and 244). Yields of each product varied with reaction time and 
temperature.  These data are in accordance with those reported in the literature.
17 
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Data for 248: 
Light yellow oil. 
Xmax  2954 (w), 2247 (w), 1728 (s), 1633 (w), 1434 (m), 1245 
(m), 1200 (m), 1121 (w), 1084 (w), 997 (w), 927 (m), 806 
(w), 752 (w). 
GH (300 MHz, CDCl3)  5.89 (2H, dd, J=17.6, 11.0 Hz, 2 ×CH=CH2), 5.27 (2H, d, 
J=11.0  Hz,  2  ×CH=CH2),  5.10  (2H,  d,  J=17.6  Hz, 
2 × CH=CH2),  3.67  (3H,  s,  OCH3),  2.38±2.22  (2H,  m, 
CH2CH2CN), 2.22±2.06 (2H, m, CH2CH2CN). 
GC (75 MHz, CDCl3)  172.9  (C=O),  136.9  (2  ×  CH),  119.5  (CN),  117.3 
(2 × CH2), 54.7 (C), 52.6 (CH3), 31.4 (CH2), 13.0 (CH2). 
LRMS (ES
+)  202 [M+Na]
+ (100). 
 
Data for 249: 
Clear oil. 
Xmax  3460 (w), 3057 (w), 2950 (w), 2360 (w), 2340 (w), 2246 
(w), 2153 (w), 1708 (s), 1647 (w), 1582 (w), 1477 (w), 
1441 (m), 1384 (w), 1295 (w), 1260 (m), 1193 (w), 1160 
(m), 1123 (w), 1085 (w), 1040 (s), 999 (w), 928 (w). 
GH (300 MHz, CDCl3)  7.í7.48  (5H,  m,  5  ×  ArH),  6.96  (1H,  q,  J=7.2  Hz, 
C=CHCH3),  3.70  (3H,  s,  OCH3)í H,  m, 
CH2CHH623K í H,  m,  CHHCHHSOPh), 
2.í2.51  (1H,  m,  CHHCH2SOPh),  1.81  (3H,  d, 
J=7.2 Hz, C=CHCH3). 
GC (75 MHz, CDCl3)  167.4 (C=O), 143.5 (C), 140.3 (CH), 130.9 (CH), 129.7 
(C),  129.1  (2  ×  CH),  124.0  (2  ×  CH),  55.5  (CH2), 
51.8(CH3), 19.3 (CH2), 14.3 (CH3). 
LRMS (ES
+)  316 ([M+MeCN+Na]
+, 100%), 275 ([M+Na]
+, 23%. Chapter 6: Experimental 
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Data for 250: 
Clear oil, 1:1 mixture of diastereoisomers. 
Xmax  3460 (w), 3057 (w), 2952 (w), 2360 (w), 2247 (w), 1727 
(s), 1636 (w), 1582 (w), 1476 (w), 1444 (m), 1306 (w), 
1254 (m), 1204 (m), 1155 (w), 1085 (m), 1042 (s), 999 
(w), 932 (w). 
GH (300 MHz, CDCl3)  í  (5H+5H,  m,  2  ×  (5  ×  ArH)),  5.88  (1H,  dd, 
J=17.8,  11.0  Hz,  CH=CH2),  5.85  (1H,  dd,  J=17.8, 
11.0 Hz, CH=CH2), 5.34 (1H, d, J=11.0 Hz, CH=CHH), 
5.30  (1H,  d,  J=11.0  Hz,  CH=CHH),  5.15  (1H,  d, 
J=17.8 Hz,  AH=CHH),  5.05  (1H,  d,  J=17.8  Hz, 
CH=CHH),  3.71  (3H,  s,  OCH3),  3.69  (3H,  s,  OCH3), 
í++m, 2 × CH+í++P
2 × CHH), 2.í2.22 (2H+2H, m, 2 × 2 CHH) 2.05 - 2.21 
(2H+2H,  m,  2  ×  2  CHH)  1.82  -  2.04  (2H+2H,  m, 
2 × 2 CHH). 
GC (75 MHz, CDCl3)  173.2 (C=O), 143.1+143.0 (C), 136.5+136.4 (CH), 131.2 
(CH),  129.3  (2  ×  CH),  123.9  (2  ×  CH),  119.0  (CN), 
117.7+117.6 (CH2), 52.6+52.6 (OCH3), 51.5+51.3 (CH2), 
50.9 (C), 32.3+32.1 (CH2), 27.9+27.6 (CH2), 12.8+12.72 
(CH2). 
LRMS (ES
+)  369 ([M+MeCN+Na]
+, 20%), 328 ([M+Na]
+, 100%). 
 
Data for 244: 
Brown oil, complex mixture of diastereoisomers. 
Xmax  3449  (br.  w),  3056  (w),  2952  (w),  2250  (w),  1725  (s), 
1477 (w), 1443 (m), 1306 (w), 1207 (m), 1165 (m), 1086 
(m), 1038 (s), 998 (m), 920 (w). 
GH (300 MHz, CDCl3)  7.74±7.48  (10H,  m,  ArH),  3.67±3.51  (3H,  m,  OCH3), 
2.83±2.55 (2H, m, CH2CH2SOPh), 2.54±2.32 (2H, dddd, 
J=12.4,  12.4,  12.2,  4.8  Hz,  CH2CH2SOPh),  2.19±2.04 Chapter 6: Experimental 
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(2H, m, 2 × CHH), 2.04±1.85 (2H, m,2 × CHH), 1.85±
1.74 (2H, m, 2 × CHH), 1.74±1.61 (2H, m, 2 × CHH). 
GC (75 MHz, CDCl3)  173.8 (C=O), 142.9+142.8+142.8+142.7 (2 × C), 131.3 
(2  ×  CH),  129.4  (4×  CH),  124.0  (4×  CH),  118.6  (CN), 
52.7 (OCH3), 5.06+50.4+50.3+50.2 (2 × CH2), 47.1+47.1 
(C),  30.7+30.6+30.5  (CH2),  25.6+25.4+25.2  (2  ×  CH2), 
12.3 (CH2). 
LRMS(ES
+)  454 ([M+Na]
+, 100%). 
 
 
4-Cyano-2,2-divinylbutyric acid methyl ester (248) 
 
A solution of nitrile 244 (73 mg, 0.169 mmol) in DMF (5 mL) was heated to reflux. 
After 5 h the reaction mixture was cooled to RT then water (10 mL) and ethyl 
acetate (10 mL) were added and the phases separated.  The aqueous phase was 
extracted with ethyl acetate (2 x 10 mL) and the combined organic phases washed 
with  water  (4  x  10  mL),  brine  (20  mL),  then  dried  (MgSO4)  and  concentrated 
in vacuo.    Purification  by  column  chromatography  (0±25%  diethyl  ether  in 
petroleum  ether)  afforded  the  title  compound  as  a  pale  yellow  oil 
(12 mg, 0.067 mmol, 40%).  
Data as previously reported. 
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4-Cyano-2,2-divinylbutyric acid methyl ester (248) 
 
A solution of nitrile 250 (444 mg, 1.45 mmol) in DMF (18 mL) was heated to reflux. 
After 5 h the reaction mixture was cooled to RT then water (50 mL) and ethyl 
acetate (50 mL) were added and the phases separated.  The aqueous phase was 
extracted with ethyl acetate (2 x 50 mL) and the combined organic phases washed 
with water (4 x 100 mL), brine (200 mL), then dried (MgSO4) and concentrated 
in vacuo.    Purification  by  column  chromatography  (0±25%  diethyl  ether  in 
petroleum  ether)  afforded  the  title  compound  as  a  pale  yellow  oil 
(197 mg, 1.10 mmol, 76%).  
Data as previously reported. 
 
 
4-Hydroxymethyl-4-vinylhex-5-enenitrile(251) 
 
To a solution of ester 248 (200mg, 1.12 mmol) in THF (12 mL) at 78 °C was 
added LiAlH4 (1.0 M solution in THF, 2.64 mL, 2.64 mmol) dropwise over 5 min. 
After  6  h  the  reaction  mixture  was  warmed  to  0  °C  and  water  (4  mL)  added 
dropwise maintaining a temperature of 0 °C.  The reaction mixture was warmed to 
RT and 2 M HCl (7 mL) and diethyl ether (15 mL) were added and the phases 
separated.  The aqueous phase was extracted with diethyl ether (2 × 15 mL).  The 
combined organic phases were washed with brine (40 mL), then dried (MgSO4) 
and the solvent removed in vacuo to afford the title compound as a pale yellow oil 
(156 mg, 1.03 mmol, 92%).  These data are in accordance with those reported in 
the literature.
17 
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Xmax      3447 (br. m), 3084 (w), 3004 (w), 2933 (w), 2360 (w), 
2339 (w), 2249 (w), 1920 (w), 1853 (w), 1635 (w), 1453 
(w), 1419 (w), 1044  (m), 1004 (m), 924 (s), 741 (w). 
GH (300 MHz, CDCl3)  5.67 (2H, dd, J=17.9, 11.0 Hz, 2 × CH=CH2), 5.26 (2H, d, 
J=11.0  Hz,  2  ×  CH=CHH),  5.08  (2H,  d,  J=17.9  Hz, 
2 × CH=CHH), 3.47 (2H, s, CH22+í2.15 (2H, m, 
CH2CH2CN), 1.96í1.81 (2H, m, CH2CH2CN), 1.58 (1H, 
br. s, CH2OH). 
GC (75 MHz, CDCl3)  139.2 (2 × CH), 120.3 (CN), 117.5 (2× CH2), 67.1 (CH2), 
48.5 (C), 30.1 (CH2), 12.6 (CH2). 
LRMS (CI)    169 ([M+NH4]
, 100 %), 140 (87%), 138 (77%). 
 
 
2-Iodoxybenzoic acid, IBX (365) 
 
To  a  suspension  of  2-iodobenzoic  acid  (10.0  g,  40.3  mmol)  in  aq.H2SO4 
(0.73 M, 100 mL) was added KBrO3 (8.75 g, 52.4 mmol) and heated to 75 °C.  The 
reaction gases were scrubbed through saturated sodium thiosulfate solution.  After 
4.5  h  the  reaction  mixture  was  cooled  to  RT  and  the  precipitate  collected  by 
filtration,  washed  with  water  (200  mL)  and  ethanol  (100  mL)  and  dried  under 
vacuum to afford the title compound as a white solid (9.71 g, 34.7 mmol, 86%). 
These data are in accordance with those reported in the literature.
78 
 
Xmax  3430 (br. m), 2998 (w), 2914 (w), 1663 (w), 1436 (m), 
1406 (m), 1311 (m), 1017 (s), 952 (s). 
GH (300 MHz, DMSO)  8.15  (1H,  d,  J=7.7  Hz,  ArH),  8.08±7.95  (2H,  m,  ArH), 
7.84 (1H, app. t, J=7.1 Hz, ArH). 
GC (75 MHz, DMSO)  167.5 (C=O), 146.6 (C), 133.4 (CH), 132.9 (CH), 131.5 
(C), 130.1 (CH), 125.0 (CH). 
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4-Formyl-4-vinylhex-5-enenitrile (252) 
 
To  a  solution  of  Dess-Martin  Periodinane  (690mg,  1.63  mmol)  in  chloroform 
(14 mL) at RT was added alcohol 251 (182 mg, 1.20 mmol) in chloroform (3.5 mL) 
dropwise over 5 min.  After 4 h the reaction mixture was concentrated in vacuo 
and dry loaded onto silica.  Purification by column chromatography (30% diethyl 
ether  in  petroleum  ether)  afforded  the  title  compound  as  a  yellow  oil 
(172 mg, 1.15 mmol, 96%).  These data are in accordance with those reported in 
the literature.
17 
 
Xmax      3088 (w), 2935 (w), 2822 (w), 2723 (w), 2248 (w), 1722 
(s), 1630 (w), 1450 (w), 1421 (w), 1355 (w), 1165 (w), 
996 (m), 931 (s), 797 (w). 
GH (300 MHz, CDCl3)  9.32  (1H,  s,  CHO),  5.78  (2H,  dd,  J=17.8,  10.8 
Hz,2 × CH=CH2), 5.52 (2H, d, J=10.8 Hz, 2 × CH=CHH), 
5.24 (2H, d, J=17.8 Hz, 2 × CH=CHH), 2.44±2.27 (2H, m, 
CH2CH2CN), 2.19±2.06 (2H, m, CH2CH2CN).
 
GC (75 MHz, CDCl3)  197.5  (C=O),  134.8  (2  ×  CH),  120.5  (2  ×  CH2),  119.5 
(CN), 59.1 (C), 29.4 (CH2), 12.6 (CH2). 
LRMS (ES
+)    259 (100%), 172 ([M+Na]
+, 24%). 
 
 
4-[1,3]Dioxolan-2-yl-4-vinylhex-5-enenitrile (253) 
 
To a solution of aldehyde 252 (172 mg, 1.15 mmol) in toluene (20 mL) was added 
pTSA (11 mg, 0.06 mmol) and ethylene glycol (0.32 mL, 5.75 mmol).  The reaction 
mixture  was  heated  at  reflux  under  Dean  and  Stark  conditions  for  6  h.    The Chapter 6: Experimental 
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reaction mixture was cooled to RT and then diethyl ether (10 mL) and saturated 
K2CO3  solution  (20  mL)  were  added  and  the  phases  separated.    The  organic 
phase  was  washed  with  brine  (20  mL),  then  dried  (MgSO4)  and  the  solvent 
removed in vacuo to afford the title compound as a yellow oil (212 mg, 1.10 mmol, 
95%).  These data are in accordance with those reported in the literature.
17 
 
Xmax  3085 (w), 2980 (w), 2955 (w), 2887 (m), 2246 (m), 1636 
(w), 1455 (w), 1418 (w), 1377 (w), 1146 (m), 1114 (m), 
1081 (m), 1032 (m), 1002 (m), 925 (s), 774 (w). 
GH (300 MHz, CDCl3)  5.76 (2H, dd, J=17.8, 11.0 Hz, 2 × CH=CH2), 5.30 (2H, 
dd,  J=11.0,  0.6  Hz,  2  ×  CH=CHH),  5.18  (2H,  dd, 
J=17.8, 0.6 Hz, 2 × CH=CHH), 4.68 (1H, s, CHOCH2), 
3.96±3.70  (4H,  m,  OCH2CH2O),  2.35±2.25  (2H,  m, 
CH2CH2CN), 2.00±1.90 (2H, m, CH2CH2CN). 
GC (75 MHz, CDCl3)  137.3 (2 × CH), 120.3 (CN), 117.7 (2 × CH2), 107.4 (CH), 
65.3 (2 × CH2), 50.2 (C), 28.3 (CH2), 12.5 (CH2). 
LRMS (ES
+)  216 ([M+Na]
+, 100%). 
 
   
4-[1,3]Dioxolan-2-yl-4-vinylhex-5-en-1-amine (254) 
 
To a solution of nitrile 253 (178 mg, 0.92 mmol) in THF (8 mL) at 0 °C was added 
LiAlH4  (1.0  M  in  THF,  0.9  mL,  0.9  mmol)  dropwise  over  5  min.    The  reaction 
mixture was then heated to 60 °C for 4 h.  The reaction mixture was cooled to 0 °C 
and water (8 mL) was added, followed by 2 M NaOH (5 mL).  The reaction mixture 
was extracted with diethyl ether (3 × 10 mL) and the combined organic phases 
washed  with  brine  (50  mL),  then  dried  (MgSO4)  and  concentrated  in  vacuo  to 
afford the title compound as a yellow oil (174 mg, 0.90 mmol, 96%).  These data 
are in accordance with those reported in the literature.
17 
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Xmax  3082 (w), 2947 (m), 2879 (m), 1634 (w), 1572 (m), 1473 
(m), 1383 (m), 1318 (m), 1112 (s), 1033 (m), 920 (s). 
GH (300 MHz, CDCl3)  5.87 (2H, dd, J=17.8, 11.1 Hz, 2 × CH=CH2), 5.25 (2H, 
dd,  J=11.1,  1.3  Hz,  2  ×  CH=CHH),  5.14  (2H,  dd, 
J=17.8, 1.3 Hz, 2 × CH=CHH), 4.80 (1H, s, CHOCH2), 
4.01±3.75 (4H, m, OCH2CH2O), 2.66 (2H, t, J=7.0 Hz, 
CH2NH2), 1.70±1.56 (2H, m, CH2CH2CH2NH2),1.49±1.39 
(2H, m, CH2CH2CH2NH2). 
GC (75 MHz, CDCl3)  138.9  (2  ×  CH),  116.2  (2  ×  CH2),  107.8  (CH),  65.2 
(2 × CH2), 50.3 (C), 42.9 (CH2), 30.4 (CH2), 28.2 (CH2). 
LRMS (ES
+)  198 ([M+H]
+, 100%). 
N.B. This compound is prone to decomposition. 
 
 
5,5-Divinyl-2,3,4,5-tetrahydropyridine (221) 
 
To  a  solution  of  254  (74  mg,  0.38  mmol)  in  diethyl  ether  (1  mL)  was  added 
10% HCl (1 mL) and after 2 h 10% NaOH (~pH 10) was added.  After a further 
2.5 h the reaction mixture was then extracted with diethyl ether (3 × 10 mL) and 
the  combined  organic  phases  then  dried  (MgSO4)  and  concentrated  in  vacuo. 
Purification  by  column  chromatography  (100%  diethyl  ether)  afforded  the  title 
compound  as  a  colourless  oil  (18mg,  0.13mmol,  34%).  These  data  are  in 
accordance with those reported in the literature.
17 
 
Xmax  3075 (w),2924 (m), 2953 (m), 2361 (m), 2332 (w), 2160 
(m), 2018 (w), 1716 (w), 1647 (w), 1540 (w), 1457 (w), 
1115 (w), 1003 (w), 920 (w). 
GH (300 MHz, CDCl3)  7.55 (1H, br. s, N=CH), 5.76 (2H, dd, J=17.6, 10.6 Hz, 
2 ×  CH=CH2),  5.21  (2H,  dd,  J=10.6,  0.7  Hz, Chapter 6: Experimental 
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2 × CH=CHH),  5.08  (2H,  dd,  J=17.6,  0.7  Hz, 
2 × CH=CHH), 3.70±3.46 (2H, m, NCH2), 1.79±1.67 (2H, 
m, NCH2CHHCHH), 1.68±1.49 (2H, m, NCH2CHHCHH). 
GC (75 MHz, CDCl3)  164.1(CH), 141.3 (2 x CH), 115.7 (2 x CH), 49.4 (CH2), 
47.6 (C), 30.3 (CH2), 18.2 (CH2). 
LRMS (ES
+)  136 ([M+H]
+, 100%). 
N.B. This compound is prone to decomposition. 
 
 
3-Diazodihydrofuran-2(3H)-one (261) 
 ﾠ
To a solution of sodium azide (2.42 g, 37.2 mmol), tetrabutylammonium bromide 
(15 mg, 0.047 mmol) and 2 M NaOH (70 mL) in hexanes (35 mL) at 0 °C was 
added  Tf2O  (3.13  mL,  18.6  mmol)  dropwise  over  5  min.  After  10 
min2-acetyl-butyrolactone  260  (0.60  g,  4.68  mmol)  in  acetonitrile  (45  mL)  was 
added in one portion.  After 30 min the reaction mixture was diluted with ice water 
(20 mL) and ethyl acetate (25 mL) added.  The phases were separated and the 
aqueous phase washed with ethyl acetate (2 × 25 mL).  The combined organic 
phases were dried (MgSO4) and concentrated in vacuo.  Purification by column 
chromatography  (50%  ethyl  acetate  in  petroleum  ether)  afforded  the  title 
compound as a bright yellow solid (211 mg, 1.73 mmol, 37%).  These data are in 
accordance with those reported in the literature.
52 
 
MP  í&(EtOAc / petroleum ether), /LWí&.
52 
Xmax  3525 (w), 3270 (w), 2925 (w), 1754 (s), 1664 (w), 1623 
(w), 1521 (w), 1482 (w), 1453 (w), 1419 (w), 1257 (m), 
1226 (m), 1176 (m), 1108 (m), 1020 (s), 953(w). 
GH (300 MHz, CDCl3)  4.38 (2H, t, J=7.8 Hz, CH2CH2), 3.36 (2H, t, J=7.8 Hz, 
CH2CH2). Chapter 6: Experimental 
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GC (75 MHz, CDCl3)  170.6 (C=O), 65.2 (CH2), 23.03 (CH2). 
N.B. One quaternary centre not observed. 
LRMS (EI)  >0í12]
+, 100%), 51 (72%). ﾠ
 
 
1-(Trimethylsilyl)-5-oxaspiro[2.4]hept-1-en-4-one (262) 
 ﾠ
To a solution of Rh2(OAc)4 (8 mg, 0.018 mmol) in trimethylsilyl acetylene (3 mL) at 
reflux  was  added  a  suspension  of  261  (145mg,  1.29  mmol)  in  trimethylsilyl 
acetylene (4.5 mL) dropwise over 5 h.  After 16 h the reaction mixture was cooled 
to  RT  and  concentrated  in  vacuo.    Purification  by  column  chromatography 
(25% ethyl  acetate  in  petroleum  ether)  afforded  the  title  compound  as  a  pale 
brown oil (28mg, 0.15 mmol, 12%).  These data are in accordance with those 
reported in the literature.
52 
 
GH (300 MHz, CDCl3)  7.21 (1H, s, CH), 4.42 (2H, app. t, J=7.7 Hz, CH2CH2), 
2.26í2.08  (1H,  m,  CH2CHH),  2.06í1.91  (1H,  m, 
CH2CHH), 0.25 (9H, s, Si(CH3)3). 
GC (75 MHz, CDCl3)  181.1  (C=O),  116.8  (C),  114.9  (CH),  65.1  (CH2),  30.3 
(CH2), 24.0 (C), í1.5 (Si(CH3)3). 
 
 
Dimethyl 2-diazomalonate (263) 
 
To a solution of dimethyl malonate 246(1.00 g, 7.57 mmol) and p-toluenesulfonyl 
azide (1.49 g, 7.57 mmol) in diethyl ether (10 mL) at 0 °C was added diethylamine Chapter 6: Experimental 
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(0.78 mL, 7.57 mmol).  After 15 min the reaction mixture was warmed to RT for 
60 h.    Hexanes  (75  mL)  was  added  and  the  resultant  precipitate  removed  by 
filtration.    The  filtrate  was  concentrated  in  vacuo.    Purification  by  column 
chromatography  (25%  diethyl  ether  in  petroleum  ether)  afforded  the  title 
compound as a pale yellow oil (638 mg, 4.04 mmol, 53%).  These data are in 
accordance with those reported in the literature.
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Xmax  2993 (w), 2958 (w), 2132 (s), 1758 (s), 1734 (s), 1687 
(s),  1435  (s),  1353  (m),  1326  (s),  1271  (s),  1189  (m), 
1083 (s), 972 (w), 934 (w), 820 (w), 758 (s). 
GH (300 MHz, CDCl3)  3.84 (6H, s, 2 × OCH3). 
GC (75 MHz, CDCl3)  161.4 (2 × C=O), 52.5 (2 × CH3).  
N.B. One quaternary centre not observed. 
LRMS (EI)  222 (M+MeCN+Na]
+, 100%). 
 
 
Dimethyl 2-(trimethylsilyl)cycloprop-2-ene-1,1-dicarboxylate (264) 
 
To a solution of Rh2(OAc)4 (6 mg, 0.013 mmol) in trimethylsilyl acetylene (1.9 mL) 
at  55  °C  was  added  a  solution  of  diazomalonate  263  (200  mg,  1.26  mmol)  in 
trimethylsilyl  acetylene  (0.6  mL)  dropwise  over  2  h.    After  1.5  h  the  reaction 
mixture  was  cooled  to  RT  and  concentrated  in  vacuo.    Purification  by  column 
chromatography  (5±20%  diethyl  ether  in  petroleum  ether)  afforded  the  title 
compound as a pale yellow oil (224 mg, 0.98 mmol, 78%).  These data are in 
accordance with those reported in the literature.
83 
 
Xmax  3166 (w), 3120 (m), 3003 (w), 2956 (m), 2847 (w), 2360 
(w), 2192 (w), 2056 (w), 1987 (w), 1730 (s), 1670 (w), Chapter 6: Experimental 
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1546 (w), 1436 (m), 1286 (s), 1252 (s), 1193 (w), 1146 
(w), 1067 (s), 988 (w). 
GH (300 MHz, CDCl3)  7.05 (1H, s, CH), 3.70 (6H, s, 2 x OCH3), 0.25 (9H, s, 
Si(CH3)3). 
GC (75 MHz, CDCl3)  172.1  (2  ×  C=O),  113.7  (C),  110.6  (CH),  52.1 
(2 × OCH3), 30.4 (C), ±1.9 (Si(CH3)3). 
LRMS (ES
+)  220 ([M±TMS+MeCN+Na]
+, 100%). 
 
 
Dimethyl cycloprop-2-ene-1,1-dicarboxylate (265) 
 ﾠ
To a solution of cyclopropene 264 (201mg, 0.88 mmol) in ethanol (4.5 mL) at 0 °C 
was added a solution of KOH (0.25 M in ethanol, 0.13 mL) dropwise over 5 min. 
After 5 min the reaction mixture was neutralised with a solution of 0.25 M HCl. 
Ethyl acetate (10 mL) was then added and the phases separated.  The aqueous 
phase was then washed with ethyl acetate (3 × 10 mL) and the combined organic 
phases  washed  with  water  (10  mL),  brine  (30  mL),  then  dried  (MgSO4)  and 
concentrated in vacuo to afford the title compound as a pale yellow oil (80 mg, 
0.51  mmol,  58%).  These  data  are  in  accordance  with  those  reported  in  the 
literature.
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Xmax  3853 (w), 3734 (w), 3167 (w), 3121 (m), 3004 (w), 2956 
(m), 2848 (w), 2361 (m), 2340 (m), 2179 (w), 2163 (w), 
1723 (s), 1672 (w), 1435 (m), 1247 (s), 1192 (w), 1144 
(w), 1062 (s), 987 (w), 949 (w).  
GH (300 MHz, CDCl3)  6.91 (2H, s, CH=CH), 3.73 (6H, s, 2 × OCH3). 
GC (75 MHz, CDCl3)  171.3 (2 × C=O), 102.4 (2 × CH), 52.4 (2 × OCH3), 29.8 
(C). 
LRMS (ES
+)  220 ([M+MeCN+Na]
+, 100%). Chapter 6: Experimental 
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Methyl 3-(tert-butylamino)propanoate (270) 
 
To a solution of methyl acrylate 269 (1.05 mL, 11.62 mmol) in methanol (2.5 mL) 
was added 
tBuNH2 (1.22 mL, 11.62 mmol) at RT.  After 60 h the reaction mixture 
was  concentrated  in  vacuo  to  afford  the  title  compound  as  a  colourless  oil 
(1.24 g, 7.79 mmol, 67%).  These data are in accordance with those reported in 
the literature.
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Xmax  2961 (m), 2867 (w), 2361 (w), 2339 (w), 2179 (w), 2163 
(w), 1737 (s), 1438 (w), 1391 (w), 1362 (m), 1317 (w), 
1231 (m), 1212 (m), 1170 (m), 1102 (w), 1065 (w). 
GH (300 MHz, CDCl3)  3.66  (3H,  s,  OCH3),  2.80  (2H,  t,  J=6.7  Hz,  CH2),  2.49 
(2H, t, J=6.7 Hz, CH2), 1.08 (9H, s, NHC(CH3)3). 
GC (75 MHz, CDCl3)  173.3  (C=O),  51.4  (OCH3),  50.3  (C),  38.0  (CH2),  35.4 
(CH2), 28.9 (3 × CH3). 
LRMS (ES
+)  160 ([M+H]
+, 100%). 
 
 
Ethyl 3-(tert-butyl(3-methoxy-3-oxopropyl)amino)-3-oxopropanoate (272) 
 ﾠ
To a solution of malonate 271 (6.42 g, 37.7 mmol) in diethyl ether (60 mL) was 
added  pivaloyl  chloride  (0.85  mL,  6.91  mmol)  at  0  °C.    After  4  h  NEt3 
(0.96 mL, 6.91  mmol),  dimethylaminopyridine  (100mg,  0.82  mmol)  and  270 
(1.00 g, 6.28 mmol) were added at RT. After 40 h saturated aq. NaHCO3 (10 mL) 
was  added  and  the  phases  separated.    The  organic  phase  was  washed  with 
saturated  aq.  NaHCO3  (2  ×  10  mL),  brine  (20  mL),  then  dried  (MgSO4)  and Chapter 6: Experimental 
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concentrated  in  vacuo.    Purification  by  column  chromatography  (10±30%  ethyl 
acetate  in  petroleum  ether)  afforded  the  title  compound  as  a  pale  yellow  oil 
(421 mg, 1.54 mmol, 25%).  
 
Xmax  3396 (br. w), 2981 (br. m), 2810 (br. w), 2664 (w), 2495 
(w), 2361 (m), 2340 (w), 2184 (w), 1939 (w), 1732 (s), 
1580 (s), 1440 (m), 1405 (m), 1379 (s), 1322 (w), 1302 
(w), 1246 (w), 1205 (m), 1093 (w), 1033 (w). 
GH (300 MHz, CDCl3)  4.20  (2H,  q,  J=7.1  Hz,  CH2CH3),  3.70  (3H,  s,  OCH3), 
3.66±3.57 (2H, m, CH2CH2), 3.46 (2H, s, C(O)CH2C(O)), 
2.68±2.51  (2H,  m,  CH2CH2),  1.45  (9H,  s,  NHC(CH3)3), 
1.28 (3H, t, J=7.1 Hz, CH2CH3). 
GC (75 MHz, CDCl3)  171.1  (C=O),  168.0  (C=O),  166.8  (C=O),  61.3  (CH2), 
57.8 (C), 51.9 (CH3), 43.8 (CH2), 41.5 (CH2), 36.1 (CH2), 
28.8 (3 × CH3), 14.1 (CH3). 
LRMS  Did not fly by ES/EI or CI. 
 
 
1-(tertButyl)piperidine-2,4-dione (273) 
 ﾠ
To a suspension of NaH (60% in mineral oil, 507 mg, 12.67 mmol) in cyclohexane 
(20 mL) at reflux was added 272 (1.69 g, 6.18 mmol) in toluene (4 mL) dropwise 
over 40 min.  After 45 min the reaction mixture was cooled to RT and the resultant 
precipitate  isolated  by  filtration  and  washed  with  cyclohexane  (25  mL).    The 
isolated solid was suspended in aqueous 10% AcOH (25 mL) and heated at reflux. 
After 3 h the reaction mixture was cooled to RT and neutralised with saturated 
aqueous NaHCO3 and DCM added (10 mL).  The phases were separated and the 
aqueous phase washed with DCM (2 × 10 mL).  The combined organic phases 
were washed with brine (50 mL), then dried (MgSO4) and concentrated in vacuo to Chapter 6: Experimental 
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afford the title compound as a colourless oil (671 mg, 3.97 mmol, 64%).  These 
data are in accordance with those reported in the literature.
86 
 
Xmax  2973 (m), 2925 (w), 2361 (w), 2339 (w), 2161 (w), 1728 
(m), 1648 (s), 1477 (w), 1458 (w), 1413 (m), 1392 (m), 
1364 (m), 1328 (m), 1198 (s), 1078 (w), 1034 (w). 
GH (300 MHz, CDCl3)  3.66  (2H,  t,  J=5.9  Hz,  CH2CH2),  3.35  (2H,  s, 
C(O)CH2C(O)),  2.51  (2H,  t,  J=5.9  Hz,  CH2CH2), 
1.48 (9H, s, NHC(CH3)3). 
GC (75 MHz, CDCl3)  204.7 (C=O), 166.8 (NC=O), 57.9 (C), 52.2 (CH2), 39.7 
(CH2), 39.5 (CH2), 28.8 (3 × CH3). 
LRMS (EI)  170 ([M+H]
+, 100%), 154 (MCH3]
, 24%). 
 
 
1-(tert-Butyl)-3-diazopiperidine-2,4-dione (274) 
 ﾠ
To  a  solution  of  273  (634  mg,  3.75  mmol)  and  p-toluenesulfonyl  azide 
(740 mg, 3.75 mmol)  in  diethyl  ether  (20  mL)  at  0  °C  was  added  diethylamine 
(0.39 mL, 3.75 mmol).  After 15 min the reaction mixture was warmed to RT for 
60 h.    Hexanes  (75  mL)  were  added  and  the  resultant  precipitate  removed  by 
filtration.    The  filtrate  was  concentrated  in  vacuo.    Purification  by  column 
chromatography  (25±35%  ethyl  acetate  in  petroleum  ether)  afforded  the  title 
compound as a pale yellow oil (548mg, 2.81 mmol, 75%).  
 
Xmax  2973 (w), 2927 (w), 2361 (w), 2340 (w), 2136 (m), 1669 
(m), 1639 (s), 1481 (w), 1414 (m), 1340 (s), 1327 (s), 
1290 (w), 1269 (w), 1201 (m), 1062 (w), 1038 (w). 
GH (300 MHz, CDCl3)  3.51 (2H, t, J=6.4 Hz, CH2CH2), 2.56 (2H, t, J=6.4 Hz, 
CH2CH2), 1.49 (9H, s, NHC(CH3)3). Chapter 6: Experimental 
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GC (75 MHz, CDCl3)  188.7 (C=O), 161.6 (NC=O), 58.2 (C), 39.2 (CH2), 37.3 
(CH2), 28.7 (3 × CH3). 
N.B. One quaternary centre not observed. 
LRMS (ES
+)  413 ([2M+Na]
+, 91%), 226 (100%). 
 ﾠ
 
5-(tert-Butyl)-1-(trimethylsilyl)-5-azaspiro[2.5]oct-1-ene-4,8-dione (275) 
 ﾠ
To  a  solution  of  Rh2(OAc)4  (2.3  mg,  0.005  mmol)  in  trimethylsilyl  acetylene 
(1.1 mL) at reflux was added 274 (100mg, 0.51 mmol) in trimethylsilyl acetylene 
(0.4 mL) dropwise over 2 h.  After 2 h the reaction mixture was cooled to RT and 
concentrated  in  vacuo.    Purification  by  column  chromatography  (25±50%  ethyl 
acetate  in  hexanes)  afforded  the  title  compound  as  an  orange  oil 
(12 mg, 0.045 mmol, 9%). 
 
Xmax  2962  (w),  2919  (m),  2851  (w),  2361  (w),  2339  (w), 
1732(w), 1717 (w), 1646 (s), 1563 (s), 1459 (m), 1415 
(w), 1365 (w), 1320 (w), 1197 (s), 1035 (w), 800 (w), 752 
(s). 
GH (300 MHz, CDCl3)  6.84  (1H,  s,  CH=CSi(CH3)3),  3.50  (2H,  t,  J=7.0  Hz, 
CH2CH2), 2.49 (2H, t, J=7.0 Hz, CH2CH2), 1.47 (9H, s, 
3 × CH3) 0.24 (9H, s, Si(CH3)3). 
GC (75 MHz, CDCl3)  116.8 (CH), 44.6 (CH2), 37.4 (CH2), 28.6 (3 × CH3), ±
1.84 (Si(CH3)3). 
N.B. Quaternary centres not observed. 
LRMS (ES
+)  288 ([M+Na]
+, 66%), 167 ([M±CHCSi(CH3)3]
+, 50%), 151 
(100%). 
HRMS  Sample decomposed.   Chapter 6: Experimental 
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6.3 Experimental Procedures for Chapter 4 
1-(2-Bromobenzyl)-3,3-dimethylindolin-2-one (287) and 1-(2-bromobenzyl)-3-
methylindolin-2-one (288) 
 
To  a  solution  of  224  (287 mg,  0.95 mmol)  in  DMF  (12 mL)  was  added  NaH 
(60% in mineral  oil,  95 mg,  2.38 mmol).    After  2  h,  methyl  iodide 
(0.15 mL, 2.38 mmol) in DMF (2 mL) was added dropwise over 10 min.  After 16 h 
water (20 mL) and ethyl acetate (20 mL) were added.  The aqueous phase was 
separated and extracted with ethyl acetate (2 × 20 mL) then the combined organic 
phases were washed with water (60 mL) and brine (60 mL), dried (MgSO4) and 
concentrated in vacuo.  Purification by column chromatography (10±30% diethyl 
ether  in  petroleum  ether)  afforded  firstly  287  as  an  orange  oil 
(126 mg, 0.38 mmol, 40%)  and  then  288  as  an  orange  oil  (31 mg,  0.10 mmol, 
11%). 
 
Data for 287: 
Xmax  3057 (w), 2967 (w), 2926 (w), 2866 (w), 1708 (s), 1612 
(s), 1569 (w), 1488 (m), 1468 (m), 1458 (m), 1439 (m), 
1383 (m), 1348 (s), 1308 (w), 1274 (w), 1192 (m), 1173 
(m), 1120 (m). 
GH (300 MHz, CDCl3)   7.51  (1H,  dd,  J=7.7,  1.2  Hz,  ArH),  7.19±7.00  (4H,  m, 
4 × ArH),  6.97  (1H,  app.  td,  J=7.4,  0.8  Hz,  ArH), 
6.90 (1H, dd, J=7.4, 1.2 Hz, ArH), 6.58 (1H, d, J=7.7 Hz, 
ArH), 4.93 (2H, s, NCH2Ar), 1.39 (6H, s, 2 × CH3). 
GC (75 MHz, CDCl3)   181.5  (C=O),  141.4  (C),  135.6  (C),  134.7  (C),  132.9 
(CH), 128.9 (CH), 127.7 (CH), 127.7 (CH), 127.5 (CH), Chapter 6: Experimental 
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122.8 (C), 122.7 (CH), 122.4 (CH), 109.1 (CH), 44.3 (C), 
43.5 (CH2), 24.6 (2 × CH3). 
LRMS (ES
+)  
79Br: 393 ([M+Na+MeCN]
+, 36%). 
HRMS   C17H16BrNNaO[M+Na]
+  requires  352.0307;  found: 
352.0313. 
 
Data for 288: 
Xmax  3025 (br. m), 3093 (w), 2961 (m), 2931 (w), 2874  (w), 
2359 (w), 1698 (s), 1619 (s), 1598 (w), 1486 (m), 1470 
(s), 1387 (w), 1369 (w), 1345 (m), 1318 (w), 1297 (w), 
1265 (w), 1222 (m), 1202 (w), 1117 (w), 1097 (w), 1078 
(w), 1019 (w). 
GH (300 MHz, CDCl3)   7.60 (1H, dd, J=7.7, 1.4 Hz, ArH), 7.29 (1H, d, J=7.4 Hz, 
ArH), 7.24±7.00 (5H, m, 5 × ArH), 6.67 (1H, d, J=7.7 Hz, 
ArH),  5.02  (2H,  s,  NCH2Ar),  3.60  (1H,  q,  J=7.6  Hz, 
CHCH3), 1.58 (3H, d, J=7.6 Hz, CH3). 
GC (75 MHz, CDCl3)   178.8  (C=O),  142.7  (C),  134.5  (C),  132.9  (CH),  130.5 
(C),  129.0  (CH),  127.9  (CH),  127.8  (CH),  127.6  (CH), 
123.6  (CH),  122.8  (C),  122.7  (CH),  109.0  (CH),  43.7 
(CH2), 40.6 (CH), 15.7 (CH3). 
LRMS (ES
+)  
79Br: 379 ([M+Na+MeCN]
+, 10%). 
HRMS  C16H15BrNO [M+H]
+ requires 316.0332; found: 316.0335. 
 
 
1-(2-Bromobenzyl)-3,3-dimethylindoline (289) 
 
To a solution of 287 (126 mg, 0.38 mmol) in toluene (5 mL) at ±78 °C was added 
AlH3 (0.5 M in toluene, 1.52 mL, 0.76 mmol) dropwise over 10 min.  After 20 min Chapter 6: Experimental 
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the reaction mixture was warmed to RT for 3 h and then cooled to 0 °C.  Methanol 
(2 mL)  then  1  M  HCl  (2 mL)  were  added  cautiously  followed  after  10  min  by 
saturated NaHCO3 (~pH 10).  The aqueous phase was separated and extracted 
with ethyl acetate (3 × 20 mL).  The combined organic phases were then washed 
with  brine  (60 mL),  dried  (MgSO4)  and  concentrated  in  vacuo.    Purification  by 
column  chromatography  (5%  chloroform  in  petroleum  ether)  afforded  the  title 
compound as a yellow oil (87 mg, 0.28 mmol, 74%). 
 
Xmax  3048 (w), 2955 (w), 2917 (w), 2860 (w), 2820 (w), 1605 
(m), 1567 (w), 1486 (s), 1456 (m), 1439 (m), 1361 (w), 
1345 (w), 1302 (w), 1263 (br. m), 1196 (w), 1157 (w), 
1116 (w). 
GH (400 MHz, CDCl3)   7.64 (1H, dd, J=7.8, 1.3 Hz, ArH), 7.49 (1H, dd, J=7.6, 
1.5 Hz, ArH), 7.34 (1H, app. td, J=7.5, 1.3 Hz, ArH), 7.20 
(1H,  app.  td,  J=7.8,  1.5  Hz,  ArH),  7.15±7.09  (2H,  m, 
2 × ArH),  6.79  (1H,  app.  td,  J=7.6,  1.0  Hz,  ArH), 
6.49 (1H,  d,  J=7.6  Hz,  ArH),  4.38  (2H,  s,  NCH2Ar), 
3.26 (2H, s, NCH2), 1.40 (6H, s, 2 × CH3). 
GC (100 MHz, CDCl3)   150.7 (C), 138.7 (C), 137.5 (C), 132.7 (CH), 129.2 (CH), 
128.5 (CH), 127.4 (2 × CH), 123.4 (C), 121.7 (CH), 117.8 
(CH), 106.8 (CH), 68.2 (CH2), 53.4 (CH2), 40.4 (C), 27.6 
(2 × CH3). 
LRMS (ES
+)  
79Br: 316 ([M+H]
+, 100%). 
HRMS  Sample decomposed. 
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(2,6-Diiodo-3,4,5-trimethoxyphenyl)-methanol (291)
 
 
To  a  solution  of  3,4,5-trimethoxybenzyl  alcohol  290  (200  mg,  1.01 mmol)  in 
chloroform (20 mL) at 0 °C was added silver trifluoroacetate (560 mg, 2.53 mmol).  
To  this  suspension  was  added  a  solution  of  iodine  (640  mg,  2.53 mmol)  in 
chloroform  (100 mL)  dropwise  over  1  h.    The  reaction  mixture  was  allowed  to 
warm to RT and after 16 h was filtered.  The filtrate was washed with saturated 
sodium  thiosulfate  (100 mL)  then  the  organic  phases  were  separated,  dried 
(MgSO4) and concentrated in vacuo to afford the title compound as a yellow oil 
(450 mg, 1.01 mmol, 99%).  These data are in accordance with those reported in 
the literature.
17 
 
Xmax  2937 (w), 2362 (s), 2340 (s), 2174 (w), 2143 (w), 2115 
(w), 2030 (w), 1460 (m), 1401 (s), 1371 (s), 1311 (m), 
1261 (w), 1084 (w), 1004 (m), 945 (w). 
GH (300 MHz, CDCl3)   5.15 (2H, s, CH2OH), 3.91 (3H, s, OCH3), 3.89 (6H, s, 
2 × OCH3), 2.07 (1H, br. s, OH). 
GC (75 MHz, CDCl3)  154.0 (2 × C), 144.9 (C), 139.4 (C), 92.6 (2 × C±I), 74.8 
(CH2), 61.0 (CH3), 60.8 (2 × CH3). 
LRMS (ES
+)  923 ([2M+Na]
+, 49%), 505 ([M+MeOH+Na]
+, 100%).   
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1-Chloromethyl-2,6-diiodo-3,4,5-trimethoxybenzene (292) 
 
To a solution of benzyl alcohol 291 (400 mg, 0.89 mmol) in DCM (40 mL) at 0 °C 
was  added  thionyl  chloride  (0.07 mL,  0.89 mmol)  dropwise  over  5  min.    The 
reaction mixture was warmed to RT and after 16 h was concentrated in vacuo to 
afford the title compound as a yellow oil (420 mg, 0.89 mmol, 100%).  These data 
are in accordance with those reported in the literature.
17 
 
Xmax  3005 (w), 2967 (w), 2934 (w), 2850 (w), 1785 (w), 1550 
(w),  1459  (s),  1401  (s),  1371  (s),  1341  (w),  1317  (s), 
1262 (w), 1216 (w), 1196 (w). 
GH (300 MHz, CDCl3)  5.13 (2H, s, ClCH2Ar), 3.92 (3H, s, OCH3), 3.89 (6H, s, 
2 × OCH3). 
GC (75 MHz, CDCl3)  154.2 (2 × C), 145.0 (C), 136.8 (C), 92.7 (2 × C±I), 61.0 
(CH3), 60.8 (2 × CH3), 57.9 (CH2). 
LRMS (EI)   468 ([M]
, 83%), 433 >0í&O@
+, 100%), 291 (26%). 
 
 
1-(2,6-Diiodo-3,4,5-trimethoxy-benzyl)indoline (293) 
 ﾠ
A  solution  of  indoline  (46 mg,  0.39 mmol),  benzyl  chloride  292 
(272 mg, 0.58 mmol), K2CO3 (323 mg, 2.34 mmol) and KI (96 mg, 0.58 mmol) in 
acetone (40 mL) was heated at reflux for 16 h.  The reaction mixture was cooled to 
RT and water (60 mL) and diethyl ether (60 mL) were added.  The aqueous phase Chapter 6: Experimental 
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was separated and extracted with diethyl ether (2 × 40 mL) then the combined 
organic  phases  were  washed  with  brine  (100 mL),  dried  (MgSO4)  and 
concentrated in vacuo.  Purification by column chromatography (10% diethyl ether 
in  petroleum  ether)  afforded  the  title  compound  as  a  brown  oil 
(190 mg, 0.25 mmol, 41%). 
 
Xmax   2932 (w), 2848 (w), 2362 (w), 1606 (m), 1487 (m), 1458 
(s), 1402 (s), 1371 (s), 1355 (w), 1309  (m), 1279 (w), 
1251 (w), 1213  (w), 1161 (w). 
GH (400 MHz, CDCl3)   7.18±7.09 (2H, m, 2 × ArH), 6.76 (1H, d, J=7.7 Hz, ArH), 
6.70  (1H,  app.  td,  J=7.4,  0.9  Hz,  ArH),  4.69  (2H,  s, 
NCH2Ar),  3.94  (3H,  s,  CH3),  3.91  (6H,  s,  2  ×  CH3), 
3.27 (2H, t, J=8.2 Hz, CH2CH2), 2.90 (2H, t, J=8.2 Hz, 
CH2CH2). 
GC (100 MHz, CDCl3)   153.8 (2 × C), 151.6 (C), 144.3 (C), 136.5 (C), 130.1 (C), 
127.1  (CH),  124.4  (CH),  117.7  (CH),  107.4  (CH),  94.1 
(2 × C±I), 62.2 (CH2), 61.0 (CH3), 60.8 (2 × CH3), 52.4 
(CH2), 28.5 (CH2). 
LRMS  Did not fly by ES/EI or CI 
 
 
3-(Propan-2-ylidene)indolin-2-one (294)
 
 ﾠ
A solution of oxindole 236 (1.00 g, 7.51 mmol), piperidine (1.49 mL, 15.02 mmol) 
and acetone (0.61 mL, 8.26 mmol) in ethanol (8 mL) was heated at reflux for 2.5 h, 
then cooled to RT.  The resulting precipitate was collected by filtration, washed 
with cold ethanol (2 × 10 mL) and dried in vacuo to afford the title compound as a 
yellow solid (870 mg, 5.03 mmol, 67%).  These data are in accordance with those 
reported in the literature.
88 Chapter 6: Experimental 
110 ﾠ
 ﾠ
MP  191±193 °C (EtOH), Lit.
[14] 189±191 °C (EtOH). 
Xmax   3139 (w), 3100 (w), 3076 (w), 3024 (w), 2893 (w), 2837 
(w), 2699 (w), 2360 (w), 2341 (w), 1691 (s), 1627 (w), 
1614 (m), 1587 (w), 1556 (w), 1489 (w), 1466 (m). 
GH (300 MHz, CDCl3)  8.62  (1H,  br.  s,  NH),  7.52  (1H,  d,  J=7.7  Hz,  ArH), 
7.19 (1H,  app.  t,  J=7.7  Hz,  ArH),  7.02  (1H,  app.  td, 
J=7.7, 1.1 Hz,  ArH),  6.89  (1H,  d,  J=7.7  Hz,  ArH), 
2.63 (3H, s, CH3), 2.39 (3H, s, CH3). 
GC (75 MHz, CDCl3)   169.7  (C=O),  155.5  (C),  139.4  (C),  127.5  (CH),  124.3 
(C), 123.7 (CH), 123.0 (C), 121.5 (CH), 109.3 (CH), 25.2 
(CH3), 23.1 (CH3). 
LRMS (CI)   173  ([M]
+,  100%),  158  ([M±CH3]
+,  90%),  130  ([M±
C(CH3)2]
+, 21%). 
 
 ﾠ
3-Isopropylindolin-2-one (296)
 
 ﾠ
To 294 (400 mg, 2.31 mmol) and 10% Pd/C (40 mg) was added methanol:DCM 
(1:1, 25 mL).  The mixture was degassed with argon then stirred vigorously under 
an atmosphere of H2 for 4 h.  The reaction mixture was purged of H2 by flushing 
with argon, then filtered (Celite
®) and washed with DCM (2 × 30 mL).  The solvent 
was  removed  in  vacuo  to  afford  the  title  compound  as  a  pale  yellow  solid 
(404 mg, 2.31 mmol, 100%).  These data are in accordance with those reported in 
the literature.
89 
 
MP  141±143 °C (EtOH), Lit.
[6] 108±109 °C (EtOAc/hexanes). 
Xmax  3057 (w), 2925 (w), 2851 (w), 1712 (s), 1613 (m), 1569 
(w), 1488 (m), 1466 (m), 1440 (m), 1375 (m), 1349 (m), 
1311 (w), 1265 (w), 1203 (m), 1169 (m), 1102 (w). Chapter 6: Experimental 
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GH (300 MHz, CDCl3)
  8.76  (1H,  br.  s,  NH),  7.26  (1H,  d,  J=8.0  Hz,  ArH), 
7.22 (1H,  t,  J=7.7  Hz,  ArH),  7.02  (1H,  app.  td,  J=7.6, 
0.9 Hz, ArH), 6.90 (1H, d, J=7.7 Hz, ArH), 3.41 (1H, d, 
J=3.5  Hz,  CHC=O),  2.52  (1H,  sept.  d,  J=7.0,  3.5  Hz, 
CH(CH3)2),  1.14  (3H,  d,  J=7.0  Hz,  CH3),  0.93  (3H,  d, 
J=7.0 Hz, CH3). 
GC (75 MHz, CDCl3)
  180.0  (C=O),  142.0  (C),  128.3  (C),  127.8  (CH),  124.6 
(CH), 122.0 (CH) 109.5 (CH), 52.1 (CH), 30.7 (CH) 19.8 
(CH3), 17.9 (CH3). 
LRMS (EI)  175 ([M]
, 23%), 133 ([M±C(CH3)2]
+, 100%). 
 
 
3-Isopropyl-1H-indole (298)and3-isopropylindoline (297) 
 
To a solution of 296 (250 mg, 1.43 mmol) in THF (15 mL) at 0 °C was added 
BH3ÂDMS (10 M, 0.54 mL, 5.42 mmol) dropwise over 5 min.  The reaction mixture 
was allowed to warm to RT and after 16 h water (20 mL) was added cautiously 
and  followed  after  30  min  by  diethyl  ether  (20  mL).    The  aqueous  phase  was 
separated  and  extracted  with  diethyl ether (20  mL) then  the  combined  organic 
phases were washed with water (50 mL) and brine (50 mL), dried (MgSO4) and 
concentrated in vacuo.  Purification by column chromatography (5% diethyl ether 
in  petroleum  ether)  afforded  firstly  298  as  a  colourless  oil  (60 mg,  0.38  mmol, 
27%) and then 297 as a colourless oil (76 mg, 0.47 mmol, 33%).  These data are 
in accordance with those reported in the literature.
90,91 
 
Data for 298: 
Xmax  3412 (br. m), 3055 (w), 2957 (m), 2868 (w), 2360 (w), 
1619 (w), 1485 (w), 1456 (m), 1418 (w), 1382 (w), 1362 
(w), 1338 (w), 1242 (w), 1226 (w), 1150 (w), 1097 (w). Chapter 6: Experimental 
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GH (300 MHz, CDCl3)
  7.71 (1H, br. s, NH), 7.65 (1H, dd, J=7.8, 0.5 Hz, ArH), 
7.28 (1H, d, J=7.8 Hz, ArH), 7.20±7.05 (2H, m, 2 × ArH), 
6.87 (1H, d, J=2.2 Hz, ArH), 3.20 (1H, sept., J=6.8 Hz, 
CH(CH3)2), 1.34 (6H, d, J=6.8 Hz, 2 × CH3). 
GC (75 MHz, CDCl3)
   136.5 (C), 126.7 (C), 123.9 (C), 121.8 (CH), 119.3 (CH), 
119.2  (CH),  118.9  (CH),  111.1  (CH),  25.4  (CH),  23.3 
(2 x CH3). 
LRMS (EI)  159 ([M]
, 29%), 144 ([M±CH3]
+, 100%). 
 
Data for 297: 
Xmax  3381 (w), 3031 (w), 2956 (m), 2926 (w), 2869 (m), 2360 
(w), 1606 (m), 1487 (m), 1460 (m), 1385 (w), 1366 (w), 
1313 (w), 1246 (m), 1151 (w), 1103 (w). 
GH (300 MHz, CDCl3)
  7.14 (1H, d, J=7.3 Hz, ArH), 7.06 (1H, app. t, J=7.6 Hz, 
ArH),  6.75  (1H,  app.  t,  J=7.4  Hz,  ArH),  6.66  (1H,  d, 
J=7.7 Hz,  ArH),  3.60  (1H,  app.  t,  J=9.2  Hz,  CHCHH), 
3.50  (1H,  br.  s,  NH),  3.40  (1H,  dd,  J=9.2,  6.3  Hz, 
CHCHH),  3.26  (1H,  ddd,  J=9.2,  6.3,  5.6  Hz,  CHCH2), 
2.08 (1H, sept. d, J=6.8, 5.6 Hz, CH(CH3)2), 1.03 (3H, d, 
J=6.8 Hz, CH3), 0.93 (3H, d, J=6.8 Hz, CH3). 
GC (75 MHz, CDCl3)
  151.9  (C),  131.7  (C),  127.3  (CH),  124.7  (CH),  118.2 
(CH), 109.5 (CH), 49.2 (CH2), 48.3 (CH), 30.9 (CH), 20.4 
(CH3), 18.5 (CH3). 
LRMS (ES
+)  162 ([M+H]
+, 40%). 
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1-(2-Bromobenzyl)-3-isopropylindoline (299) 
 
To a solution of 297 (76 mg, 0.47 mmol) in acetonitrile (8 mL) at RT was added 
K2CO3 (130 mg, 0.94 mmol) and KI (8 mg, 0.05 mmol).  After 1 h, 2-bromobenzyl 
bromide  (118 mg,  0.47 mmol)  in  acetonitrile  (2 mL)  was  added  dropwise  over 
10 min.  After 12 h ethyl acetate (10 mL) and water (10 mL) were added.  The 
aqueous phase was separated and extracted with ethyl acetate (3 × 10 mL).  The 
combined organic phases were then washed with brine (20 mL), dried (MgSO4) 
and  concentrated  in  vacuo.    Purification  by  column  chromatography  (0±1% 
chloroform  in  petroleum  ether)  afforded  the  title  compound  as  a  colourless  oil 
(96 mg, 0.29 mmol, 62%). 
 
Xmax   3049 (w), 2955 (w), 2923 (w), 2868 (w), 1603 (m), 1567 
(w), 1489 (m), 1459 (m), 1439 (m), 1384 (w), 1346 (m), 
1305 (w), 1257 (m), 1156 (m), 1106 (w), 1044 (w). 
GH (300 MHz, CDCl3)   7.62 (1H, d, J=7.9 Hz, ArH), 7.44 (1H, d, J=7.6 Hz, ArH), 
7.31  (1H,  app.  t,  J=7.5  Hz,  ArH),  7.22±7.04  (3H,  m, 
3 × ArH), 6.72 (1H, app. t, J=7.4 Hz, ArH), 6.43 (1H, d, 
J=7.8  Hz,  ArH),  4.38  (1H,  d,  J=16.5  Hz,  NCHHAr), 
4.31 (1H,  d,  J=16.5  Hz,  NCHHAr),  3.55±3.41  (1H,  m, 
CHCH2), 3.37±3.20 (2H, m, CHCH2), 2.18±1.96 (1H, m, 
CH(CH3)2),  1.03  (3H,  d,  J=6.8  Hz,  CH3),  0.94  (3H,  d, 
J=6.8 Hz, CH3). 
GC (75 MHz, CDCl3)   152.5 (C), 137.5 (C), 132.7 (CH), 132.0 (C), 129.1 (CH), 
128.4 (CH), 127.5 (CH), 127.4 (CH), 124.5 (CH), 123.3 
(C), 117.3 (CH), 106.5 (CH), 56.2 (CH2), 53.9 (CH2), 46.9 
(CH), 31.1 (CH), 20.4 (CH3), 18.6 (CH3). 
LRMS (ES
+) 
79Br: 330 ([M+H]
+, 79%). Chapter 6: Experimental 
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HRMS  C18H21BrN [M+H]
+ requires 330.0852; found: 330.0859. 
 
 
3-(Benzylidene)indolin-2-one (295)
 
 ﾠ
A solution of oxindole 236 (600 mg, 4.51 mmol), piperidine (0.9 mL, 9.02 mmol) 
and benzaldehyde (526 mg, 4.96 mmol) in ethanol (4 mL) was heated at reflux for 
4 h.  The reaction mixture was cooled to RT and ethyl acetate (20 mL) and water 
(20  mL)  were  added  and  the  phases  separated.    The  aqueous  phase  was 
extracted with ethyl acetate (2 × 20 mL) and the combined organic phases washed 
with water (20 mL), brine (40 mL), then dried (MgSO4) and concentrated in vacuo.  
Purification by column chromatography (20±50% diethyl ether in petroleum ether) 
afforded the title compound as a bright yellow solid (854 mg, 3.86 mmol, 86%). 
These data are in accordance with those reported in the literature.
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MP  179±181 °C (MeOH). 
Xmax   3181 (m), 3060 (m), 3024 (m), 1697 (s), 1610 (s). 
GH (300 MHz, CDCl3)  9.32 (1H, br. s, NH), 7.91 (1H, s, C=CH), 7.80±7.63 (3H, 
m, 3 × ArH), 7.60±7.43 (3H, m, 3 × ArH), 7.36±7.19 (1H, 
app.  t,  J=7.8  Hz,  ArH),  7.00  (1H,  d,  J=7.7  Hz,  ArH), 
6.92 (1H, app. t, J=7.7 Hz, ArH). 
GC (75 MHz, CDCl3)   170.7  (C=O),  141.8  (C),  137.5  (CH),  134.9  (C),  129.9 
(CH), 129.7 (CH), 129.4 (2 × CH), 128.7 (2 × CH), 127.7 
(C), 123.0 (CH), 121.8 (CH), 121.0 (C), 110.4 (CH). 
LRMS (ES
+)  244 ([M+Na]
+, 100%).   
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3-Benzyl-1-(2-bromobenzyl)indolin-2-one (300) 
 
To  a  solution  of  295  (1.00 g,  4.52 mmol)  in  DMF  (10 mL)  was  added  NaH 
(60% in mineral oil, 199 mg, 4.97 mmol).  After 15 min, 2-bromobenzyl bromide 
(1.24 g, 4.97 mmol) in DMF (2 mL) was added dropwise over 5 min.  After 16 h the 
reaction  mixture  was  quenched  with  water  (10 mL)  and  extracted  with  MTBE 
(2 × 10 mL).  The combined organic phases were dried (MgSO4) and the solvent 
removed in vacuo to afford a yellow oil (1.76 g, 4.51 mmol, quant.) which was 
diluted with acetic acid (7 mL).  Zn dust (1.73 g, 0.026 g-atom) and conc. HCl 
(0.05 mL) were then added.  After 16 h the reaction mixture was filtered through 
Celite
®  with  additional  ethyl  acetate.    The  filtrate  was  washed  with  saturated 
NaHCO3 (2 × 20 mL) and brine (20 mL), then dried (MgSO4) and concentrated 
in vacuo.  Purification by column chromatography (10% diethyl ether in petroleum 
ether) afforded the title compound as a white solid (1.13 g, 2.88 mmol, 64%). 
 
MP  160±163 °C (EtOAc / hexanes). 
Xmax  3059 (w), 3030 (w), 2921 (w), 2853 (w), 2248 (w), 1708 
(s), 1613 (m), 1569 (w), 1488 (m), 1466 (m), 1454 (w), 
1440 (m), 1422 (w), 1381 (w), 1360 (m), 1310 (w), 1268 
(w), 1216 (w), 1026 (m), 907 (m), 747 (s), 725 (s), 698 
(s). 
GH (400 MHz, CDCl3)  7.58  (1H,  dd,  J=7.9,  1.3  Hz,  ArH),  7.41±7.22  (3H,  m, 
3 × ArH), 7.21±7.13 (4H, m, 4 × ArH), 7.10 (1H, app. td, 
J=7.6,  1.7  Hz,  ArH),  7.07±6.98  (2H,  m,  2  ×  ArH), 
6.52 (1H, d, J=7.8 Hz, ArH), 6.22 (1H, dd, J=7.7, 0.8 Hz, 
ArH),  5.15  (1H,  d,  J=16.9  Hz,  NCHHAr),  4.76  (1H,  d, 
J=16.9  Hz,  NCHHAr),  3.96  (1H,  dd,  J=7.4,  4.3  Hz, Chapter 6: Experimental 
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CHCH2Ph),  3.56  (1H,  dd,  J=13.6,  4.3  Hz,  CHCHHPh), 
3.30 (1H, dd, J=13.6, 7.4 Hz, CHCHHPh). 
GC (100 MHz, CDCl3)  176.8  (C=O),  143.1  (C),  137.0  (C),  133.9  (C),  132.6 
(CH), 129.7 (2 × CH), 128.6 (CH), 128.2 (2 × CH), 128.0 
(CH),  127.9  (C),  127.7  (CH),  127.2  (CH),  126.6  (CH), 
124.4  (CH),  122.5  (C),  122.3  (CH),  108.9  (CH),  47.1 
(CH), 43.5 (CH2), 36.2 (CH2). 
LRMS (ES
+) 
79Br: 455 ([M+Na+MeCN]
+, 100%). 
HRMS  C22H19BrNO [M+H]
+ requires 392.0645; found: 392.0640. 
 
 
3-Benzyl-1-(2-bromobenzyl)-2,3-dihydro-1H-indole (301) 
 
To a solution of 300 (100 mg, 0.25 mmol) in toluene (3 mL) at ±78 °C was added 
AlH3 (0.5 M in toluene, 1.0 mL, 0.50 mmol) dropwise over 5 min.  After 20 min the 
reaction mixture was warmed to RT for 4 h and then cooled to 0 °C.  Methanol 
(1.5 mL) then 1 M HCl (1.5 mL) were added cautiously followed after 10 min by 
saturated NaHCO3 (~pH10).  The aqueous phase was separated and extracted 
with ethyl acetate (3 × 10 mL).  The combined organic phases were washed with 
brine (30 mL), dried (MgSO4) and the solvent removed in vacuo to afford the title 
compound as a pale yellow oil (28 mg, 0.074 mmol, 30%). 
 
Xmax  3025 (w), 2916 (w), 2825 (w), 1604 (m), 1567 (w), 1487 
(m),1458 (w), 1439 (w). 
GH (300 MHz, CDCl3)   7.61  (1H,  dd,  J=7.9,  1.1  Hz,  ArH),  7.42±7.21  (7H,  m, 
7 × ArH),  7.21±7.09  (2H,  m,  2  ×  ArH),  7.05  (1H,  d, 
J=7.2 Hz,  ArH),  6.74  (1H,  app.  t,  J=7.3  Hz,  ArH), 
6.48 (1H,  d,  J=7.8  Hz,  ArH),  4.37  (1H,  d,  J=16.3  Hz, Chapter 6: Experimental 
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NCHHAr), 4.30 (1H, d, J=16.3 Hz, NCHHAr), 3.74±3.57 
(1H, m, NCH2CH), 3.49 (1H, app. t, J=8.7 Hz, NCHHCH), 
3.29±3.10 (2H, m, NCHHCH and CHCHHPh), 2.90 (1H, 
dd, J=13.6, 9.1 Hz, CHCHHPh). 
GC (75 MHz, CDCl3)  152.0 (C), 139.9 (C), 137.4 (C), 132.7 (CH), 129.1 (CH), 
129.0 (2 × CH), 128.5 (CH), 128.4 (2 × CH), 127.8 (CH), 
127.4  (CH),  126.2  (CH),  123.9  (CH),  123.3  (C),  117.6 
(CH),  106.9  (CH),  59.5  (CH2),  53.6  (CH2),  42.3  (CH), 
40.5 (CH2), N.B. One quaternary signal not observed. 
LRMS (ES
+)  
79Br: 378 ([M+H]
+, 100%). 
HRMS  Sample decomposed. 
 
 
3-Allyl-3-benzyl-1-(2-bromobenzyl)indolin-2-one  (302)  and  3-(oxyallyl)-3-
benzyl-1-(2-bromobenzyl)indolin-2-one (303) 
 
To a solution of  300 (188 mg, 0.48 mmol) in DMF (13 mL) at 0 °C was added 
sodium hydride (60% in mineral oil, 29 mg, 0.72 mmol).  After 1.5 h, allyl bromide 
(0.06 mL, 0.72 mmol) in DMF (2 mL) was added dropwise over 10 min.  After 16 h 
at RT water (20 mL) and ethyl acetate (10 mL) was added.  The aqueous phase 
was separated and extracted with ethyl acetate (2 × 10 mL).  The organic phases 
were combined, washed with water (3 × 10 mL) and brine (20 mL), dried (MgSO4) 
and concentrated in vacuo.  Purification by column chromatography (40% DCM in 
petroleum ether) afforded firstly 302 as a pale yellow oil (60 mg, 0.14 mmol, 29%) 
and then 303 as a colourless oil (44 mg, 0.10 mmol, 21%). 
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Data for 302: 
Xmax  3059 (w), 3031 (w), 2915 (w), 2849 (w), 2362 (w), 2247 
(w), 1709 (s), 1640 (w), 1612 (m), 1569 (w), 1489 (m), 
1466 (m), 1455 (w), 1439 (m), 1382 (m), 1364 (m), 1349 
(m), 1309 (w), 1269 (w), 1226 (w), 1198 (w). 
GH (400 MHz, CDCl3)   7.51  (1H,  dd,  J=7.8,  1.3  Hz,  ArH),  7.41±7.34  (1H,  m, 
ArH),  7.20±7.14  (1H,  m,  ArH),  7.14±7.05  (4H,  m, 
4 × ArH),  7.02  (1H,  app.  td,  J=7.5,  1.5  Hz,  ArH),  6.92 
(2H,  d,  J=7.0  Hz,  2  ×  ArH),  6.85  (1H,  app.  td,  J=7.5, 
1.5 Hz,  ArH),  6.36±6.31  (1H,  m,  ArH),  5.76  (1H,  d, 
J=8.0 Hz,  ArH),  5.53  (1H,  ddt,  J=17.2,  9.9,  7.3  Hz, 
CH=CH2),  5.11  (1H,  dd,  J=17.2,  2.0  Hz,  CH=CHH), 
5.00 (1H,  dd,  J=9.9,  2.0  Hz,  CH=CHH),  4.99  (1H,  d, 
J=17.4 Hz, NCHHAr), 4.60 (1H, d, J=17.4 Hz, NCHHAr), 
3.30 (1H, d, J=13.1 Hz, CHHPh), 3.20 (1H, d, J=13.1 Hz, 
CHHPh),  2.82  (1H,  dd,  J=13.6,  8.0  Hz,  CHHCH=CH2) 
2.76 (1H, dd, J=13.6, 7.0 Hz, CHHCH=CH2). 
GC (100 MHz, CDCl3)  178.4  (C=O),  142.7  (C),  136.0  (C),  133.9  (C),  132.5 
(CH), 132.2 (CH), 130.6 (C), 130.2 (2 × CH), 128.4 (CH), 
128.0  (CH),  127.9  (2  ×  CH),  127.6  (CH),  127.2  (CH), 
126.6  (CH),  123.7  (CH),  122.3  (C),  122.3  (CH),  119.2 
(CH2), 108.9 (CH), 54.9 (C), 43.5 (CH2), 43.0 (CH2), 42.4 
(CH2). 
LRMS (ES
+)  
79Br: 495 ([M+Na+MeCN]
+, 13%), 454 ([M+Na]
+, 2%). 
HRMS  C25H22BrNNaO  [M+Na]
+  requires  454.0777;  found: 
454.0793. 
 
Data for 303: 
Xmax  3059 (w), 3030 (w), 2921 (w), 2853 (w), 1724 (s), 1612 
(s), 1569 (w), 1487 (m), 1466 (s), 1440 (m), 1423 (w), 
1378 (w), 1352 (m), 1304 (w), 1277 (w), 1199 (w), 1170 
(m). Chapter 6: Experimental 
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GH (400 MHz, CDCl3)   7.52  (1H,  dd,  J=8.0,  1.0  Hz,  ArH),  7.39  (1H,  dd, 
J=7.3, 1.3  Hz,  ArH),  7.24±7.14  (3H,  m,  3  ×  ArH), 
7.11 (2H,  app.  t,  J=7.5  Hz,  2  ×  ArH),  7.04  (1H,  td, 
J=7.5, 1.5  Hz,  ArH),  6.94  (2H,  d,  J=7.5  Hz,  2  ×  ArH), 
6.88 (1H,  app.  td,  J=7.5,  1.0  Hz,  ArH),  6.36  (1H,  d, 
J=7.0 Hz,  ArH),  5.92  (1H,  ddt,  J=17.2,  10.4,  5.7  Hz, 
CH=CH2), 5.73 (1H, d, J=7.5 Hz, ArH), 5.24 (1H, app. dq, 
J=17.2,  1.5  Hz,  CH=CHH),  5.15  (1H,  app.  dq,  J=10.4, 
1.5 Hz,  CH=CHH),  5.06  (1H,  d,  J=17.1  Hz,  NCHHAr), 
4.56  (1H,  d,  J=17.1  Hz,  NCHHAr),  3.82  (1H,  ddt, 
J=11.6, 5.7,  1.4  Hz,  OCHHCH=CH2),  3.69  (1H,  ddt, 
J=11.6,  5.7,  1.4  Hz,  OCHHCH=CH2),  3.46  (1H,  d, 
J=12.6 Hz, CHHPh), 3.41 (1H, d, J=12.6 Hz, CHHPh). 
GC (100 MHz, CDCl3)  175.7  (C=O),  143.1  (C),  134.1  (CH),  133.7  (C),  133.6 
(C), 132.6 (CH), 130.8 (2 × CH), 130.0 (CH), 128.6 (CH), 
128.0  (2  ×  CH),  127.8  (CH),  127.1  (CH),  126.9  (CH), 
126.5  (C),  124.8  (CH),  123.0  (CH),  122.3  (C),  117.4 
(CH2), 109.4 (CH), 83.5 (C), 66.7 (CH2), 43.9 (CH2), 43.8 
(CH2). 
LRMS (ES
+)  
79Br: 511 ([M+Na+MeCN]
+, 37%), 470 ([M+Na]
+, 33%). 
HRMS   C25H22BrNNaO2[M+Na]
+  requires  470.0726;  found: 
470.0726. 
 
 
3-Allyl-3-benzyl-1-(2-bromobenzyl)indoline (304) 
 
To a solution of 302 (60 mg, 0.14 mmol) in toluene (2 mL) at ±78 °C was added 
AlH3 (0.5 M in toluene, 0.56 mL, 0.28 mmol) dropwise over 5 min.  After 20 min the Chapter 6: Experimental 
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reaction mixture was warmed to RT for 4 h and then cooled to 0 °C.  Methanol 
(1 mL)  then  1  M  HCl  (1 mL)  were  added  cautiously  followed  after  10  min  by 
saturated NaHCO3 (~pH 10).  The aqueous phase was separated and extracted 
with ethyl acetate (3 × 10 mL).  The combined organic phases were then washed 
with  brine  (30 mL),  dried  (MgSO4)  and  concentrated  in  vacuo.    Purification  by 
column chromatography (10±40% chloroform in petroleum ether) afforded the title 
compound as a yellow oil (41 mg, 0.10 mmol, 71%). 
 
Xmax  3061 (w), 3026 (w), 2916 (w), 2849 (w), 1698 (w), 1638 
(w),  1604  (s),  1567  (w),  1489  (s),  1459  (m),  1439  (s), 
1346 (w), 1263 (m), 1198 (w), 1158 (w), 1111 (w). 
GH (400 MHz, CDCl3)
   7.55  (1H,  dd,  J=7.8,  1.4 Hz,  ArH),  7.26±7.18  (3H,  m, 
3 × ArH), 7.17 (1H, dd, J=7.5, 1.4 Hz, ArH), 7.12 (1H, dd, 
J=7.7,  1.8  Hz,  ArH),  7.08  (1H,  app.  td,  J=7.7,  1.3  Hz, 
ArH),  6.99±6.93  (3H,  m,  3  ×  ArH),  6.90  (1H,  dd, 
J=7.6, 1.8  Hz,  ArH),  6.72  (1H,  app.  td,  J=7.4,  0.9  Hz, 
ArH),  6.31  (1H,  d,  J=7.8  Hz,  ArH),  5.87±5.73  (1H,  m, 
CH=CH2), 5.13±5.11 (1H, m, CH=CHH), 5.09 (1H, ddt, 
J=7.2, 2.2, 1.1 Hz, CH=CHH), 4.28 (1H, d, J=16.6 Hz, 
NCHHAr), 4.15 (1H, d, J=16.6 Hz, NCHHAr), 3.40 (1H, d, 
J=9.0  Hz,  NCHH),  3.24  (1H,  d,  J=9.0  Hz,  NCHH), 
2.99 (1H, d, J=13.3 Hz, CHHPh), 2.93 (1H, d, J=13.3 Hz, 
CHHPh),  2.56  (1H,  ddt,  J=14.0,  7.0,  1.4  Hz, 
CHHCH=CH2)  2.51  (1H,  ddt,  J=14.0,  8.0,  1.1  Hz, 
CHHCH=CH2). 
GC (100 MHz, CDCl3)
  151.8  (C)  138.0  (C)  137.4  (C)  134.8  (CH)  134.5  (C) 
132.5 (CH) 130.5 (2 × CH) 129.0 (CH) 128.3 (CH) 127.9 
(CH) 127.8 (2 × CH) 127.4 (CH) 126.2 (CH) 123.5 (CH) 
123.1 (C) 118.0 (CH2) 117.3 (CH) 106.7 (CH) 62.6 (CH2) 
53.5 (CH2) 48.3 (C) 45.2 (CH2) 42.7 (CH2). 
LRMS (ES
+)  
79Br: 418 ([M+H]
+, 30%). 
HRMS   C25H24BrN[M+H]
+ requires 418.1165; found: 418.1166. 
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¶-(2-Bromobenzyl)spirocyclopent-3-ene-¶-indolin-¶-one (305) 
 
A  solution  of  242  (77 mg,  0.20 mmol)  and  Hoveyda-*UXEEV¶ ,, FDWDO\VW
(3 mg, 0.004 mmol) in toluene (2 mL) was heated at reflux for 22 h, then cooled to 
RT  and  concentrated  in  vacuo.    Purification  by  column  chromatography 
(10% diethyl ether in petroleum ether) afforded the title compound as a pale brown 
oil (62 mg, 0.175 mmol, 88%). 
 
Xmax  3056 (w), 2921 (w), 2842 (w), 1714 (s), 1610 (m), 1569 
(w), 1486 (m), 1466 (m), 1440 (m), 1381 (m), 1349 (m), 
1308 (w), 1268 (w), 1206 (m), 1160 (w). 
GH (400 MHz, CDCl3)  7.61  (1H,  dd,  J=7.9,  1.1  Hz,  ArH),  7.31  (1H,  dd, 
J=7.4, 0.8  Hz,  ArH),  7.21  (1H,  app.  td,  J=7.4,  1.1  Hz, 
ArH),  7.18±7.11  (2H,  m,  2  ×  ArH),  7.06±6.97  (2H,  m, 
2 × ArH),  6.66  (1H,  d,  J=7.5  Hz,  ArH),  5.89  (2H,  s, 
CH2CH=CH),  5.04  (2H,  s,  NCH2Ar),  3.12  (2H,  d, 
J=14.6 Hz,  2  ×  CHHCH=CH),  2.71  (2H,  d,  J=14.6  Hz, 
2 × CHHCH=CH). 
GC (100 MHz, CDCl3)   181.6  (C=O),  141.3  (C),  137.2  (C),  134.6  (C),  132.9 
(CH),  128.9  (CH),  128.9  (2  ×  CH),  127.8  (CH),  127.7 
(CH),  127.6  (CH),  123.1  (CH),  122.8  (C),  121.8  (CH), 
108.9 (CH), 52.2 (C), 45.2 (2 × CH2), 43.8 (CH2). 
LRMS (ES
+)  
79Br: 417 ([M+Na+MeCN]
+, 28%). 
HRMS   C19H16BrNNaO  [M+Na]
+  requires  376.0307;  found: 
376.0313. 
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1'-(2-Bromobenzyl)spirocyclopent-3-ene-1,3'-indoline (306) 
 
To a solution of 305 (62 mg, 0.18 mmol) in toluene (2 mL) at ±78 °C was added 
AlH3 (0.5 M in toluene, 0.72 mL, 0.36 mmol) dropwise over 5 min.  After 20 min the 
reaction mixture was warmed to RT for 4 h and then cooled to 0 °C.  Methanol 
(1 mL)  then  1  M  HCl  (1 mL)  were  added  cautiously  followed  after  10  min  by 
saturated NaHCO3 (~pH 10).  The aqueous phase was separated and extracted 
with ethyl acetate (3 × 10 mL).  The combined organic phases were washed with 
brine (30 mL), then dried (MgSO4) and concentrated in vacuo to afford the title 
compound as a yellow oil (60 mg, 0.176 mmol, 98%). 
 
Xmax  3050 (w), 2917 (w), 2838 (w), 1604 (m), 1567 (w), 1485 
(s), 1459 (m), 1439 (m), 1344 (m), 1260 (m), 1024 (m), 
738 (s). 
GH (300 MHz, CDCl3)  7.60  (1H,  dd,  J=7.9,  1.0  Hz,  ArH),  7.47  (1H,  dd, 
J=7.6, 0.8  Hz,  ArH),  7.31  (1H,  app.  td,  J=7.5,  1.2  Hz, 
ArH),  7.20±7.13  (2H, m, 2 ×   ArH),  7.10  (1H,  app. td, 
J=7.7,  1.3  Hz,  ArH),  6.74  (1H,  app.  td,  J=7.4,  0.9  Hz, 
ArH),  6.48  (1H,  d,  J=7.9  Hz,  ArH),  5.76  (2H,  s, 
CH2CH=CH), 4.34 (2H, s, NCH2Ar), 3.38 (2H, s, NCH2), 
2.76 (2H, d, J=15.2 Hz, 2 × CHHCH=CH), 2.65 (2H, d, 
J=15.2 Hz, 2 × CHHCH=CH). 
GC (75 MHz, CDCl3)  151.3 (C), 138.1 (C), 137.5 (C), 132.8 (CH), 129.3 (3 × 
CH),  128.5  (CH),  127.6  (CH),  127.4  (CH),  123.4  (C), 
121.8  (CH),  118.1  (CH),  106.9  (CH),  69.5  (CH2),  53.5 
(CH2), 50.0 (C), 46.8 (2 × CH2). 
LRMS (ES
+)  
79Br: 340 ([M+H]
+, 100%). 
HRMS  C19H19BrN [M+H]
+ requires 340.0695; found: 340.0690. Chapter 6: Experimental 
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Methyl indoline-2-carboxylate (308) 
 ﾠ
To a solution of carboxylic acid 307 (500 mg, 3.06 mmol) in methanol (50 mL) was 
added thionyl chloride (0.34 mL, 4.59 mmol) dropwise over 5 min.  The reaction 
mixture  was  heated  to  reflux  for 2  h  and  then  cooled  to  RT  and  concentrated 
in vacuo.    Saturated  aq.  NaHCO3  (50  mL)  was  then  added  and  the  reaction 
mixture  extracted  with  DCM  (3  ×  50  mL),  the  combined  organic  phases  were 
washed with brine (150 mL) and concentrated in vacuo.  Purification by column 
chromatography (30% ethyl acetate in hexanes) afforded the title compound as a 
pale brown oil (454 mg, 2.56 mmol, 84 %).  These data are in accordance with 
those reported in the literature.
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ȣmax  3368  (br.  w),  3032  (w),  2951  (w),  2852  (w),  1731  (s), 
1608 (m), 1531 (w), 1485 (m), 1467 (m), 1436 (m), 1405 
(w), 1340 (w), 1321 (w), 1308 (w), 1199 (s), 1157 (m), 
1109 (w). 
įH (300 MHz, CDCl3)  7.13±6.99 (2H, m, 2 × ArH), 6.83±6.64 (2H, m, 2 × ArH), 
4.40  (1H,  dd,  J=10.1,  5.7  Hz,  CHCH2),  3.77  (3H,  s, 
CO2CH3), 3.49±3.24 (2H, m, CHCH2). 
įC (75 MHz, CDCl3)  174.6  (C=O),  150.0  (C),  127.6  (CH),  126.6  (C),  124.4 
(CH),  119.5  (CH),  110.1  (CH),  59.8  (CH),  52.4  (CH3), 
33.7 (CH2). 
LRMS (ES
+)  219 ([M+MeCN]
+, 100%). 
N.B. This compound is prone to decomposition. 
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Methyl 1-(2-bromobenzyl)indoline-2-carboxylate (309) 
 ﾠ
To a solution of 308 (500 mg, 2.82 mmol) in acetonitrile (40 mL) was added K2CO3 
(780 mg,  5.64 mmol)  and  KI  (46 mg,  0.28 mmol).    After  1  h,  2-bromobenzyl 
bromide  (705 mg,  2.82 mmol)  in  acetonitrile  (20 mL)  was  added  dropwise  over 
30 min.  After 12 h ethyl acetate (50 mL) and water (50 mL) were added.  The 
aqueous phase was separated and extracted with ethyl acetate (3 × 50 mL) then 
the combined organic phases were washed with brine (100 mL), dried (MgSO4) 
and concentrated in vacuo.  Purification by column chromatography (5% diethyl 
ether  in  petroleum  ether)  afforded  the  title  compound  as  a  pale  brown  oil 
(592 mg, 1.71 mmol, 61%). 
 
Xmax  3053 (w), 3028 (w), 2950 (w), 2914 (w), 2850 (w), 1745 
(s), 1607 (m), 1568 (w), 1485 (s), 1462 (m), 1439 (m), 
1388 (w), 1347 (m), 1317 (w), 1262 (m), 1197 (s), 1168 
(s), 1088 (w), 1060 (w), 1044 (w), 1024 (m), 1002 (w). 
GH (300 MHz, CDCl3)   7.59  (1H,  dd,  J=8.0,  1.0  Hz,  ArH),  7.48  (1H,  dd, 
J=7.7, 0.9  Hz,  ArH),  7.28  (1H,  app.  td,  J=7.4,  1.0  Hz, 
ArH),  7.16  (1H,  dd,  J=7.8,  1.6  Hz,  ArH),  7.12  (1H,  t, 
J=8.0  Hz,  ArH),  7.06  (1H,  app.  t,  J=7.8  Hz,  ArH), 
6.73 (1H, app. t, J=7.4 Hz, ArH), 6.34 (1H, d, J=7.7 Hz, 
ArH), 4.47 (2H, s, NCH2Ar), 4.39 (1H, dd, J=10.3, 8.0 Hz, 
CHCHH),  3.68  (3H,  s,  OCH3),  3.48  (1H,  dd, 
J=16.1, 10.3 Hz, CHCHH), 3.27 (1H, dd, J=16.1, 8.0 Hz, 
CHCHH). 
GC (75 MHz, CDCl3)   173.2  (C=O),  151.0  (C),  136.9  (C),  132.6  (CH),  129.2 
(CH),  128.6  (CH),  127.8  (CH),  127.5  (CH),  126.7  (C), Chapter 6: Experimental 
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124.1  (CH),  123.1  (C),  118.3  (CH),  107.0  (CH),  66.1 
(CH3), 52.9 (CH2), 52.1 (CH), 33.6 (CH2). 
LRMS (EI) 
79Br: 207 ([M±CO2Me±Br]
+, 75%). 
HRMS  C17H17BrNO2[M+H]
+ requires 346.0437; found: 346.0432. 
 
 
1-(3,4,5-Trimethoxybenzyl)indoline  (312a)  and  8,9,10-trimethoxy-10b,11-
dihydro-6H-isoindolo[2,1-a]indole (366) 
 ﾠ
A solution of 293 (106 mg, 0.19 mmol), tributyltin hydride (0.23 mL, 0.84 mmol) 
and VAZO (9 mg, 0.04 mmol) in toluene (6 mL) was heated at reflux for 18 h, then 
cooled to RT and concentrated in vacuo.  Purification by column chromatography 
(10% w/w anhydrous K2CO3-silica; 20% diethyl ether in petroleum ether) afforded 
firstly 312a, as a colourless oil (54 mg, 0.18 mmol, 95%) and then finally trace 366 
as a pale yellow oil (3 mg, 0.01 mmol, 5%) identified by comparison with literature 
data.
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Xmax  2923 (w), 2837 (w), 1590 (m), 1504 (m), 1487 (m), 1456 
(m), 1419 (m), 1377 (w), 1357 (w), 1327 (m), 1270 (w), 
1228 (m), 1181 (w), 1122 (s), 1008 (m). 
GH (300 MHz, CDCl3)   7.16±7.03  (2H,  m,  2 ×  ArH),  6.71  (1H,  app.  td,  J=7.4, 
0.9 Hz, ArH), 6.63 (2H, s, ArH), 6.55 (1H, d, J=7.6 Hz, 
ArH),  4.19  (2H,  s,  NCH2Ar),  3.88  (3H,  s,  OCH3), 
3.86 (6H, s, 2 × OCH3), 3.33 (2H, t, J=8.3 Hz, NCH2CH2), 
3.01 (2H, t, J=8.3 Hz, NCH2CH2). 
GC (75 MHz, CDCl3)  153.3 (2 × C), 152.5 (C), 136.9 (C), 134.3 (C), 130.0 (C), 
127.3 (CH), 124.5 (CH), 117.9 (CH), 107.2 (CH), 104.5 Chapter 6: Experimental 
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(2 × CH), 60.8 (CH3), 56.1 (2 × CH3), 54.3 (CH2), 53.8 
(CH2), 28.5 (CH2). 
LRMS (ES
+)   299 ([M]
+, 13%). 
HRMS   C18H21NNaO3[M+Na]
+  requires  322.1414;  found: 
322.1414. 
 
 
1-Benzyl-3,3-dimethylindoline (312b) 
 ﾠ
A solution of 289 (87 mg, 0.28 mmol), tributyltin hydride (0.17 mL, 0.62 mmol) and 
VAZO (15 mg, 0.06 mmol) in toluene (9 mL) was heated at reflux for 18 h, then 
cooled to RT and concentrated in vacuo.  Purification by column chromatography 
(10% w/w anhydrous K2CO3-silica; 5% chloroform in petroleum ether) afforded the 
title compound as a colourless oil (66 mg, 0.28 mmol, 100%). 
 
Xmax  3025 (w), 2956 (w), 2922 (w), 2860 (w), 2803 (w), 1605 
(m), 1486 (m), 1453 (m), 1361 (m), 1297 (w), 1260 (m), 
1194 (m), 1157 (m), 1117 (w). 
GH (300 MHz, CDCl3)   7.33±7.10 (5H, m, 5 × ArH), 7.03±6.91 (2H, m, 2 × ArH), 
6.62  (1H,  app.  td,  J=7.3,  0.9  Hz,  ArH),  6.41  (1H,  d, 
J=7.8 Hz,  ArH),  4.18  (2H,  s,  NCH2Ph),  3.00  (2H,  s, 
NCH2), 1.22 (6H, s, 2 × CH3). 
GC (75 MHz, CDCl3)   151.1 (C), 138.9 (C), 138.6 (C), 128.4 (2 × CH), 127.7 
(2 ×  CH),  127.4  (CH),  127.0  (CH),  121.7  (CH),  117.7 
(CH), 106.9 (CH), 67.8 (CH2), 53.0 (CH2), 40.2 (C), 27.54 
(2 × CH3). 
LRMS (ES
+)   238 ([M+H]
+, 28%). 
HRMS   C17H20N[M+H]
+ requires 238.1590; found: 238.1590. Chapter 6: Experimental 
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1-Benzyl-3-isopropylindoline (312c) 
 ﾠ
A solution of 299 (96 mg, 0.29 mmol), tributyltin hydride (0.17 mL, 0.64 mmol) and 
VAZO (15 mg, 0.06 mmol) in toluene (8 mL) was heated at reflux for 18 h, then 
cooled  and  concentrated  in  vacuo.    Purification  by  column  chromatography 
(10% w/w anhydrous K2CO3-silica; 10% chloroform in petroleum ether) afforded 
the title compound as a pale yellow oil (70 mg, 0.28 mmol, 97%). 
 
Xmax  3027 (w), 2955 (w), 2924 (w), 2869 (w), 2825 (w), 2361 
(w), 1603 (m), 1490 (s), 1454 (s), 1384 (w), 1358 (w), 
1309 (w), 1242 (m), 1202 (w), 1173 (w), 1154 (w), 1104 
(w). 
GH (300 MHz, CDCl3)
  7.31±7.11 (5H, m, 5 × ArH), 7.05±6.93 (2H, m, 2 × ArH), 
6.59  (1H,  app.  td,  J=7.4,  1.0  Hz,  ArH),  6.39  (1H,  d, 
J=7.7 Hz,  ArH),  4.21  (1H,  d,  J=15.1  Hz,  NCHHPh), 
4.13 (1H,  d,  J=15.1  Hz,  NCHHPh),  3.25  (1H,  app.  t, 
J=11.0  Hz,  CHCH2),  3.14±3.04  (2H,  m,  CHCH2), 
1.95 (1H, sept. d, J=6.8, 5.2 Hz, CH(CH3)2), 0.89 (3H, d, 
J=6.8 Hz, CH3), 0.79 (3H, d, J=6.8 Hz, CH3). 
GC (75 MHz, CDCl3)
  152.8 (C), 138.7 (C), 132.2 (C), 128.4 (2 × CH), 127.7 
(2 ×  CH),  127.5  (CH),  127.0  (CH),  124.5  (CH),  117.1 
(CH),  106.6  (CH),  55.7  (CH2),  53.4  (CH2),  46.8  (CH), 
31.0 (CH), 20.4 (CH3), 18.5 (CH3). 
LRMS (ES
+)  252 ([M+H]
+, 100%). 
HRMS  Sample decomposed. ﾠ
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1-Benzyl-1H-indole (313d) 
 
A solution of 301 (60 mg, 0.16 mmol), tributyltin hydride (0.1 mL, 0.35 mmol) and 
VAZO  (7 mg,  0.03 mmol)  in  toluene  (5 mL) was  heated  at  reflux  for 64  h then 
cooled to RT and an additional charge of tributyltin hydride (0.1 mL, 0.35 mmol) 
and VAZO (7 mg, 0.03 mmol) added.  After a further 1 h at reflux, the reaction 
mixture  was  cooled  to  RT  and  concentrated  in  vacuo.    Purification  by  column 
chromatography (10% w/w anhydrous K2CO3-silica; 5% DCM in petroleum ether) 
afforded the title compound as a colourless oil (19 mg, 0.092 mmol, 58%).  These 
data are in accordance with those reported in the literature.
93 
 
Xmax  3029 (w), 2919 (w), 1612 (w), 1511 (w), 1495 (w), 1484 
(w), 1463 (m). 
GH (300 MHz, CDCl3)  7.66  (1H,  dd,  J=7.9,  1.0  Hz,  ArH),  7.36±7.22  (4H,  m, 
4 × ArH),  7.21±7.06  (5H,  m,  5  ×  ArH),  6.56  (1H,  d, 
J=3.2 Hz, ArH), 5.32 (2H, s, NCH2Ar). 
GC (75 MHz, CDCl3)  137.7 (2 × C), 136.5 (C), 128.9 (2 × CH), 128.4 (CH), 
127.8  (CH),  126.9  (2  ×  CH),  121.9  (CH),  121.1  (CH), 
119.7 (CH), 109.9 (CH), 101.9 (CH), 50.3 (CH2). 
LRMS (ES
+)   360 (100%), 208 ([M+H]
+, 24%). 
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3-Allyl-1-benzyl-1H-indole (313e) 
 
A solution of 243 (51 mg, 0.14 mmol), tributyltin hydride (0.08 mL, 0.31 mmol) and 
VAZO (7 mg, 0.03 mmol) in toluene (4 mL) was heated at reflux for 18 h, then 
cooled to RT and concentrated in vacuo.  Purification by column chromatography 
(10% w/w anhydrous K2CO3-silica; 0±25% DCM in petroleum ether) afforded the 
title compound as a colourless oil (30 mg, 0.12 mmol, 86%).  These data are in 
accordance with those reported in the literature.
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Xmax  3058 (w), 3029 (w), 2917 (w), 1715 (w), 1670 (w), 1638 
(w), 1604 (m), 1553 (w), 1494 (w), 1481 (w), 1465 (m), 
1453 (m), 1439 (w), 1392 (w), 1356 (m), 1352 (m), 1298 
(w). 
GH (300 MHz, CDCl3)  7.63 (1H, d, J=7.7 Hz, ArH), 7.36±7.24 (4H, m, 4 × ArH), 
7.18 (1H, app. td, J=7.5, 1.1 Hz, ArH), 7.15±7.07 (3H, m, 
3  ×  ArH),  6.93  (1H,  s,  ArH),  6.09  (1H,  ddt, 
J=16.9, 10.2, 6.4 Hz, CH2CH=CH2), 5.29 (2H, s, CH2Ph), 
5.24±5.02  (2H,  m,  CH2CH=CH2),  3.55  (2H,  dd, 
J=6.4, 0.9 Hz, CH2CH=CH2). 
GC (75 MHz, CDCl3)   137.7 (C), 137.4 (CH), 128.7 (2 × CH), 128.1 (C), 127.5 
(CH),  126.8  (2  ×  CH),  125.9  (CH),  121.7  (CH),  119.2 
(CH), 118.9 (CH), 115.1 (CH2), 113.6 (C), 109.6 (CH), 
49.9 (CH2), 29.8 (CH2), N.B. One quaternary signal not 
observed. 
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3-Allyl-1-benzyl-1H-indole  (316)  and  1,3-dibenzyl-1H-indole  (315)and3-allyl-
1,3-dibenzylindoline (367) 
 
A solution of 314 (41 mg, 0.10 mmol), tributyltin hydride (0.06 mL, 0.22 mmol) and 
VAZO (5 mg, 0.02 mmol) in toluene (3 mL) were heated at reflux for 18 h, then 
cooled to RT and concentrated in vacuo.  Purification by column chromatography 
(10% w/w anhydrous K2CO3-silica; 0±1% chloroform in petroleum ether) afforded 
an  inseparable  mixture  of  316,  315  and  367  (10:5:2)  as  a  colourless  oil 
(13 mg, 0.048 mmol, 48%). 
 
Xmax  3059 (w), 3028 (w), 2917 (w), 2852 (w), 2358 (w), 2336 
(w), 1638 (w), 1604 (w), 1553 (w), 1495 (w), 1481 (w), 
1466 (m), 1453 (m), 1439 (w), 1392 (w), 1357 (m), 1332 
(m), 1299 (w), 1260 (w), 1203 (w), 1173 (w), 1126 (w), 
1106 (w), 1075 (w). 
GH (400 MHz, CDCl3)  Peaks  attributed  to  316  7.60  (1H,  d,  J=7.6 Hz,  ArH), 
7.35±6.98 (8H, m, 8 × ArH), 6.90 (1H, s, ArH), 6.06 (1H, 
ddt,  J=17.0,  10.2,  6.4  Hz,  CH2CH=CH2),  5.26  (2H,  s, 
CH2Ar),  5.19±5.01  (2H,  m,  CH2CH=CH2),  3.51  (2H,  d, 
J=6.4 Hz, CH2CH=CH2); Peaks attributed to 315 7.33±
6.80 (15H, m, 15 × ArH),5.27 (2H, s, NCH2Ph), 4.11 (2H, 
s, CCH2Ph); Peaks attributed to 367 7.51 (1H, d, J=7.6, 
1.4 Hz, ArH), 7.33±6.80 (11H, m, 11 × ArH), 6.66 (1H, 
app. t, J=7.4 Hz, ArH), 6.38 (1H, d, J=7.6 Hz, ArH), 5.80±
5.66  (1H,  m,  CH=CH2),  í + REVF
m,CH2CH=CH2),4.23  (1H,  d,  J=15.7  Hz,  NCHHAr), 
4.05 (1H, d, J=15.7 Hz, NCHHAr), 3.24 (1H, d, J=9.1 Hz, Chapter 6: Experimental 
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NCHH),  3.07  (1H,  d,  J=9.1  Hz,  NCHH),  2.90  (1H,  s, 
CCH2Ph), 2.52±2.38 (2H, m, CH2CH=CH2). 
LRMS (ES
+)  340  ([367+H]
+,  100%),  298  ([315+H]
+,  20%),  248 
([316+H]
+, 20%). 
 
 
1'-Benzylspirocyclopent-3-ene-1,3'-indoline (317) 
 
A solution of 306 (137 mg, 0.40 mmol), tributyltin hydride (0.24 mL, 0.88 mmol) 
and VAZO (20 mg, 0.08 mmol) in toluene (10 mL) was heated at reflux for 18 h, 
then  cooled  to  RT  and  concentrated  in  vacuo.    Purification  by  column 
chromatography  (10%  w/w  anhydrous  K2CO3-silica;  0±2%  diethyl  ether  in 
petroleum  ether)  afforded  the  title  compound  as  a  colourless  oil 
(61 mg, 0.23 mmol, 58%). 
 
Xmax  3051  (w),  3026  (w),  2918  (br.  w),  2839  (w),  1716  (w), 
1678 (w), 1603 (m), 1485 (s), 1459 (m), 1453 (m), 1437 
(m), 1375 (w), 1357 (m), 1330 (w), 1311 (w), 1294 (w), 
1260 (m), 1202 (w), 1155 (m). 
GH (400 MHz, CDCl3)   7.40±7.32 (3H, m, 3 × ArH), 7.31±7.26 (2H, m, 2 × ArH), 
7.15±7.05  (2H,  m,  2  ×  ArH),  6.72  (1H,  app.  td, 
J=7.4, 0.9 Hz,  ArH),  6.55  (1H,  d,  J=7.8  Hz,  ArH), 
5.73 (2H, s, CH=CH), 4.27 (2H, s, NCH2Ph), 3.25 (2H, s, 
NCH2), 2.75±2.67 (2H, m, CH2CHCH), 2.64±2.56 (2H, m, 
CH2CHCH). 
GC (100 MHz, CDCl3)  151.6 (C), 138.5 (2 × C), 129.3 (2 × CH), 128.5 (2 × CH), 
127.9  (2  ×  CH),  127.5  (CH),  127.1  (CH),  121.8  (CH), Chapter 6: Experimental 
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118.1 (CH), 107.1 (CH), 69.0 (CH2), 53.3 (CH2), 49.8 (C), 
46.7 (2 × CH2). 
LRMS (ES
+)   262 ([M+H]
+, 68%). 
HRMS   C19H20N [M+H]
+ requires 262.1590; found: 262.1592. 
 
 
Methyl 1-benzyl-1H-indole-2-carboxylate (321)and methyl 1-benzylindoline-2-
carboxylate (320)  
 
A solution of  309 (569 mg, 1.64 mmol), tributyltin hydride (0.97 mL, 3.61 mmol) 
and VAZO (81 mg, 0.33 mmol) in toluene (50 mL) was heated at reflux for 18 h, 
then  cooled  to  RT  and  concentrated  in  vacuo.    Purification  by  column 
chromatography  (10%  w/w  anhydrous  K2CO3-silica;  2±5%  diethyl  ether  in 
petroleum ether) afforded firstly 321 as a colourless oil (102 mg, 0.38 mmol, 24%) 
and then 320 as a pale yellow oil (290 mg, 1.09 mmol, 67%). 
 
Data for 321: 
Xmax  3062 (w), 3031 (w), 2946 (w), 2857 (w), 1706 (s), 1614 
(w), 1605 (w), 1518 (m), 1496 (w), 1480 (w), 1452 (m), 
1434 (m), 1404 (w), 1353 (m), 1319 (m), 1248 (s), 1191 
(s), 1163 (m), 1138 (m), 1118 (w), 1095 (m), 1076(w). 
GH (300 MHz, CDCl3)
  7.76 (1H, d, J=8.1 Hz, ArH), 7.44 (1H, s, ArH), 7.41 (1H, 
d,  J=8.1  Hz,  ArH),  7.36  (1H,  dd,  J=6.6,  1.1  Hz,  ArH), 
7.28 (1H, d, J=7.5 Hz, ArH), 7.33±7.17 (3H, m, 3 × ArH), 
7.10 (2H, m, 2 × ArH), 5.89 (2H, s, NCH2Ph), 3.91 (3H, s, 
OCH3). 
GC (75 MHz, CDCl3)
  162.3 (C=O), 139.5 (C), 138.2 (C), 128.5 (2 × CH), 127.3 
(CH), 127.1 (C), 126.2 (2 × CH), 126.1 (C), 125.3 (CH), Chapter 6: Experimental 
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122.7 (CH), 120.8 (CH), 111.1 (CH), 110.8 (CH), 51.61 
(CH3) 47.79 (CH2). 
LRMS (EI)  265  ([M]
,  57%),  233  ([M±MeOH]
+,  12%),  206  ([M±
CO2Me]
+,  6%),  188  ([M±Ph]
+,  4%),  115  ([M±CO2Me±
Ph]
+, 5%), 91 ([Bn]
, 100%). 
HRMS   C17H15NNaO2[M+Na]
+requires  288.0995;  found: 
288.0994. 
 
Data for 320: 
Xmax  3053 (w), 3027 (w), 2950 (w), 2849 (w), 1733 (s), 1605 
(m), 1484 (s), 1461 (m), 1453 (m), 1435 (m), 1385 (w), 
1351 (m), 1319 (w), 1265 (m), 1195 (s), 1156 (s), 1088 
(w), 1076 (w), 1022 (m), 1000 (m). 
GH (300 MHz, CDCl3)   7.32±7.14 (5H, m, 5 × ArH), 7.02±6.93 (2H, m, 2 ×  ArH), 
6.62  (1H,  app.  td,  J=7.4,  0.7  Hz,  ArH),    6.39  (1H,  d, 
J=7.8 Hz,  ArH),  4.44  (1H,  d,  J=15.4  Hz,  NCHHPh), 
4.25 (1H,  d,  J=15.4  Hz,  NCHHPh),  4.19  (1H,  dd, 
J=10.3, 8.1 Hz, CHCHH), 3.59 (3H, s, OCH3), 3.31 (1H, 
dd,  J=15.9,  10.3  Hz,  CHCHH),  3.12  (1H,  dd, 
J=15.9, 8.1 Hz, CHCHH). 
GC (75 MHz, CDCl3)  173.3 (C=O), 151.3 (C), 137.7 (C), 128.4 (2 × CH), 127.8 
(2 × CH), 127.7 (CH), 127.2 (CH), 126.8 (C), 124.1 (CH), 
118.1  (CH),  107.2  (CH),  65.2  (CH),  52.1  (CH2),  52.0 
(CH3), 33.4 (CH2). 
LRMS (EI)  267  ([M]
,  25%),  208  ([M±CO2Me]
+,  54%),  117  ([M±
CO2Me±Bn]
+, 17%), 91 ([Bn]
, 100%). 
HRMS   C17H17NNaO2[M+Na]
+  requires  290.1151;  found: 
290.1156. 
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6.4 Experimental Procedures for Chapter 5 
N-Methyl-3-bromo-1H-indole-2-carbaldehyde (323) 
 ﾠ
To a solution of aldehyde 322 (796 mg, 5.00 mmol) in DMF (10 mL) was added 
N-bromosuccinimide (890 mg, 5.00 mmol) dropwise in DMF (5 mL).  After 20 h at 
RT the reaction mixture was poured onto ice water (100 mL) and the resultant 
white precipitate collected by filtration and washed with cold ethanol to afford the 
title compound as a white solid (1.12 g, 4.71 mmol, 94%).  These data are in 
accordance with that reported in the literature.
96 
 
MP  113±116 °C (EtOH), Lit. 86±89 °C.
96 
ȣmax  3035 (w), 2945 (w), 2824 (m),  2724 (w), 1663 (s), 1613 
(m), 1567 (w), 1507 (m), 1469 (s), 1426 (w), 1395 (m), 
1350 (m), 1329 (m), 1238 (m), 1182 (m), 738 (s). 
 
įH (300 MHz, CDCl3)  10.13  (1H,  s,  CHO),  7.70  (1H,  d,  J=8.1  Hz,  ArH), 
7.48 (1H,  ddd,  J=8.4,  7.0,  1.1  Hz,  ArH),  7.38  (1H,  d, 
J=8.7 Hz, ArH), 7.26 (1H, ddd, J=8.1, 7.0, 1.1 Hz, ArH), 
4.08 (3H, s, CH3). 
įC (75 MHz, CDCl3)   182.6  (CHO),  139.4  (C),  130.0  (C),  128.1  (CH),  126.2 
(C), 121.6 (CH), 121.5 (CH), 110.5 (CH), 106.0 (C), 31.8 
(CH3). 
LRMS (EI) 
79Br:  237  (M
   >0í&+2@
+,  16%),  129 
>0í&+2í%U@
+, 33%), 114 (32%). 
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N-Methyl-3-(tributylstannyl)indole-2-carboxaldehyde (325) 
 ﾠ
To a stirred solution of N,O-dimethylhydroxylamine (147 mg, 1.51 mmol) in THF 
(7 mL) at ±78 °C was added nBuLi (1.18 mL, 2.56 M in hexanes, 3.02 mmol).  
After 1 h a solution of aldehyde 323 (300 mg, 1.26 mmol) in THF (3 mL) was 
added, followed after 15 min by nBuLi (1.13 mL, 2.56 M, 2.90 mmol).  The solution 
was warmed to ±40 °C and after 3 h tributyltin chloride (0.41 mL, 1.51 mmol) was 
added.  The solution was warmed to RT and after 16 h, water (5 mL) and diethyl 
ether (10 mL) were added.  The aqueous phase was separated and washed with 
diethyl ether (10 mL). The combined organic phases were then washed with brine 
(20 mL),  dried  (MgSO4)  and  concentrated  in  vacuo.    Purification  by  column 
chromatography  (10%  w/w  anhydrous  K2CO3-silica;  5±10%  diethyl  ether  in 
petroleum  ether)  afforded  the  title  compound  as  a  pale  yellow  oil 
(245 mg, 0.55 mmol, 44%). 
 
ȣmax  2954 (m), 2921 (m), 2870 (m), 2851 (m), 2360 (w), 2341 
(w), 1662 (s), 1609 (m), 1561 (w), 1520 (w), 1464 (s), 
1421 (w), 1382 (m), 1340 (s), 1234 (w), 870 (s), 740 (s).
 
įH (400 MHz, CDCl3)  9.89  (1H,  s,  CHO),  7.75  (1H,  dt,  J=8.2,  0.9  Hz,  ArH), 
7.42 (2H, m, 2 × ArH),7.17 (1H, ddd, J=8.1, 5.4, 2.6 Hz, 
ArH),  4.13  (3H,  s,  NCH3),  1.61í1.52(6H,  m, 
3 × SnCH2(CH2)2CH3),  1.36  (6H,  sxt,J=7.3  Hz, 
3 × Sn(CH2)2CH2CH3),  1.27í1.21  (6H,  m, 
3 × SnCH2CH2CH2CH3),  0.89  (9H,  t,  J=7.3  Hz, 
3 × Sn(CH2)3CH3). 
įC (100 MHz, CDCl3)  185.0 (CHO), 142.1 (C), 141.7 (C), 134.3 (C), 129.9 (C), 
127.1  (CH),  125.5  (CH),  120.9  (CH),  110.9  (CH),  32.2 
(NCH3), 29.5 (3 x CH2), 27.7 (3 x CH2), 14.0 (3 x CH3), 
11.8 (3 x CH2). Chapter 6: Experimental 
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 ﾠ
LRMS (EI) 
120Sn:   >0í%X@
+   >0í%X@
+,  21%),  159 
>0í6Q%X3]
+, 100%). 
HRMS  Sample decomposed. 
 
 
Indole-2-carboxaldehyde (327) 
 ﾠ
To a solution of carboxylic acid 326 (500 mg, 3.10 mmol) in THF (6 mL) at 0 °C 
was added thionyl chloride (0.41 mL, 5.60 mmol) in THF (1 mL) dropwise over 
5 min.  The resulting mixture was heated to 50 °C for 4 h then cooled to RT and 
concentrated in vacuo.  The residue was washed with hexanes (2 x 5 mL) then 
dissolved in THF (4 mL).  Pd(PPh3)4 (23 mg, 0.02 mmol) was then added, followed 
by tributyltin hydride (0.92 mL, 2.07 mmol), dropwise over 5 min.  After 1 h at RT 
the  reaction  mixture  was  filtered  through  Celite
®  and  concentrated  in  vacuo.  
Purification  by  column  chromatography  (10%  w/w  anhydrous  K2CO3-silica; 
10% ethyl acetate in petroleum ether) afforded the title compound as a white solid 
(87 mg, 0.60 mmol, 19% over two steps).  These data are in accordance with that 
reported in the literature.
98 
 
MP  141±144 °C (PhMe / hexanes), Lit. 139±140 °C.
98 
ȣmax  3310  (s),  3210  (br.  w),  2861  (w),  1677  (s),  1619  (w), 
1574 (w), 1527 (m), 1451 (w), 1428 (w), 1366 (w), 1341 
(m), 1242 (w), 1231 (m), 1127 (m), 821 (m), 744 (m). 
 
įH (300 MHz, CDCl3)  9.87 (1H, s, CHO), 9.14 (1H, br. s, NH), 7.77 (1H, ddd, 
J=8.2,  1.9,  1.0  Hz,  ArH),  7.47  (1H,  ddd,  J=8.4,  1.9, 
1.0 Hz,  ArH),  7.41  (1H,  ddd,  J=8.4,  6.9,  1.1 Hz,  ArH), 
7.30 (1H, dd, J=2.1, 0.9 Hz, ArH), 7.20 (1H, ddd, J=8.1, 
6.9, 1.1 Hz, ArH).
 
įC (75 MHz, CDCl3)  182.1  (CHO),  138.0  (C),  136.0  (C),  127.3  (CH),  123.4 
(CH), 121.3 (CH), 114.8 (CH), 112.4 (CH). Chapter 6: Experimental 
137 ﾠ
 ﾠ
  N.B. One aromatic quaternary centre not observed. 
LRMS (CI)  145 (M
>0í&+2@
+, 26%), 89 (100%). 
 
 
2-(Ethyoxycarbonyl)indole (328) 
 ﾠ
To a solution of carboxylic acid 326 (1.00 g, 6.21 mmol) in ethanol (15 mL) was 
added conc. H2SO4 (0.15 mL).  The reaction mixture was heated at reflux for 20 h 
then cooled to RT, concentrated in vacuo to ~5 mL then poured into sat.NaHCO3 
(25 mL) at 0 °C.  The resulting precipitate was dissolved in diethyl ether (50 mL) 
and  the  aqueous  phase  was  extracted  with  diethyl  ether  (2  x  50  mL).  The 
combined organic phases were dried (MgSO4) and concentrated in vacuo to afford 
the title compound as a white fibrous solid (1.08 g, 5.71 mmol, 92%).  These data 
are in accordance with that reported in the literature.
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MP  149±151 °C (EtOH), Lit. 120±121 °C.
99 
ȣmax  3310 (s), 3081 (w), 2985 (w), 2940 (w), 2907 (w), 2360 
(w), 2342 (w), 1692 (s), 1619 (w), 1528 (m), 1475 (w), 
1446 (w), 1435 (w), 1397 (w), 1383 (m), 1370 (w), 1341 
(m), 1310 (m), 1253 (s), 1206 (s), 773 (m), 747 (m).
 
įH (300 MHz, CDCl3)  9.14 (1H, br. s, NH), 7.71 (1H, dd, J=8.1, 1.1 Hz, ArH), 
7.45 (1H, dd, J=8.3, 1.0 Hz, ArH), 7.34 (1H, ddd, J=8.3, 
7.0,  1.1  Hz,  ArH),  7.26  (1H,  dd,  J=2.1,  1.0  Hz,  ArH), 
7.17 (1H,  ddd,  J=8.1,  7.0,  1.0  Hz,  ArH),  4.45  (2H,  q, 
J=7.1  Hz,  CO2CH2CH3),  1.44  (3H,  t,  J=7.1  Hz, 
CO2CH2CH3). 
įC (75 MHz, CDCl3)  162.1 (C=O), 136.8 (C), 127.5 (2 × C), 125.3 (CH), 122.6 
(CH), 120.7 (CH), 111.9 (CH), 108.6 (CH), 61.0 (CH2), 
14.4 (CH3). Chapter 6: Experimental 
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 ﾠ
LRMS (CI)  189 (M
+>0í(W@
+>0í(W2+@
+, 
>0í&22Et]
+, 82%). ﾠ
 
 
2-(Hydroxymethyl)indole (329) 
 
To a solution of ester 328 JPPROLQ7+)P/DWí&ZDV
added LiAlH4 (2.14 g, 56.3 mmol) portionwise.  The reaction mixture was warmed 
to 0 °C.  After 1 h water (5 mL) was added cautiously, followed by 15% aq. NaOH 
(5 mL) and water (15 mL).  After 30 min MgSO4 (25.00 g) was added and after 
16 h the white suspension was removed by filtration and the filtrate concentrated 
in vacuo.  Recrystallisation from benzene / petrol afforded the title compound as 
pale orange needles (3.72 g, 25.3 mmol, 99%).  These data are in accordance 
with that reported in the literature.
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MP  71±73 °C (benzene / petrol), Lit.75±76 °C.
98 
ȣmax  3379  (s),  3300  (br.  w),  3051  (w),  2859  (w),  2358  (w), 
1489 (w), 1455 (m), 1417 (m), 1385 (w), 1341 (w), 1309 
(w), 1291 (m), 1138 (m), 1061 (m), 1016 (m), 1004 (m), 
967 (m), 929 (w), 793 (m), 782 (m), 750 (s), 736 (s).
 
įH (300 MHz, CDCl3)
  8.37  (1H,  br.  s,  NH),  7.60  (1H,  d,  J=7.4  Hz,  ArH), 
7.32 (1H, d, J=7.7 Hz, ArH), 7.21 (1H, td, J=7.4, 1.1 Hz, 
ArH), 7.13 (1H, td, J=7.7, 1.1 Hz, ArH), 6.40 (1H, s, ArH), 
4.77 (2H, s, ArCH2OH), 2.21 (1H, br. s, ArCH2OH). 
įC (75 MHz, CDCl3)
  137.5 (C), 136.3 (C), 128.0 (C), 122.2 (CH), 120.6 (CH), 
119.9 (CH), 111.0 (CH), 100.5 (CH), 58.6 (CH2). 
LRMS (CI)  148 ([M+H]
+, 100%), 57 (31%), 43 (25%). 
 
 
   Chapter 6: Experimental 
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Indole-2-carboxaldehyde (327) 
 
To a solution of alcohol 329 (5.13 g, 34.9 mmol) in DCM (140 mL) was added 
barium manganate(VI) (8.93 g, 34.9 mmol) and activated MnO2 (72.7 g, 0.84 mol; 
azeotroped with toluene to activate).  The reaction mixture was stirred vigorously 
for 5 days and then SiO2 (73.0 g) was added.  The black suspension was filtered 
through Celite
®, which was then washed with DCM (100 mL) and the combined 
organic phases concentrated in vacuo.  Purification by column chromatography 
íGLHWK\OHWKHULQSHWUROHXPHWKHUDIIRUGHGWKHWLWOHFRPSRXQGDVDZKLWH
solid (3.45 g, 23.8 mmol, 68%). 
Data as previously reported. 
 
 
3-Iodoindole-2-carboxaldehyde (331) 
 
To a solution of aldehyde  327 (500mg, 3.44 mmol) in DMF (3 mL) at RT was 
added powdered KOH (736 mg, 13.11 mmol) portionwise.  After 15 min a solution 
of iodine (874 mg, 3.44 mmol) in DMF (2 mL) was added dropwise over 5 min. 
After 1.5 h in the dark the reaction mixture was poured into a stirred solution of 
25%  aq.  NaHSO3  (2  mL),  25%  aq.  NH4OH  (4  mL)  and  water  (60  mL).    The 
resultant pale brown suspension was collected by filtration and washed with cold 
ethanol (20 mL).  Recrystallisation from ethanol afforded the title compound as a 
pale brown solid (921 mg, 3.40 mmol, 99% over two crops).  These data are in 
accordance with that reported in the literature.
100 
 
MP  196±197 °C (EtOH), Lit. 193±194 °C (EtOH).
100 Chapter 6: Experimental 
140 ﾠ
 ﾠ
ȣmax  3289 (s), 2840 (w), 2180 (w), 2146 (w), 1650 (s), 1614 
(w), 1568 (w), 1503 (m), 1446 (w), 1413 (m), 1360 (w), 
1334 (m), 1226 (m), 1151 (w), 1122 (w).
 
įH (400 MHz, acetone)  11.40 (1H, br. s, NH), 9.88 (1H, s, CHO), 7.61±7.54 (2H, 
m, ArH), 7.45 (1H, ddd, J=8.3, 7.1, 1.0 Hz, ArH), 7.26 
(1H, ddd, J=8.3, 7.1, 1.0 Hz, ArH). 
įC (100 MHz, acetone)  183.3  (CHO),  139.0  (C),  134.9  (C),  131.4  (C),  128.8 
(CH), 123.7 (CH), 122.7 (CH), 114.3 (CH), 71.7 (C-I). 
LRMS (CI)  271  ([M]
+,  100%),  215  (10%),  144  ([M-I]
+,  8%),  116 
(16%), 89 (41%). 
 
 
3-Bromoindole-2-carboxaldehyde (330) 
 
To a solution of aldehyde 327 (560 mg, 3.86 mmol) in DMF (7 mL) was added 
dropwise a solution of N-bromosuccinimide (694 mg, 3.90 mmol) in DMF (3 mL). 
After 20 h at RT the reaction mixture was poured onto ice water (60 mL).  The 
resultant white precipitate was collected by filtration and washed with cold ethanol 
affording the title compound as a white solid (833 mg, 3.72 mmol, 96%).  These 
data are in accordance with those reported in the literature.
101 
 
MP  191±193 °C (EtOH). 
ȣmax  3284 (br. m), 1773 (w), 1695 (m), 1651 (s), 1614 (m), 
1573 (w), 1515 (m), 1450 (w), 1419 (w), 1362 (w), 1338 
(m), 1294 (w), 1240 (w), 1228 (w), 1189 (m), 1153 (w), 
1053 (m), 863 (m), 751 (m), 740 (m).
 
įH (400 MHz, CDCl3)  10.00 (1H, s, CHO), 9.49 (1H, br. s, NH), 7.72 (1H, dd, 
J=8.2, 0.9 Hz, ArHíH, m, ArHí
(1H, m, ArH). Chapter 6: Experimental 
141 ﾠ
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įC (100 MHz, CDCl3)  181.3  (CHO),  136.9  (C),  131.5  (C),  128.5  (CH),  127.2 
(C), 122.0 (CH), 121.5 (CH), 112.7 (CH), 104.3 (C). 
LRMS (EI) 
79Br: 223 (M
>0í&+2@
+, 18%), 145 
>0í%U@
+>0í&+2í%U@
+, 34%). 
 
 
2-(Tributylstannyl)pyridine (333) 
 ﾠ
To  a  solution  of  2-bromopyridine  332  (1.00  g,  6.33  mmol)  in  THF  (12  mL)  at 
í78 °C  was  added  nBuLi  (2.38  M  in  hexanes,  2.66  mL,  6.33  mmol)  dropwise.  
After 0.5 h tributyltin chloride (1.72 mL, 6.33 mmoL) was added dropwise.  After 
1 h the reaction mixture was warmed to RT and after 2 h saturated aq. NH4Cl 
(25 mL) was added.  The reaction mixture was extracted with diethyl ether (3 x 
50 mL) then the combined organic phases were washed with brine (100 mL), dried 
(MgSO4)  and  concentrated  in  vacuo.    Purification  by  column  chromatography 
(10% w/w anhydrous K2CO3-silica; 2% ethyl acetate in hexanes) afforded the title 
compound  as  a  pale  yellow  oil  (1.97  g,  5.35  mmol,  85%).  These  data  are  in 
accordance with that reported in the literature.
97 
 
ȣmax  3058 (w), 2955 (s), 2922 (s), 2870 (m), 2851 (m), 2360 
(w), 2342 (w), 1567 (m), 1556 (m), 1463 (m), 1448 (s), 
1414 (m), 1376 (m), 1358 (w), 1340 (w), 1292 (w), 1275 
(w), 1263 (w), 985 (m), 748 (s), 689 (m), 667 (m). 
įH (400 MHz, CDCl3)  8.74 (1H, ddd, J=4.9, 1.9, 1.1 Hz, ArHíH, 
m,  ArH í H,  m,  ArH í H,  m, 
ArH í H,  m,  SnCH2(CH2)2CH3), 
í (6H, m, Sn(CH2)2CH2CH3íH, m, 
SnCH2CH2CH2CH3)íH, m, Sn(CH2)3CH3).
 Chapter 6: Experimental 
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įC (100 MHz, CDCl3)  174.1  (C),  150.5  (CH),  133.2  (CH),  132.4  (CH),  122.0 
(CH), 29.1 (3 x CH2), 27.3 (3 x CH2), 13.7 (3 x CH3), 9.8 
(3 x CH2). ﾠ
LRMS (EI) 
120Sn:   >0í%X@
+   >0í%X@
+,  57%),  198 
>0í%X@
+, 100%). 
 
 
3-(Pyridin-2-yl)indole-2-carboxaldehyde (334) 
 ﾠ
To a degassed solution of indole  331 (405 mg, 1.49 mmol) and stannane  333 
(659 mg,  1.79  mmol)  in  DMF  (11  mL)  at  RT  was  added  Pd(PPh3)4 
(173 mg, 0.15 mmol) and anhydrous CuI (57 mg, 0.30 mmol).  After 2 days water 
(20  mL)  was  added  and  the  reaction  mixture  was  extracted  with  ethyl  acetate 
(3 x 20 mL).  The combined organic phases were washed with brine (100 mL), 
dried (MgSO4) and concentrated in vacuo.  Purification by column chromatography 
(10% w/w anhydrous K2CO3-silica; 30% diethyl ether in petroleum ether) afforded 
the title compound as a yellow solid (323 mg, 1.45 mmol, 98%). 
 
MP  224±226°C (EtOAc / heptane). 
ȣmax  3294 (m), 3053 (w), 2907 (w), 1650 (s), 1586 (m), 1573 
(w), 1531 (m), 1475 (m), 1453 (w), 1426 (m), 1383 (m), 
1335 (m), 1229 (m), 1205 (w), 1145 (w), 1090 (w).
 
įH (400 MHz, CDCl3)  10.33 (1H, s, CHO), 9.26 (1H, br. s, NH), 8.80 (1H, ddd, 
J=4.9,  1.8,  1.0  Hz,  ArH),  8.04  (1H,  dd,  J=8.2,  0.9  Hz, 
ArH), 7.86 (1H, app. td, J=7.7, 1.8 Hz, ArH), 7.80 (1H, dt, 
J=7.8, 1.1 Hz, ArH), 7.50 (1H, dt, J=8.3, 1.0 Hz, ArH), 
7.45 (1H, ddd, J=8.4, 6.8, 1.1 Hz, ArH), 7.33 (1H, ddd, 
J=7.4, 4.9, 1.3 Hz, ArH), 7.30±7.22 (1H, obsc. m, ArH). Chapter 6: Experimental 
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įC (100 MHz, CDCl3)  184.5  (CHO),  152.3  (C),  150.3  (CH),  136.9  (C),  136.7 
(CH),  133.1  (C),  127.3  (CH),  126.2  (C),  124.4  (CH), 
122.3  (CH),  122.2  (CH),  122.2  (C),  122.0  (CH),  112.5 
(CH). 
LRMS (ES+)  286 ([M+Na+MeCN]
+, 13%), 223 ([M+H]
+, 18%). 
HRMS  C14H10N2NaO [M+Na]
+ requires 245.0685; found: 
245.0687. 
 
 
3-(Pyridin-2-yl)indole-2-carboxaldehyde (334) 
 ﾠ
To a degassed solution of indole 330 (250 mg, 1.12 mmol) in DMF (4 mL) at RT 
was added Pd(PPh3)4 (127 mg, 0.11 mmol) and CuO (65 mg, 0.82 mmol).  The 
reaction mixture was heated to reflux for 10 min then cooled to RT.  Stannane 333 
(302 mg, 0.82 mmol) in DMF (1 mL) was added dropwise and the reaction mixture 
heated at reflux for 16 h then cooled to RT.  Water (20 mL) was added and the 
reaction mixture  was  extracted with  ethyl acetate (3 x 20 mL).   The combined 
organic  phases  were  washed  with  brine  (100  mL),  dried  (MgSO4)  and 
concentrated  in  vacuo.    Purification  by  column  chromatography  (10%  w/w 
anhydrous K2CO3-silica; 30% diethyl ether in petroleum ether) afforded the  title 
compound as a yellow solid (68 mg, 0.31 mmol, 38%). 
Data as previously reported. 
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2-Bromopyridine-3-carboxaldehyde (335) 
 ﾠ
A solution of LDA was prepared in situ by the dropwise addition of nBuLi (2.5 M in 
hexanes, 2.64 mL, 6.60 mmol) to a solution of 
iPr2NH (1.12 mL, 8.00 mmol) in THF 
(20 mL) at ±78 °C.  After warming to RT for 1 h the reaction mixture was cooled to 
±78 °C and 2-bromopyridine 332 (948 mg, 6.00 mmol) was added dropwise.  After 
4 h DMF (4 mL) was added dropwise and after a further 30 min at ±78 °C the 
reaction mixture was warmed to RT for 16 h.  Saturated aq. NH4Cl (20 mL) was 
added and the reaction mixture was extracted with diethyl ether (3 x 20 mL).  The 
combined organic phases were washed with brine (100 mL), dried (MgSO4) and 
concentratedin vacuo.  Purification by column chromatography (10% diethyl ether 
in  petroleum  ether)  afforded  the  title  compound  as  a  white  solid 
(364 mg, 1.96 mmol, 33%).  These data are in accordance with those reported in 
the literature.
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MP  61±64 °C (ether / petrol), Lit. 64±65 °C.
73 
ȣmax  3070 (w), 3053 (w), 3026 (m), 2999 (w), 2925 (w), 2873 
(m), 1694 (s), 1658 (m), 1573 (s), 1557 (m), 1440 (w), 
1415 (m), 1372 (s), 1272 (m), 1257 (m), 1235 (m), 1058 
(m), 1050 (m), 833 (s), 803 (m), 727 (m), 705(m). 
įH (300 MHz, CDCl3)  10.35  (1H,  d,  J=0.7  Hz,  CHO),  8.58  (1H,  dd,   J=4.6, 
2.0 Hz, ArH), 8.19 (1H, dd, J=7.7, 2.2 Hz, ArH), 7.45 (1H, 
ddd, J=7.7, 4.8, 0.7 Hz, ArH). 
įC (75 MHz, CDCl3)  191.1 (CHO), 154.5 (CH), 145.4 (C), 138.0 (CH), 130.6 
(C), 123.4 (CH). 
LRMS (ES+) 
79Br: 218 ([M+MeOH+H]
+, 100%). 
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2-bromo-3-(dibromomethyl)pyridine (338) and 2-Bromo-3-(bromomethyl)-
pyridine (337) 
 
To  a  solution  of  2-bromo-3-methylpyridine  336  (0.65  mL,5.81  mmol)  in  PhCF3 
(5 mL)  was  added  N-bromosuccinimide  (1.14  g,  6.37  mmol),  VAZO 
(0.171 g, 0.70 mmol) and bromine (0.02 mL,0.29 mmol).  The reaction mixture was 
heated to reflux for 3 h then cooled to RT, filtered and the filtrate concentrated 
in vacuo.  Purification by column chromatography (10% ethyl acetate in heptane) 
afforded firstly 338 as a pale yellow oil (168 mg, 0.51 mmol, 9%) and then 337 as 
a pale yellow oil (553 mg, 2.2 mmol, 38%).  These data are in accordance with 
those reported in the literature.
102,103 
 
Data for 338: 
ȣmax  3116 (w), 3022 (w), 2924 (w), 2361 (w), 2175 (w), 1721 
(w), 1573 (m), 1557 (m), 1446 (w), 1397 (s), 1172 (w), 
1146 (m), 1121 (w), 1050 (m), 831 (m), 808 (w), 738 (m). 
įH (300 MHz, CDCl3)  8í H,  obsc.  m,  ArH),  8.31  (1H,  dd,  J=5.1, 
1.9 Hz, ArH), 7.41 (1H, dd, J=7.5, 5.1 Hz, ArH), 7.01 (1H, 
s, CHBr2). 
įC (75 MHz, CDCl3)  150.9  (CH),  139.4  (CH),  138.3  (C),  138.3  (C),  123.9 
(CH), 37.7 (CH). 
LRMS (EI) 
79Br:   >0í%U@
+,  56  >0í%U@
+,  11%),  104 
>0í%Uí&+%U2]
+, 52%). 
 
Data for 337: 
ȣmax  3292  (br.  w),  3027  (w),  2929  (w),  2359  (w),  2118  (w), 
1912 (w), 1650 (w), 1601 (m), 1577 (w), 1562 (m), 1523 
(w), 1473 (w), 1450 (m), 1424 (w), 1403 (s), 1331 (w), 
1311 (w), 1203 (m), 1169 (w), 1126 (w), 1053 (m). Chapter 6: Experimental 
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įH (400 MHz, CDCl3)  8.32 (1H, dd, J=4.7, 1.9 Hz, ArH), 7.78 (1H, dd, J=7.6, 
1.9 Hz, ArH), 7.29 (1H, dd, J=7.6, 4.7 Hz, ArH), 4.56 (2H, 
s, ArCH2Br). 
įC (100 MHz, CDCl3)  149.7  (CH),  143.7  (C),  139.2  (CH),  134.6  (C),  123.2 
(CH), 31.4 (CH2). 
 
 
2-Bromopyridine-3-carboxaldehyde (335) 
 
To a solution of pyridine 337 (4.93 g, 19.7 mmol) in acetonitrile (20 mL) was added 
4-methylmorpholine-N-oxide (3.45 g, 29.5 mmol) at RT.  After 3 h the solvent was 
removed in vacuo.  Purification by column chromatography (20% ethyl acetate in 
heptane) afforded the title compound as a white solid (2.22 g, 11.9 mmol, 61%). 
Data as previously reported. 
 
 
2-Bromopyridine-3-carboxaldehyde (335) 
 
A mixture of tribromide 338 (487 mg, 1.48 mmol) and CaCO3 (327 mg, 3.26 mmol) 
in water (12 mL) was heated at reflux for 15 h then cooled to RT and extracted 
with ethyl acetate (3 x 10 mL).  The combined organic phases were washed with 
brine (50 mL), dried (MgSO4) and concentrated in vacuo.  Purification by column 
chromatography (20% ethyl acetate in heptane) afforded the title compound as a 
white solid (147 mg, 0.79 mmol, 53%). 
Data as previously reported. 
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2-Bromo-3-vinylpyridine (339) 
 ﾠ
To a solution of methyltriphenylphosphonium bromide (860 mg, 2.41 mmol) in THF 
(20 mL) at 0 °C was added nBuLi (2.5 M in hexanes, 0.96 mL, 2.41 mmol).  The 
reaction mixture was warmed to RT over 30 min then re-cooled to 0 °C and a 
solution  of  aldehyde  335  (400  mg,  2.15  mmol)  in  THF  (20  mL)  was  added 
dropwise.  After 18 h at RT, water (20 mL) and diethyl ether (20 mL) were added.  
The aqueous phase was separated and extracted with diethyl ether (2 x 20 mL). 
The  combined  organic  phases  were  then  washed  with  brine  (50  mL),  dried 
(MgSO4)  and  concentrated  in  vacuo.    Purification  by  column  chromatography 
(10% diethyl ether in petroleum ether) afforded the title compound as a yellow oil 
(347 mg, 1.89 mmol, 88%).  These data are in accordance with that reported in the 
literature.
73 
 
ȣmax  3090 (w), 3043 (w), 1627 (m), 1572 (m), 1551 (m), 1447 
(m), 1424 (m), 1375 (s), 1272 (w), 1183 (m), 1122 (m), 
1048 (s), 805 (s), 666 (s).
 
įH (400 MHz, CDCl3)  8.27 (1H, dd, J=4.7, 2.0 Hz, ArH), 7.81 (1H, ddd, J=7.7, 
2.0, 0.5 Hz, ArH), 7.26 (1H, ddd, J=7.7, 4.7, 0.6 Hz, ArH), 
6.99 (1H, dd, J=17.4, 11.0 Hz, CH=CH2), 5.75 (1H, dd, 
J=17.4,  0.8  Hz,  CHH),  5.49  (1H,  dd,  J=11.0,  0.8  Hz, 
CHH).
 
įC (100 MHz, CDCl3)  148.9  (CH),  142.9  (C),  134.8  (C),  134.6  (CH),  134.2 
(CH=CH2), 123.0 (CH), 118.7 (CH2). 
LRMS (ES+) 
79Br: 184 ([M+H]
+, 96%). 
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2-Bromo-3-ethylpyridine (340) 
 
To a solution of vinylpyridine 339 (279 mg, 1.52 mmol) in THF:water (1:1, 60 mL) 
was added p-tosylhydrazide (1.70 g, 9.12 mmol) and NaOAc (1.26 g, 9.27 mmol). 
The reaction mixture was heated at reflux for 7 days then cooled to RT and sat. 
K2CO3 (100 mL) added.  After 2 h the reaction mixture was extracted with DCM 
(4 x 60 mL).  The combined organic phases were washed with brine (250 mL), 
dried (MgSO4) and concentrated in vacuo.  Purification by column chromatography 
(1±5% diethyl ether in petroleum ether) afforded the title compound as a yellow oil 
(212 mg, 1.14 mmol, 75%). 
 
ȣmax  3048 (w), 2970 (m), 2934 (w), 2875 (w), 1577 (m), 1557 
(m), 1460 (w), 1427 (w), 1400 (s), 1322 (w), 1266 (w), 
1073 (m), 1057 (s), 805 (m), 659 (m). 
įH (400 MHz, CDCl3)  8.20 (1H, dd, J=4.8, 1.5 Hz, ArH), 7.51 (1H, dd, J=7.5, 
1.5  Hz,  ArH),  7.20  (1H,  dd,  J=7.5,  4.8  Hz,  ArH), 
2.73 (2H, q, J=7.5 Hz, CH2), 1.24 (3H, t, J=7.5 Hz, CH3). 
įC (100 MHz, CDCl3)  147.3 (CH), 144.2 (C), 140.3 (C), 137.3 (CH), 122.9 
(CH), 28.4 (CH2), 13.5 (CH3). 
LRMS (EI) 
79Br: 185 (M
>0í&+3]
+>0í%U@
+, 
100%), 91 >0í%Uí&+3]
+>0í%Uí(W@
+, 28%). 
HRMS  C7H9BrN[M+H]
+ requires 185.9913; found: 185.9912. 
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3-Ethyl-2-(tributylstannyl)pyridine (341) 
 
To a solution of ethylpyridine 340 (200 mJPPROLQ7+)P/DWí&
was added nBuLi (2.5 M in hexanes, 0.43 mL,1.08 mmol) dropwise.  After 30 min 
Bu3SnCl  (0.29  mL,  1.08  mmol)  was  added  dropwise.    After  a  further  1  h  the 
reaction mixture was warmed to RT over 3 h then sat. NH4Cl (10 mL) was added.  
Following extraction with MTBE (3 x 20 mL), the combined organic phases were 
washed with brine (50 mL), dried (MgSO4) and concentrated in vacuo.  Purification 
by column chromatography (10% w/w anhydrous K2CO3-silica; 5% ethyl acetate in 
heptane)  afforded  the  title  compound  as  a  colourless  oil  (372  mg,  0.94  mmol, 
87%). 
 
ȣmax  3036 (w), 2956 (s), 2924 (s), 2870 (m), 2852 (m), 2360 
(w), 2031 (w), 1567 (w), 1460 (m), 1404 (m), 1376 (m), 
1339 (w), 1181 (w), 1150 (w), 1120 (w), 1073 (m). 
įH (300 MHz, CDCl3)  8.57 (1H, dd, J=4.7, 1.6 Hz, ArH), 7.39 (1H, dd, J=7.9, 
1.6 Hz, ArH), 7.08 (1H, dd, J=7.9, 4.7 Hz, ArH), 2.64 (2H, 
q,  J=7.5  Hz,  CH2CH3) í1.48  (6H,  m, 
SnCH2(CH2)2CH3),  1.33  (6H,  sxt,  J=7.2  Hz, 
Sn(CH2)2CH2CH3),  1.23  (3H,  t,  J=7.5  Hz,  CH2CH3), 
í H,  m,  SnCH2CH2CH2CH3),  0.88  (9H,  t, 
J=7.2 Hz, Sn(CH2)3CH3). 
įC (75 MHz, CDCl3)  173.7  (C),  147.6  (CH),  146.6  (C),  132.6  (CH),  121.7 
(CH), 29.2 (3 × CH2), 28.7 (CH2), 27.3 (3 × CH2), 16.2 
(CH3), 13.7 (3 × CH3), 10.7 (3 × CH2). 
LRMS (EI) 
120Sn: >0í%X@
+>0í6Q%X3]
+, 28%). 
HRMS  C19H36NSn[M+H]
+ requires 398.1864; found: 398.1868. 
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3-(3-Ethylpyridin-2-yl)-1H-indole-2-carbaldehyde (342) 
 
To a degassed solution of iodoindole 331 (198 mg, 0.73 mmol) and stannane 341 
(350 mg, 0.88 mmol) in DMF (5 mL) was added Pd(PPh3)4 (81 mg, 0.07 mmol) 
and CuI (29 mg, 0.15 mmol).  After 18 h at RT the solvent was removed in vacuo. 
Purification  by  column  chromatography  (10%  w/w  anhydrous  K2CO3-silica; 
40% ethyl acetate in heptane) afforded the title compound as a pale orange oil 
(150 mg, 0.60 mmol, 82%). 
 
ȣmax  3295 (w), 3060 (w), 2962 (w), 2923 (m), 2853 (m), 2361 
(w), 2339 (w), 2206 (w), 1651 (s), 1618 (w), 1571 (m), 
1537 (m), 1463 (m), 1368 (m), 1331 (m), 1223 (m), 1120 
(m), 1055 (w), 1024 (m), 972 (w), 732 (s). 
įH (300 MHz, CDCl3)  9.71 (1H, s, CHO), 9.63 (1H, br. s, NH), 8.62 (1H, dd, 
J=4.8, 1.5 Hz, ArH), 7.76 (1H, dd, J=7.8, 1.5 Hz, ArH), 
í 2H,  m,  2  ×  ArH í7.36  (1H,  obsc.  m, 
ArH), 7.36 (1H, dd, J=7.8, 4.8 Hz, ArH), 7.16 (1H, ddd, 
J=8.1, 6.9, 1.1 Hz, ArH), 2.66 (2H, q, J=7.5 Hz, CH2CH3), 
1.08 (3H, t, J=7.5 Hz, CH2CH3). 
įC (75 MHz, CDCl3)  182.7  (CHO),  150.3  (C),  147.2  (CH),  139.6  (C),  136.9 
(C), 136.4 (CH), 132.8 (C), 127.4 (CH), 127.4 (C), 127.0 
(C),  123.1  (CH),  122.2  (CH),  121.4  (CH),  112.6  (CH), 
25.6 (CH2), 14.9 (CH3). 
LRMS (ES
+)  342  (100%),  314  ([M+MeCN+Na]
+,  43%),  251  ([M+H]
+, 
27%). 
HRMS  C16H15N2O[M+H]
+ requires 251.1179; found: 251.1178. 
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2-(2,2-Dibromovinyl)-3-(pyridin-2-yl)-1H-indole  (343),  (Z)-2-(2-bromovinyl)-3-
(pyridine-2-yl)-1H-indole  (344)  and  (E)-2-(2-bromovinyl)-3-(pyridine-2-yl)-1H-
indole (345) 
 
To  a  suspension  of  bromomethyltriphenylphosphonium  bromide  (589  mg, 
1.35 mmol)  in  THF  (9  mL)  was  added  NaHMDS  (1.0  M  in  THF,  1.17  mL, 
1.17 mmol) dropwise over 10 min.  After 30 min the resulting solution was added 
to a solution of aldehyde 334 (200 mg, 0.90 mmol) in THF (3 mL) over 20 min. 
After 16 h water (20 mL) and ethyl acetate (20 mL) were added and the phases 
separated.  The aqueous phase was washed with ethyl acetate (2 × 20 mL) and 
the combined organic phases were washed with brine (50 mL), dried (MgSO4) and 
concentrated  in  vacuo.    Purification  by  column  chromatography  (10%  w/w 
anhydrous K2CO3-silica; 10% ethyl acetate in heptane) afforded firstly 343 as a 
yellow oil (67 mg, 0.18 mmol, 20%), then an inseparable mixture of 343, 344 and 
345  (1:1.5:1) as a pale yellow oil (90 mg, 0.28 mmol, 31%) and finally recovered 
starting material (44 mg, 0.2 mmol, 22%). 
 
Data for 343: 
ȣmax  3439 (m), 3036 (m), 2925 (w), 2854 (w), 1668 (w), 1586 
(s), 1562 (w), 1508 (m), 1476 (m), 1439 (w), 1421 (w), 
1366 (w), 1328 (m), 1285 (w), 1242 (m), 1200 (m), 1152 
(m), 1118 (w), 1095 (w). 
įH (400 MHz, CDCl3)  9.53 (1H, br. s, NH), 8.77 (1H, ddd, J=4.9, 1.8, 0.9 Hz, 
ArH),  8.23  (1H,  s,  CH=CBr2),  7.89  (1H,  d,  J=8.0  Hz, 
ArH), 7.80 (1H, app. td, J=7.7, 1.8 Hz, ArH), 7.65 (1H, d, 
J=7.9  Hz,  ArH),  7.44  (1H,  d,  J=8.2  Hz,  ArH),             
7.38±7.30 (1H, m, ArH), 7.24 (1H, obsc. ddd, J=7.5, 4.9, 
1.2 Hz, ArH), 7.23±7.18 (1H, m, ArH). Chapter 6: Experimental 
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įC (100 MHz, CDCl3)  153.7 (C), 150.0 (CH), 136.4 (CH), 135.8 (C), 130.0 (C), 
127.4  (CH),  125.8  (C),  124.4  (CH),  124.3  (CH),  121.3 
(CH),  121.1  (CH),  120.1  (CH),  119.1(C),  111.4  (CH), 
86.5 (CBr2). 
LRMS (ES
+) 
79Br: 377 ([M+H]
+, 51%). 
HRMS  C15H11Br2N2[M+H]
+ requires 376.9283; found: 376.9282. 
 
Data for inseparable mixture of 343, 344 and 345: 
įH (400 MHz, CDCl3)  Peaks attributed to 343 9.53 (1H, br. s, NH), 8.22 (1H, s, 
CH=CBr2),  7.86  (1H,  d,  J=8.1  Hz,  ArH),  7.44  (1H,  d, 
J=8.2 Hz, ArH). 
Peaks attributed to 344 9.82 (1H, br. s, NH), 7.48 (1H, d, 
J=8.2  Hz,  CH=CHBr),  6.37  (1H,  d,  J=8.2  Hz, 
CH=CHBr).Peaks attributed to 345 9.26 (1H, br. s, NH), 
7.63 (1H, obsc. d, J=14.3 Hz, CH=CHBr), 6.68 (1H, d, 
J=14.3 Hz, CH=CHBr). 
Peaks  not  attributed  8.82±8.74  (3.5H,  m,  3.5  ×  ArH), 
7.95±7.88 (2H, m, 2 × ArH), 7.84±7.76 (3H, m, 3 × ArH), 
7.70±7.61  (3.5H,  m,  3.5  ×  ArH),  7.39±7.29  (7H,  m, 
7 × ArH), 7.26±7.13 (7H, m, 7 × ArH). 
NMR Spectra of 343, 344 and 345. 
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2-(2,2-Dibromovinyl)-3-(pyridin-2-yl)-1H-indole  (343),  (Z)-2-(2-bromovinyl)-3-
(pyridine-2-yl)-1H-indole  (344)  and  (E)-2-(2-bromovinyl)-3-(pyridine-2-yl)-1H-
indole (345) 
 
To a suspension of KO
tBu (168 mg, 1.50 mmol) in THF (9 mLDWí&ZDV
added  bromomethyltriphenylphosphonium  bromide  (654  mg,  1.50  mmol) 
portionwise.  The reaction mixture was warmed to 0 °C over 1.5 h then cooled to 
í&DQGDOGHK\GH 334 (150 mg, 0.68 mmol) in THF (1 mL) added dropwise 
over 5 min.  After 15 min the reaction mixture was warmed to RT and after 16 h, 
water (10 mL) and ethyl acetate (10 mL) were added.  The aqueous phase was 
separated and washed with ethyl acetate (2 × 10 mL) then the combined organic 
phases  were  washed  with  brine  (25  mL),  dried  (MgSO4)  and  concentrated 
in vacuo.  Purification by column chromatography (20% diethyl ether in petroleum 
ether)  afforded  firstly  343  as  a  yellow  oil  (7  mg,  0.02  mmol,  3%),  then  an 
inseparable mixture of 343, 344 and 345 (1:1.8:0.2) as a pale yellow oil (53 mg, 
0.16 mmol, 24%) and finally an inseparable mixture of 344 and 345 (1:0.4) as a 
yellow oil (11mg, 0.04 mmol, 6%) contaminated with ~10% unidentified impurities. 
 
Data for 343: 
Data as previously reported. 
 
Data for inseparable mixture of 344 and 345: 
ȣmax  3075 (w), 2925 (w), 2854 (w), 2449 (w), 2160 (m), 2040 
(w), 2009 (w), 1975 (w), 1940 (w), 1717 (w), 1614 (m), 
1539 (w), 1488 (w), 1469 (w), 1388 (m), 1264 (m). 
įH (400 MHz, CDCl3)  Peaks attributed to major regioisomer 344 9.79 (1H, br. 
s,  NH),  8.76  (1H,  app.  tdd,  J=5.0,  1.8,  0.9  Hz,  ArH), 
íH, m, ArH),7.85 (1H, d, J=8.2 Hz, ArH), 7.80 Chapter 6: Experimental 
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(1H,  app.  td,  J=7.7,  1.9  Hz,  ArH í H,  m, 
ArH), 7.48 (1H, d, J=8.2 Hz, CH=CHBrí+
m, ArHí+P$UH) 6.38 (1H, d, J=8.2 Hz, 
CH=CHBr). 
Peaks attributed to minor regioisomer 345 8.56 (1H, br. 
s,  NH),  6.73  (1H,  d,  J=14.4  Hz,  CH=CHBr),  remaining 
peaks obscured. 
įC (100 MHz, CDCl3)  Peaks  attributed  to  major  regioisomer  344  154.1  (C), 
149.8 (CH), 136.4 (CH), 135.7 (C), 131.1(C), 125.9 (C), 
124.5 (CH), 124.1 (CH), 122.8 (CH), 121.1 (CH), 121.0 
(CH), 120.0 (CH), 111.4 (CH), 104.4 (CH). 
N.B. One aromatic quaternary centre not observed. 
Peaks  attributed  to  minor  regioisomer  345  153.9  (C), 
149.8  (CH),  136.5  (CH),  132.2  (C),  127.7  (CH),  126.9 
(C),  124.1  (CH),  123.9  (CH),  121.0  (CH),  121.0  (CH), 
120.2  (CH),  118.8  (C),  110.9  (CH),  107.7  (C),  106.2 
(CH). 
LRMS (ES
+) 
79Br: 299 ([M+H]
+, 100%). 
 
 
(Iodomethyl)triphenylphosphonium iodide (356) 
 
A solution of triphenylphosphine (3.00 g, 11.4 mmol) and diiodomethane (1.20 mL, 
14.9 mmol) in toluene (5 mL) was protected from light, heated to 100 °C for 20 h 
then  cooled  to  RT.  The  resulting  white  precipitate  was  collected  by  filtration, 
washed with cold toluene (50 mL) and dried in vacuo to afford the title compound 
as a white solid (5.75 g, 10.9 mmol, 95%).  These data are in accordance with that 
reported in the literature.
104 
 
MP  225±227 °C, Lit. 228±230 °C.
104 Chapter 6: Experimental 
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ȣmax  3040 (w), 2914 (m), 2847 (m), 2741 (w), 2326 (w), 2116 
(w), 1897 (w), 1821 (w), 1680 (w), 1585 (m), 1481 (m), 
1435 (s), 1334 (w), 1316 (w), 1107 (s), 996 (m). 
įH (400 MHz, DMSO)  í+P$UH), 5.06 (2H, d, J=8.7 Hz, CH2I).
 
įC (100 MHz, DMSO)  135.1 (3 × CH, d, J=3.2 Hz, p-Ph), 133.8 (6 × CH, d, 
J=10.1 Hz, o-Ph), 130.1 (6 × CH, d, J=12.4 Hz, m-Ph), 
118.3(3 × C, d, J=88.9 Hz, i-Ph), ±16.07 (1 × CH2, d, 
J=52.1 Hz, CH2I). 
įP (162 MHz, DMSO)  24.2 
LRMS (ES
+)  Did not fly by ES or EI. 
 
 
3-Phenyl-1H-indole-2-carbaldehyde (359) 
 
To a degassed solution of iodoindole 331 (464mg, 1.71 mmol) and stannane 358 
(0.37 mL, 2.05 mmol) in DMF (12 mL) was added Pd(PPh3)4 (196mg, 0.17 mmol) 
and CuI (65 mg, 0.34 mmol).  The reaction mixture heated to reflux for 3 h then 
cooled to RT and water (100 mL) and ethyl acetate (100 mL) added.  The aqueous 
phase  was  separated  and  extracted  with  ethyl  acetate  (2  x  100  mL)  then  the 
combined organic phases were washed with brine (200 mL), dried (MgSO4) and 
concentrated  in  vacuo.    Purification  by  column  chromatography  (10%  w/w 
anhydrous K2CO3-silica; 10% ethyl acetate in heptane) afforded the title compound 
as  an  inseparable  1.2:1  mixture  of  the  compound  359  and  recovered  starting 
material 331 as a yellow solid (170mg, 0.70 mmol, 41%). 
 
ȣmax  3308 (m), 3057 (w), 2921 (w), 2853 (w), 2059 (w), 1646 
(s), 1574 (w), 1538 (w), 1490 (w), 1458 (w), 1383 (w), 
1365 (w), 1335 (m), 1153 (w), 1015 (w), 932 (w). Chapter 6: Experimental 
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įH (300 MHz, CDCl3)  Peaks attributed to 359 10.07 (1H, s, CHO), 9.59 (1H, br. 
s, NH),7.84 (1H, dd, J=8.2, 0.6 Hz, ArH), 7.72 (1H, dd, 
J=8.1, 0.8 Hz, ArH), í+REVFPî$UH), 
7.17 (1H, ddd, J=8.2, 5.6, 2.4 Hz, ArH). 
Peaks attributed to 331 9.90 (1H, s, CHO), 9.18 (1H, br. 
s, NH),í+REVFPî$UH), 7.22 (1H, obsc. 
ddd, J=7.6, 6.4, 0.9 Hz, ArH). 
įC (100 MHz, CDCl3)  Peaks attributed to 359 180.6 (CHO), 130.5 (2 × CH), 
129.7 (C), 128.8 (2 × CH). 
Peak attributed to331 182.9 (CHO). 
Peaks  not  attributed  137.6  (C),  137.4  (C),  132.2  (C), 
131.9  (C),  131.8  (C),  128.0  (CH),  127.7  (CH),  127.6 
(CH),  126.8  (C),  125.0  (C),  122.2  (CH),  121.4  (CH), 
121.3 (CH), 120.4 (CH), 112.5 (CH), 112.3 (CH). 
N.B.One aromatic quaternary centre not observed. 
 
 
8H-Indolo[3,2-Į@TXLQROL]LQ-5-ium (361) 
 ﾠ
To a degassed solution of vinyl bromide 344 / 345 (Z:E 5:1, 98 mg, 0.33 mmol) in 
toluene  (8  mL) was  added  tributyltin  hydride  (0.24  mL,  0.88  mmol)  and  VAZO 
(20 mg,  0.08  mmol).  The  reaction mixture  was  heated  at  reflux  for  16 h then 
cooled to RT.  The resulting precipitate was collected by filtration and washed with 
petroleum  ether  (2  x  20  mL)  to  afford  the  title  compound  as  a  brown  solid 
(43 mg, 0.20 mmol, 60%). 
 
MP  > 350 °C. 
ȣmax  3365 (br. m), 3059 (m), 2952 (m), 2360 (w), 2342 (w), 
1642 (m), 1630 (m), 1609 (s), 1541 (m), 1496 (m), 1483 Chapter 6: Experimental 
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(m), 1469 (s), 1452 (m), 1406 (m), 1384 (s), 1327 (m), 
1286 (m), 1258 (m), 1216 (m), 1194 (m), 1168 (m).
 
įH (300 MHz, MeOD)  8.97 (1H, d, J=6.9 Hz, ArH), 8.84 (1H, d, J=7.3 Hz, ArH), 
8.65 (1H, d, J=9.0 Hz, ArH), 8.24 (1H, d, J=8.2 Hz, ArH), 
8.17  (1H,  ddd,  J=8.8,  7.2,  1.2  Hz,  ArH),  7.94  (1H,  d, 
J=7.3 Hz, ArH), 7.64 (1H, app. td, J=7.0, 1.3 Hz, ArH), 
7.63  (1H,  d,  J=9.0  Hz,  ArH),  7.55  (1H,  app.  td,  J=7.6, 
1.0 Hz, ArH), 7.39 (1H, ddd, J=8.1, 7.0, 1.2 Hz, ArH). ﾠ
įC (75 MHz, MeOD)  141.9 (C), 141.7 (C), 140.8 (C), 137.9 (CH), 137.4 (CH), 
134.7 (CH), 129.1 (CH), 124.1 (CH), 123.4 (CH), 123.0 
(CH) 122.0 (C), 120.4 (CH) 114.4 (CH) 113.6 (C), 111.7 
(CH). 
LRMS (ES+)  >0@í%U 
HRMS  C15H11N2
+ requires 219.0917; Found: 219.0918. 
 
 
8H-Indolo[3,2-Į@TXLQROL]LQ-5-ium (361) and (E)-3-(pyridin-2-yl)-2-(2-tributyl-
stannyl)vinyl)-1H-indole (363) 
 ﾠ
To a degassed mixture of dibromoalkene 343, cis-alkene 344 and trans-alkene 
345 (~6:3:2, 157 mg, 0.46 mmol) in toluene (14 mL) was added tributyltin hydride 
(0.27 mL, 1.01 mmol) and VAZO (22 mg, 0.09 mmol). After 16 h  at reflux the 
reaction mixture was cooled to RT.  The precipitate was collected by filtration and 
washed with petroleum ether (2 x 20 mL) to afford pyridinium salt 361 (16 mg, 
0.054 mmol, 12%). The filtrate was then concentrated in vacuo and purified by 
column chromatography (10% w/w anhydrous K2CO3-silica; 15% ethyl acetate in 
heptane) to afford vinylstannane 363 (12 mg, 0.024 mmol, 5%) contaminated with 
~20% of unknown impurities. Chapter 6: Experimental 
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Data for 361: 
Data as previously reported. 
 
Data for 363: 
ȣmax  3271  (br.  w),  3058  (w),  2954  (s),  2923  (s),  2855  (m), 
1589 (s), 1541 (w), 1454 (m), 1377 (w), 1335 (m), 1195 
(w), 1150 (w), 1076 (w), 1051 (w), 1021 (w), 961 (w). 
įH (400 MHz, CDCl3)  8.75 (1H, ddd, J=4.9, 1.9, 1.0 Hz, ArH), 8.47 (1H, br. s, 
NH),  7.96  (1H,  d,  J=8.0  Hz,  ArH),  7.76  (1H,  app.  td, 
J=7.6,  1.9  Hz,  ArH),  7.60  (1H,  app.  dt,  J=7.9,  1.0  Hz, 
ArH), 7.47 (1H, d, J=19.9 Hz, CH=CHSnBu3), 7.38 (1H, 
d, J=8.0 Hz, ArH), 7.24 (1H, app. td, J=7.6, 1.2 Hz, ArH), 
7.19 (1H, ddd, J=7.6, 4.9, 1.2 Hz, ArH), 7.18±7.13 (1H, 
m, ArH), 6.77 (1H, d, J=19.9 Hz, CH=CHSnBu3), 1.63±
1.50 (6H, m, SnCH2(CH2)2CH3), 1.36 (6H, sxt, J=7.3 Hz, 
Sn(CH2)CH2CH3),  1.08±0.94  (6H,  m, 
SnCH2CH2CH2CH3),  0.91  (9H,  t,  J=7.3  Hz, 
Sn(CH2)3CH3). 
įC (100 MHz, CDCl3)  149.8 (C), 149.7 (CH), 138.4 (C), 136.0 (2 × CH), 135.7 
(CH),  135.2  (C),  130.1  (CH),  128.8  (C),  124.1  (CH), 
123.3  (CH),  120.7  (CH),  120.5  (CH),  120.4  (C),  110.6 
(CH), 29.1 (3 × CH2), 27.3 (3 × CH2), 13.6 (3 × CH3), 9.8 
(3 × CH2). 
LRMS (ES
+) 
120Sn: 511 ([M+H]
+, 100%), 221 ([MH±SnBu3]
+, 55%). 
HRMS  Sample decomposed. 
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chromatographic removal of organotin impuritieswz
David C. Harrowven,*
a Dennis P. Curran,
b Sarah L. Kostiuk,
a Ian L. Wallis-Guy,
a
Sally Whiting,
a Kerri J. Stenning,
a Bencan Tang,
a Emma Packard
a and Lana Nanson
a
Received 10th May 2010, Accepted 30th June 2010
DOI: 10.1039/c0cc01328e
Organotin impurities in product mixtures can be reduced
from stoichiometric levels to B15 parts per million by column
chromatography using 10% w/w anhydrous potassium carbonate–
silica as a stationary phase.
Concerns over the toxicity of organotin reagents, products and
byproducts, and di culties associated with the puriﬁcation of
product mixtures containing organotin residues, often limit
the appeal of organotin chemistry.
1 Thus, while it is generally
easy to reduce organotin impurities to below 1% w/w, their
removal to a parts per million level is necessary for biological
screening and health-care applications.
2 To address this, many
methods of organotin removal have been developed,
3 including
water-soluble and solid-supported stannanes, catalytic proce-
dures and alternative reagents based on metal and metalloid
hydrides of lower toxicity.
4 Though many are highly e ective,
their adoption usually adds to the cost or complexity of an
experimental procedure.
Our groups have previously reported two simple and in-
expensive procedures for the removal of organotin impurities
from product mixtures.
5,6 The ﬁrst involved dilution of the
concentrated product mixture with reagent grade ether, adding
a slight excess of DBU then an ethereal solution of iodine until
the iodine colour just persists. Elution through a plug of
silica followed by standard ﬂash column chromatography
completed the puriﬁcation. The second method required no
pretreatment of product mixtures as, after concentration, the
residue is simply eluted through a stationary phase composed
of 10% ﬁnely ground potassium ﬂuoride and 90% silica (w/w).
In this way, levels of organotin impurities could be reduced
from full equivalence to below 30 ppm.
The simplicity and e ectiveness of the methods have ensured
their widespread adoption,
7,8 though neither is without draw-
backs. One practical issue with the KF/silica protocol relates
to the hygroscopic nature of the salt. On prolonged standing,
this leads to a loss of ﬂuidity in the stationary phase which in
turn reduces its e cacy for both compound separation and the
removal of reactive organotin species. Herein we detail an
improved procedure using K2CO3 as an additive, making the
method cheaper and more practicable. Its e ectiveness has
been demonstrated in a range of common applications including
the puriﬁcation of tetraorganyltin and hexaorganylditin
compounds from complex product mixtures. The latter obser-
vation broadens the method’s scope and application considerably
and o ers a fresh insight into the action of the additive.
Our investigation began with an examination of stationary
phases comprising silica mixed with various organic and
inorganic ﬂuorides. In our chosen test reaction, 1 - 2,
9 none
came close to matching the success achieved using the KF–
silica combination,
6 with many performing worse than silica
alone (Table 1). The results suggested that the basicity of
potassium ﬂuoride was a key factor, a hypothesis substan-
tiated when a mixture of KOAc and silica proved highly
e ective for the removal of organotin impurities. Thus, in
the reduction of aryl bromide 1 to arene 2 with 2 equiv.
tributyltin hydride and TBAF (Scheme 1), chromatographic
puriﬁcation using a stationary phase of 10% KOAc and 90%
silica (w/w) reduced organotin impurity levels from 2 full
equivalents to 76 ppm. The result was then eclipsed by a
combination of K2CO3 and silica, which repeatedly reduced
levels of organotin impurity to below 15 ppm in this system.
We have applied the method in Bu3SnH-mediated reductions
of aryl halides and acid chlorides,
9,10 Stille coupling
11 and
tin-mediated radical cyclisation reactions (Scheme 1).
12,13 In each
case,
1HN M Ra n a l y s i so ft h ep u r i ﬁ e dp r o d u c t ss h o w e dt h e mt o
be free of organotin impurities (see ESIz), including situations in
which a low-yielding product had to be separated from a complex
product mixture containing substantial organotin residues.
Treatment of amide 9 under standard Bu3SnH-mediated
radical cyclisation conditions proved informative as cyclisa-
tion to the arene occurred with concomitant hydrostannylation
of the terminal alkyne.
13 Importantly, the resulting vinylstannane
Table 1 The e ectiveness of various additives for the chromato-
graphic removal of tin residues
Additives Levels of tin impurity observed in 2
a
Potassium ﬂuoride 28 ppm
Potassium chloride 2–5 mol%
Sodium ﬂuoride >10 mol%
Calcium ﬂuoride >10 mol%
Ammonium ﬂuoride >10 mol%
Rochelle salt >10 mol%
Potassium acetate 110 ppm
Sodium acetate 76 ppm
Sodium carbonate >10 mol%
Potassium carbonate 13 ppm
a Tin analyses were determined independently and in duplicate at the
GSK laboratories in Stevenage, UK.
aSchool of Chemistry, University of Southampton, Highﬁeld,
Southampton, SO17 1BJ, UK. E-mail: dch2@soton.ac.uk;
Fax: +44 (0)23-80593131
bDepartment of Chemistry, University of Pittsburgh, 1101 Chevron
Science Center, 219 Parkman Ave, Pittsburgh, PA, 15260, USA
w Dedicated to Professor G. Pattenden on the occasion of his 70th
birthday.
z Electronic supplementary information (ESI) available: Experimental
details and
1H NMR spectra. See DOI: 10.1039/c0cc01328e
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10 was amenable to chromatographic puriﬁcation using
K2CO3–silica as the stationary phase, with residual organotin
compounds being eluted close to the solvent front or retained
by the stationary phase. To probe this further, a series of
commercial organotin reagents was subjected to chromato-
graphic puriﬁcation using the new methodology (Table 2). The
study conﬁrmed that tributyltin hydride, tetraorganyltin and
hexaorganylditin compounds eluted without signiﬁcant loss in
mass balance while reactive tributyltin halides and tributyltin
oxide were retained by the stationary phase (along with
carboxylic acids and phenols).
The e ectiveness of the method for the puriﬁcation of
organyltin compounds has been demonstrated further through
application.
14–17 It has proved especially valuable with products
that are prone to protodestannylation on silica (e.g. 17
18
and 18
17) and in the separation of low-yield components from
complex product mixtures containing high levels of organotin
residues.
19
In summary, a stationary phase composed of 10% powdered
anhydrous K2CO3 and silica is remarkably e ective for
the removal of organotin impurities from product mixtures,
reducing these from stoichiometric levels to B15 ppm. The
K2CO3–silica mixture may be stored for many months without
signiﬁcant loss in ﬂuidity or activity. Puriﬁcations are best
carried out on concentrated product mixtures, eliminating the
need for an aqueous work-up and treatment of the associated
waste-stream. The method is compatible with tetraorganyltin
and hexaorganylditin compounds (Table 2 and Scheme 2),
which pass through the stationary phase as distinct bands at
rates similar to those observed using silica alone. Separation
of these from other organic components relies on polarity
di erences, while reactive organotin halides and oxides are
captured by the stationary phase.
We gratefully acknowledge Dr. Dean D. Edney at GSK
Stevenage for obtaining the tin analysis data. InterReg IV,
EPSRC, GSK, MSD, Pﬁzer and Astra Zeneca are thanked for
ﬁnancial support.
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CH activation and CH2 double activation of indolines by radical
translocation: Understanding the chemistry of the indolinyl radical†
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CH activation and CH2 double activation of indolines at C2 may be achieved efﬁciently through radical
translocation. The fate of the C2 indolinyl radical is dictated by the substitution at C3. Fragmentation,
cyclisation and tandem cyclisation reactions leading to indole, azaheterocycle and azapropellane
formation, respectively, are reported.
Introduction
Indoles and indolines have long been considered ‘privileged
structures’ in medicinal chemistry owing to their ubiquitous
presence in natural and pharmaceutical products. Consequently,
their synthesis and functionalisation have been widely studied.
1–4
In recent years the introduction of transition metal-catalysed
cross-coupling and CH bond activation strategies has provided
useful methods for the direct introduction of aryl, alkyl, vinyl
and alkynyl substituents.
5 In addition, the ability to induce
intramolecular radical additions to both C2 and C3 of an indole
and to metallate indolines at C2 with strong bases are notable
advances.
3,6 CH activation of indolines leading to carbon-to-
carbon bond formation is less well developed than for indoles,
having been demonstrated under both transition metal catalysis
4
and, in a single example, through radical translocation and
capture of samarium(II) iodide.
7 Herein we describe a detailed
examination of the chemistry of the C2 indolinyl radical in which
we exposed and exploited various fates including cyclisation,
C3-fragmentation and tandem cyclisation reactions leading to
annulation, indole and azapropellane formation, respectively.
Results and discussion
Before embarking on the study we sought an efﬁcient method for
thegenerationofC2indolinylradicalintermediates.Translocation
of an aryl radical tethered through the nitrogen seemed an
appropriate starting point as this tactic has a proven track-
recordinothersaturatednitrogenheterocyclicringsystems.
8 Thus,
aSchool of Chemistry, University of Southampton, Highﬁeld, Southampton,
Hampshire, UK. E-mail: dch2@soton.ac.uk; Fax: ++44 (0)23 8059 6805;
Tel: ++44 (0)23 8059 3302
bAstraZeneca Charnwood, Bakewell Rd, Loughborough, Leics., UK LE11
5RH
cPﬁzer Ltd, Sandwich, Kent, UK CT13 9NJ
†Electronic supplementary information (ESI) available: Experimental
details for the procedures described herein and for the preparation of
starting materials are given, along with characterisation data and copies
of recorded
1Ha n d
13CN M Rs p e c t r a .S e eD O I :1 0 . 1 0 3 9 / c 1 o b 0 5 5 2 7 e
with indoline 1a we were pleased to ﬁnd that on treatment with
Bu3SnHunderstandardradical-formingconditionstheenvisioned
arene to indoline radical translocation outpaced cyclisation to
C7 to give 4a in 76% yield as a 6:1 mixture of diastereomers
(Scheme 1).
9,10 Moreover, when the same method was applied to
the analogous diiodide 1b it yielded azapropellane 5 as a 1:1
mixture of diastereoisomers in 90% yield, the result of a double
activation–tandem radical cyclisation at C2.
Scheme 1 CH activation–cyclisation and CH2 double activation–
tandem cyclisation reactions. VAZO R  –88: 1,1¢-azobis (cyclohexane-1-
carbonitrile).
The outcome was equally clear cut with indoline 6,w h e r et h e
C2 radical intermediate 8 underwent fragmentation to indole 7
ratherthancyclisationtotheproximalarenetoform9(Scheme2).
4882 | Org. Biomol. Chem.,2 0 1 1 ,9,4 8 8 2 – 4 8 8 5 This journal is © The Royal Society of Chemistry 2011
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View OnlineScheme 2 Fragmentation of a C3 benzyl substituent.
Fragmentation of C3 allyl substituents was also facile (viz. 10f  
13f)andoutpacedfragmentationofaC3benzylinthecompetition
experiment 14   15 + 13f.
11 Interestingly, no fragmentation was
observed with spirocyclopentene 16, which returned the product
of halide reduction 17 (presumably via translocation and H-atom
abstraction). Methyl, alkyl, aminoalkyl and hydrogen atoms at C3
resisted fragmentation (Scheme 3), though in the latter case this
did compete with H-atom abstraction from tributyltin hydride
when the C2 radical intermediate was stabilised by conjugation
(viz. 20   21 + 22).
12 Fragmentation of homobenzyl substituents
at C3 was also observed as a minor pathway in the reaction
10d   12d + 13d,w h i c hu n e x p e c t e d l yg a v er i s et oac o m p l e x
product mixture.
Scheme 3 As t u d yo fC 3f r a g m e n t a t i o nr e a c t i o n s .
Finally, with the conversion of indoline 23 to the fused
azaheterocycle 27 we have been able to show how the CH-
activation/fragmentation sequence can be used to set up radical
cyclisation reactions (Scheme 4). Interestingly, the product was
Scheme 4 An alternative CH activation–cyclisation strategy leading to a
fused azaheterocycle.
given as a single diastereoisomer with delivery of a hydrogen atom
to the concave face of intermediate 25. It therefore seems likely
that this too involves radical translocation to 26a or 26b providing
an opportunity for further diversiﬁcation.
Conclusions
In summary, access to the C2-indolinyl radical is conveniently
given by translocation of an aryl radical tethered to its nitrogen
centre. The fate of that radical intermediate is dictated by the
substitution at C3. Hydrogen, methyl, 1
 -a n d2
 -alkyl and
homoallyl substituents at C3 are resistant to fragmentation,
providing an opportunity to exploit the C2-indolinyl radical in
cyclisation and tandem cyclisation reactions. By contrast, benzyl
and allyl substituents at C3 readily cleave in such circumstances
leading to the corresponding indole. That fate extends, in part, to
hydrogen atoms at C3 when the C2-indolinyl radical is stabilised
by conjugation. The CH-activation/fragmentation sequence pro-
vides further opportunities for extension, as exempliﬁed by the
conversion of indoline 23 to the fused azaheterocycle 27.
Experimental†
General techniques
Unless speciﬁed, commercially reagents were used without fur-
ther puriﬁcation. All reactions were carried out in oven-dried
glassware under an atmosphere of argon. Toluene, THF and
diethyl ether were freshly distilled from a purple solution of
sodium and benzophenone. Dichloromethane and chloroform
were freshly distilled from CaH2.F l a s hc o l u m nc h r o m a t o g r a p h y
was performed using silica gel (60A Particle Size 30–70 micron)
with the stated solvent system. Chromatographic puriﬁcation
of organotin-containing reaction mixtures was performed using
10% w/w anhydrous K2CO3 in silica gel.
13 Melting points were
recorded on a Reichert Austria apparatus and are uncorrected.
Infrared spectra were recorded neat as a ﬁlm or compressed
solid using the ATR/golden gate method and are quoted in
wavenumbers (cm
-1).
1HN M Rs p e c t r aw e r er e c o r d e do ne i t h e ra
Bruker AV-300 (300 MHz) or DPX-400 (400 MHz) spectrometer
This journal is © The Royal Society of Chemistry 2011 Org. Biomol. Chem.,2 0 1 1 ,9,4 8 8 2 – 4 8 8 5| 4883
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View Onlineoperating at 298 K. ESI mass spectra were recorded using a VG
Platform Quadrupole Electrospray Ionisation mass spectrometer,
measuring mono-isotopic masses (mode: ES+ or ES-). EI and CI
spectra were measured on a Thermoquest Trace MS.
Synthetic procedures
8b-But-3-enyl-4-(3,4-dimethoxybenzyl)-3-methyl-1,2,3,3a,4,8b-
hexahydrocyclopenta[b]indole (4a). As o l u t i o no f1a (200 mg,
0.40 mmol), tributyltin hydride (0.24 mL, 0.87 mmol) and VAZO
(20 mg, 0.08 mmol) in toluene (20 mL) was heated at reﬂux
for 4 h, then cooled and concentrated in vacuo. Puriﬁcation by
column chromatography (10% w/w anhydrous K2CO3–silica;
13
10% diethyl ether in petroleum ether) afforded the title compound
as a brown oil (120 mg, 0.31 mmol, 76%), as a 6:1 mixture of
diastereoisomers.
1HNMR(400MHz,CDCl 3)majordiastereoiso-
mer d 7.48 (app. td, J = 7.9, 1.1 Hz, 1H), 7.43 (dd, J = 7.3, 1.1 Hz,
1H), 7.34–7.28 (m,3H), 7.13 (app. td, J = 7.3, 0.6 Hz, 1H), 6.87 (d,
J = 7.9 Hz, 1H), 6.16 (ddt, J = 16.7, 10.7, 6.1 Hz, 1H), 5.39–5.31
(m, 2H), 5.04 (d, J = 15.9 Hz, 1H), 4.65 (d, J = 15.9 Hz, 1H), 4.34
(s, 3H), 4.25 (s, 3H), 4.11 (d, J = 5.8 Hz, 1H), 2.59–2.46 (m, 2H),
2.45–2.35 (m, 2H), 2.34–2.02 (m, 4H), 1.82 (m, 1H), 1.57 (d, J =
6.9 Hz, 3H).
13CN M R( 1 0 0M H z ,C D C l 3) major diastereoisomer
d 153.2 (C), 148.9 (C), 148.0 (C), 138.8 (CH), 136.3 (C), 131.2 (C),
127.3 (CH), 122.8 (CH), 119.8 (CH), 117.1 (CH), 113.9 (CH2),
111.0 (CH) 110.9 (CH), 107.0 (CH), 75.0 (CH), 56.9 (C), 55.8
(CH3), 55.7 (CH3), 53.3 (CH2), 41.5 (CH), 40.9 (CH2), 40.6 (CH2),
32.6 (CH2), 30.1 (CH2), 14.9 (CH3). IR (neat) nmax 3077, 3003,
2929,2856,2827,1601,1513,1485,1461.LRMS-CI(m/z,%):378
(30), 151 (100). HRMS-ES
+ (m/z): [M + H]
+ calcd for C25H32NO2
378.2428; found, 378.2428.
2-Aza-2-(3,4,5-trimetho xybenzyl)-8,11-dimeth ylbenz[c]tri-
cyclo[3,3,3,0
1,5]u n d e c a n e( 5 ) . As o l u t i o no f1b (300 mg, 0.46
mmol), tributyltin hydride (0.55 mL, 2.02 mmol) and VAZO
(23 mg, 0.09 mmol) in toluene (20 mL) was heated at reﬂux
for 16 h, then cooled and concentrated in vacuo.P u r i ﬁ c a t i o nb y
column chromatography (10% w/w anhydrous K2CO3–silica;
13 5–
10% diethyl ether in petroleum ether) afforded the title compound
as a white solid (170 mg, 0.41 mmol, 90%) as a 1:1 mixture of
diastereoisomers.
1HN M R( 3 0 0M H z ,C D C l 3) d 7.04 (dd, J = 7.3,
1.0 Hz, 1H), 7.05 (dd, J = 7.3, 1.0 Hz, 1H), 6.92 (app. td, J = 7.7,
1.4 Hz, 1H), 6.91 (app. td, J = 7.7, 1.4 Hz, 1H), 6.63 (app. tt, J
= 7.3, 1.0 Hz, 1H + 1H), 6.57 (br. s, 1H + 1H), 6.53 (br. s, 1H +
1H), 6.01 (d, J = 7.6 Hz, 1H), 5.95 (d, J = 7.6 Hz, 1H), 4.72 (d, J
= 16.8 Hz, 1H), 4.44 (s, 1H + 1H), 4.25 (d, J = 16.8 Hz, 1H), 3.87
(s, 3H), 3.86 (s, 3H), 3.79 (s, 6H), 3.78 (s, 6H), 2.19–1.97 (m, 4H +
4H), 1.94–1.76 (m, 2H + 2H), 1.75–1.57 (m, 2H + 2H), 1.54–1.32
(m, 2H + 2H), 1.26 (d, J = 6.9 Hz, 3H), 1.11 (d, J = 6.9 Hz, 3H),
0.92 (d, J = 7.0 Hz, 3H + 3H).
13CN M R( 7 5M H z ,C D C l 3) d
153.4 (2 ¥ C), 152.6 + 151.8 (C), 138.5 + 137.9 (C), 135.3 (C),
135.1 (C), 127.2 + 127.2 (CH), 122.7 + 122.5 (CH), 117.3 + 117.0
(CH), 107.5 (CH), 105.7 (CH), 103.8 + 103.7 (CH), 91.4 + 87.4
(C), 67.5 + 64.3 (C), 61.1 (CH3), 56.3 + 56.2 (2 ¥ CH3), 52.8 +
50.8 (CH2), 44.0 + 43.6 (2 ¥ CH), 41.5 + 41.1 + 40.1 (2 ¥ CH2),
35.0 + 34.3 + 33.8 (2 ¥ CH2), 16.4 + 15.2 + 15.1 (2 ¥ CH3). IR
(neat) nmax 2933, 2868, 2848, 1687, 1588, 1499. LRMS-ES
+ (m/z,
%): 408 (50), 228 (100). HRMS-ES
+ (m/z): [M + Na]
+ calcd for
C26H33NNaO3 430.2353; found, 430.2349.
3-Benzyl-1-(3,4-dimethoxybenzyl)-1H-indole (7). As o l u t i o n
of6(350mg,0.61mmol),tributyltinhydride(0.36mL,1.34mmol)
and VAZO (0.12 mmol, 30 mg) in toluene (25 mL) was heated at
reﬂux for 16 h, then cooled and concentratedinvacuo.Puriﬁca tion
by column chromatography (10% w/w anhydrous K2CO3–silica;
13
5% diethyl ether in petroleum ether) afforded the title compound
as a brown oil (210 mg, 0.58 mmol, 95%).
1HN M R( 4 0 0M H z ,
CDCl3) d 7.60 (dd, J = 7.8, 0.9 Hz, 1H), 7.38–7.31 (m, 4H), 7.26–
7.21 (m, 3H), 7.14 (ddd, J = 7.8, 6.9, 1.0 Hz, 1H), 6.93 (s, 1H),
6.86 (d, J = 8.1 Hz, 1H), 6.75 (dd, J = 8.1, 1.9 Hz, 1H), 6.71 (d,
J = 1.9 Hz, 1H), 5.27 (s, 2H), 4.20 (s, 2H), 3.92 (s, 3H), 3.83 (s,
3H).
13CN M R( 1 0 0M H z ,C D C l 3) d 149.3 (C), 148.5 (C), 141.4
(C), 136.9 (C), 130.2 (2 ¥ C), 128.6 (2 ¥ CH), 128.3 (2 ¥ CH),
126.4 (CH), 125.8 (CH), 121.7 (CH), 119.3 (CH), 119.2 (CH),
119.0 (CH), 114.8 (C), 111.3 (CH), 110.1 (CH), 109.6 (CH), 55.9
(CH3), 55.8 (CH3), 49.7 (CH2), 31.5 (CH2). IR (neat) nmax 3052,
3027, 2999, 2933, 2901, 2823, 1514, 1463, 1452. LRMS-ES
+ (m/z,
%): 258 (100). HRMS-ES
+ (m/z): [M + H]
+ calcd for C24H24NO2
358.1802; found, 358.1804.
Methyl1-benzylindoline-2-carboxylate(21)andmethyl1-benzyl-
1H-indole-2-carboxylate (22). As o l u t i o no f20 (569 mg, 1.64
mmol), tributyltin hydride (0.97 mL, 3.61 mmol) and VAZO
(81 mg, 0.33 mmol) in toluene (50 mL) was heated at reﬂux
for 18 h, then cooled and concentrated in vacuo. Puriﬁcation by
column chromatography (10% w/w anhydrous K2CO3–silica;
13
2–5% diethyl ether in petroleum ether) afforded ﬁrstly 22 as a
colourless oil (102 mg, 0.38 mmol, 24%).
1HN M R( 3 0 0M H z ,
CDCl3) d 7.76 (d, J = 8.1 Hz, 1H), 7.44 (s, 1H), 7.41 (d, J =
8.1 Hz, 1H), 7.36 (dd, J = 6.6, 1.1 Hz, 1H), 7.28 (d, J = 7.5 Hz,
1H), 7.33–7.17 (m, 3H), 7.10 (m, 2H), 5.89 (s, 2H), 3.91 (s, 3H).
13CN M R( 7 5M H z ,C D C l 3) d 162.3 (C), 139.5 (C), 138.2 (C),
128.5 (2 ¥ CH), 127.3 (CH), 127.1 (C), 126.2 (2 ¥ CH), 126.1
(C), 125.3 (CH), 122.7 (CH), 120.8 (CH), 111.1 (CH), 110.8 (CH),
51.6 (CH3)4 7 . 8( C H 2). IR (neat) nmax 3062, 3031, 2857, 1706,
1605, 1518, 1248, 1191. LRMS-EI (70 eV, m/z, %): 265 (57), 233
(12), 206 (6), 188 (4), 91 (100). HRMS-ES
+ (m/z): [M + Na]
+
calcd for C17H15NNaO2 288.0995; found, 288.0994. Then 21 as a
pale yellow oil (290 mg, 1.09 mmol, 67%).
1HN M R( 3 0 0M H z ,
CDCl3) d 7.32–7.14 (m, 5H), 7.02–6.93 (m, 2H), 6.62 (app. td, J
= 7.4, 0.7 Hz, 1H), 6.39 (d, J = 7.8 Hz, 1H), 4.44 (d, J = 15.4 Hz,
1H), 4.25 (d, J = 15.4 Hz, 1H), 4.19 (dd, J = 10.3, 8.1 Hz, 1H),
3.59 (s, 3H), 3.31 (dd, J = 15.9, 10.3 Hz, 1H), 3.12 (dd, J = 15.9,
8.1 Hz, 1H).
13CN M R( 7 5M H z ,C D C l 3) d 173.3 (C), 151.3 (C),
137.7(C),128.4(2¥CH),127.8(2¥CH),127.7(CH),127.2(CH),
126.8 (C), 124.1 (CH), 118.1 (CH), 107.2 (CH), 65.2 (CH), 52.1
(CH2), 52.0 (CH3), 33.4 (CH2). IR (neat) nmax 3053, 3027, 2950,
2849, 1733, 1605, 1484, 1195, 1156. LRMS-EI (70 eV, m/z,% ) :
267 (25), 208 (54), 117 (17), 91 (100). HRMS-ES
+ (m/z): [M +
Na]
+ calcd for C17H17NNaO2 290.1151; found, 290.1156.
11-Benzyl-8,9,10-trimethoxy-10b,11-dihydro-6H-isoindolo [2,1-
a]indole (27). As o l u t i o no f23 (500 mg, 0.68 mmol), tributyltin
hydride (3.01 mmol, 0.81 mL) and VAZO (0.14 mmol, 33 mg)
in toluene (40 mL) was heated at reﬂux for 16 h, then cooled
and concentrated in vacuo. Puriﬁcation by column chromatog-
raphy (10% w/w anhydrous K2CO3–silica;
13 5% diethyl ether in
petroleum ether) afforded the title compound as a colourless oil
(160 mg, 0.40 mmol, 60%).
1HN M R( 4 0 0M H z ,C D C l 3) d 7.42–
7.36 (m, 4H), 7.31 (m, 1H), 7.17 (app. dt, J = 7.5, 1.3 Hz, 1H),
4884 | Org. Biomol. Chem.,2 0 1 1 ,9,4 8 8 2 – 4 8 8 5 This journal is © The Royal Society of Chemistry 2011
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View Online6.87–6.80 (m, 2H), 6.78 (ddd, J = 7.9, 7.2, 0.8 Hz, 1H), 6.51 (s,
1H), 5.06 (br. s, 1H), 4.55 (dd, J = 14.6, 1.3 Hz, 1H), 4.48 (d, J =
14.6 Hz, 1H), 4.18 (br. dt, J = 7.5, 1.9 Hz, 1H), 3.83 (s, 3H), 3.82
(s, 3H), 3.70 (s, 3H), 3.16 (dd, J = 13.3, 8.2 Hz, 1H), 3.07 (dd, J =
13.3, 7.3 Hz, 1H).
13CN M R( 1 0 0M H z ,C D C l 3) d 154.1 (C), 154.1
(C), 149.5 (C), 140.9 (C), 140.0 (C), 135.0 (C), 134.0 (C), 129.7 (2
¥ CH), 128.2 (2 ¥ CH), 127.8 (CH), 127.1 (C), 126.1 (CH), 124.8
(CH),120.3(CH),112.0(CH),101.3(CH),74.7(CH),60.8(CH3),
60.3 (CH3), 59.4 (NCH2), 56.1 (CH3), 48.1 (CH), 43.2 (CH2). IR
(neat) nmax 3032, 2995, 2938, 2856, 1597. LRMS-CI (m/z,% ) :3 8 8
(80), 296 (100), 280 (15), 195 (20), 167 (20), 91 (30). HRMS-ES
+
(m/z): [M + H]
+ calcd for C25H26NO3 388.1907; found, 388.1901.
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